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ABSTRACT 
 The APOBEC3 restriction factors belong to a family of cytidine deaminases that are able 
to suppress the replication of viruses with a single-stranded DNA intermediate by inducing 
mutagenesis and functional inactivation of the virus. Of the seven common human APOBEC3 
enzymes, only APOBEC3-D, -F, -G and -H appear to be relevant to HIV-1 restriction in CD4+ T 
cells. The restriction of HIV-1 by APOBEC3 enzymes occurs most potently in the absence of 
HIV-1 Vif, which counteracts APOBEC3s by inducing polyubiquitination and subsequent 
degradation of APOBEC3 enzymes. Virion-encapsidated APOBEC3s can deaminate cytosines to 
uracils in viral (-)DNA. Upon replication of (-)DNA to (+)DNA, the HIV-1 reverse transcriptase 
incorporates adenines opposite to the uracils hereby inducing C/G to T/A transition mutations. 
Among all APOBEC3 enzymes that are relevant to HIV-1 restriction, APOBEC3G is the most 
studied APOBEC3 enzyme. APOBEC3G has been shown to processively catalyze deamination 
reactions on single-stranded (-)DNA using a mechanism called facilitated diffusion, which 
involves sliding and jumping movements in search of target cytosine-containing motifs. This 
single-stranded DNA scanning mechanism allows APOBEC3G to efficiently deaminate multiple 
cytosines within one enzyme-DNA encounter and it is important for the mutational inactivation 
of HIV-1 in vivo. Vif attempts to neutralize APOBEC3G’s function not only by inducing 
proteasomal degradation, but also by several degradation-independent mechanisms, such as 
inhibiting APOBEC3G virion encapsidation, mRNA translation, and for those APOBEC3G 
molecules that still become virion encapsidated, Vif has been shown to inhibit APOBEC3G’s 
deamination activity.  
My Ph.D. thesis work investigated the molecular mechanism of degradation-independent 
Vif-mediated inhibition of APOBEC3G and APOBEC3H deamination activity. This research  
led to the development of the hypothesis that Vif has developed a unique interaction with each 
APOBEC3 enzyme due to the different selection pressures they impose on HIV-1. Thus, we 
investigated how the interaction of Vif differs between APOBEC3G and APOBEC3H and 
characterized the activity of APOBEC3H as a restriction factor. This research allowed us to have 
a better understanding of the molecular determinants that govern an efficient APOBEC3-
degradatation by HIV-1 Vif and provide insights for APOBEC3-based HIV-1 therapeutics. 
Two Vif variants obtained from HIV-1 laboratory isolates, VifHXB2 and VifIIIB, were used 
to determine the degradation-independent effects of Vif on APOBEC3G. Biochemical assays 
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using a model HIV-1 replication assay and synthetic single-stranded or partially double-stranded 
DNA substrates demonstrated that APOBEC3G has an altered processive mechanism in the 
presence of Vif, and this caused APOBEC3G to be less effective at inducing mutagenesis in a 
model HIV-1 replication assay.    
APOBEC3H is unique in that it is the only single-domain common APOBEC3 enzyme 
that restricts HIV-1. APOBEC3H exists in humans as seven haplotypes (I-VII) with different 
cellular stabilities. Amongst three stable APOBEC3H haplotypes, haplotype II and V occur most 
frequently in the population. I characterized the single-stranded DNA scanning mechanisms that 
haplotype II and V use to search their single-stranded substrate for cytosine-containing 
deamination motif.  APOBEC3H haplotype II was able to processively deaminate its substrate 
using Brownian motion-driven movements termed sliding, jumping and intersegmental transfer, 
whereas haplotype V showed compromised sliding and intersegmental transfer abilities but was 
able to jump along single-stranded DNA. Since an Asp or Glu at amino acid 178 differentiates 
these two haplotypes, these data suggest this amino acid on predicted helix 6 contributes to 
processivity. I found the optimal processivity on ssDNA also required dimerization of 
APOBEC3H through the β2 strands. The diminished processivity of APOBEC3H haplotype V 
did not result in a reduced efficiency to restrict HIV-1 replication in single-cycle infectivity assay. 
This suggests a redundancy in the contribution of jumping and intersegmental transfer to 
mutagenic efficiency.  
VifHXB2, but not VifIIIB, can cause degradation of APOBEC3H even though APOBEC3H 
interacts with both Vif variants. APOBEC3G is degraded after interaction with both of these Vif 
variants. To define the parameters for efficient Vif-induced degradation of an APOBEC3 
enzyme, I used an in vitro quantitative method to determine the binding strength of APOBEC3G 
and APOBEC3H with Vif variant heterotetramers (Vif/CBFβ/EloB/EloC), the most stable form 
of Vif. Our biochemical analysis, along with cellular experiments to determine Vif-induced 
degradation efficiency and APOBEC3-Vif interactions in cells, support a model in which the 
degradation efficiency of Vifs correlates with both the APOBEC3-Vif binding strength and 
APOBEC3-Vif interface.  
I also investigated how APOBEC3 enzymes restrict the replication of retrotransposon 
LINE-1. Retrotransposons are DNA sequences that replicate using a “copy-and-paste” 
mechanism through an RNA intermediate. The degradation of deaminated L1 cDNA rendered it 
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difficult to detect any APOBEC3-induced G-to-A mutations while the addition of uracil DNA 
glycosylase inhibitor allowed for the recovery of the APOBEC3-mediated deamination events. I 
found that two stable A3H haplotypes (haplotype II and haplotype V) use a deamination-
independent mechanism to restrict L1 mobilization and compared the ability of APOBEC3H’s to 
inhibit LINE1 with that of APOBEC3A and APOBEC3G, two APOBEC3s whose LINE1 
restriction ability have been previously characterized. Taken together, these studies of the 
molecular mechanisms that APOBEC3G and APOBEC3H use to inhibit HIV-1 and LINE1 have 
allowed us to better understand their biological properties as cytidine deaminases and the 
determinants in APOBEC3s that made them efficient host innate immune restriction factors.  
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1.0 Introduction and Literature Review 
1.1 General HIV-1 biology 
1.1.1 The basics of HIV replication  
 Human immunodeficiency virus type 1 (HIV-1, referred to as HIV) is a major global 
public health issue and currently infects approximately 37 million people worldwide. Sub-
Saharan Africa is the most affected area and accounts for two-thirds of the global total of new 
HIV infections [1]. HIV targets immune cells, primarily CD4+ T cells and macrophages, for 
infection and impairs the function of immune defence system against other infections. This can 
gradually render the infected individuals immunodeficient and eventually leads to acquired 
immunodeficiency syndrome (AIDS), the most advanced stage of HIV infection [2, 3]. Although 
highly active anti-retroviral therapy (HAART) can effectively control viraemia, variations of 
HIV that arise while a person is taking the medication can lead to drug-resistant strains of HIV 
and cause the therapy to fail [4]. Currently there is no cure for HIV infection. 
 HIV belongs to the genus lentivirus, part of the family Retroviridae [5]. Similar to all 
retroviruses, HIV contains two copies of non-covalently linked, positive-sense singled-stranded 
(ss) RNAs enclosed in a capsid composed of the viral protein p24 [6]. The HIV genome is 9.7-kb 
in length and it contains three genes that are essential for HIV replication: gag (group-specific 
antigen), pol (polymerase) and env (envelope) [7] (Fig. 1.1A). Gag encodes the precursor gag 
polyprotein which is subject to cleavage by the viral protease to generate the internal structural 
subunits of the virion including capsid, matrix and nucleocapsid; pol encodes the reverse 
transcriptase (RT), integrase, and protease enzymes that are crucial for genome replication, 
proviral integration, and gag polyprotein processing, respectively; env encodes the viral envelope 
protein which is essential for infection of target host cells [3]. HIV also encodes two regulatory 
proteins, the transcriptional transactivator (Tat) and the regulator of virion gene expression (Rev), 
which are required for transcriptional regulation and mRNA nuclear export, respectively. In 
addition, HIV contains four genes that encode accessory proteins: the viral protein r (Vpr), the 
viral protein u (Vpu), viral infectivity factor (Vif) and negative regulatory factor (Nef) [8-10]. 
HIV accessory proteins are not always required for viral replication, but instead are involved in 
enhancing viral fitness by allowing the viruses to evade host innate and adaptive immune 
mechanisms [8, 9]. These accessory proteins (Vpr, Vpu, Nef, and Vif) generally take advantage 
of the host protein degradative pathways to remove proteins such as restriction factors or  
	 2	
 
c 5’LTR pol 
gag vif 
A 
B 
 rev 
tat 
c 
nef 
env 3’LTR vpr 
vpu PR   RT IN 
  MA CA NC p6 
SU   TM 
binding fusion 
	
reverse transcription   
PIC  
formation 
integration 
5’LTR 3’LTR 
transcription 
RNA export 
translation 
nuclear 
assembly 
budding 
maturation 
	 3	
 
Figure 1.1 Schematic overview of the HIV genome structure and life cycle. (A) Schematic of 
HIV genome and encoded proteins. HIV contains three genes (yellow) that are common to all 
retroviruses. These three genes (gag, pol and env) encode polyproteins that will be subsequently 
processed to their mature forms (green). The 9.7-kb HIV genome contains open reading frames 
for 15 distinct proteins: the Gag and Env structural proteins MA (matrix), CA (capsid), NC 
(nucleocapsid), p6, SU (surface), and TM (transmembrane); the Pol proteins: PR (protease), RT 
(reverse transcriptase), and IN (integrase); two regulatory proteins Tat and Rev (orange); four 
accessory proteins Nef, Vif, Vpr, and Vpu (wheat) [11]. (B) HIV replication cycle. The figure 
illustrates the major steps involved in the HIV replication cycle. HIV envelope glycoprotein 
binds to the cell surface receptor, which triggers the fusion of the viral and cellular membranes 
and entry of the viral particle into the cell. Uncoating of the viral capsid, coupled with reverse 
transcription, leads to the formation of a double-stranded DNA and a pre-integration complex 
(PIC). PIC will be transported into the nucleus and with PIC-associated viral integrase (vertical 
box) forms an integrated provirus. Proviral DNA (red) transcription is mediated by the host RNA 
polymerase II, producing viral mRNA transcripts (red) of different sizes. These mRNAs serve as 
templates for viral protein production. After assembly, viral particle buds off and is released 
followed by protease-mediated maturation and results in the generation of infectious virions. The 
assembly virion contains the viral genome (two single-stranded RNA molecules), cellular 
tRNAlys,3, some viral proteins such as Env, Gag polyprotein, NC, RT, IN, Vpr, and cellular 
proteins such as A3s [7, 12]. For simplicity, only one protein (shown in purple) is represented 
inside the virion structure.  
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immune signaling components that would otherwise interfere with the viral replication and 
propagation [8, 9]. For example, Vpr hijacks an E3 ubiquitin ligase complex and induces G2 cell 
cycle arrest, Vpu enhances viral particle budding by degradation and sequestration of the host 
restriction factor Bone marrow stromal cell antigen 2 (BST-2)/tetherin, and Nef downregulates h 
(MHC-1) cell surface expression to prevent viral antigen presentation and clearance of infected 
cells by cytotoxic T lymphocytes [8, 9]. Central to this thesis work is the accessory protein Vif. 
Vif mediates the degradation of the Apolipoprotein B mRNA-editing enzyme-catalytic 
polypeptide-like 3 (APOBEC3, referred to as A3) family of cytidine deaminases, which 
suppresses their ability to hypermutate and inactivate the viral genome. The function of Vif will 
be examined further in section 1.4.  
The HIV replication cycle begins with the binding of the virus envelope glycoprotein 
gp120 to the CD4 receptor as well as to the chemokine co-receptor CC receptor type 5 (CCR5) 
or CXC receptor type 4 (CXCR4) on the surface of target CD4+T cells, followed by fusion of the 
viral and cellular membranes and uncoating of capsid [13] (Fig. 1.1B). Although early research 
indicated that the capsid dissembles near the membrane immediately after the fusion [14, 15], a 
more favourable model proposes that capsid would remain intact until the incoming viral 
complexes reach the nuclear membrane and that uncoating occurs at the nuclear pore upon 
completion of reverse transcription, a process during which HIV converts its ss positive sense 
RNA genome into double-stranded DNA using host-encoded RT [13] (Fig 1.2). An intact capsid 
is important for keeping a high stoichiometry of HIV reverse transcriptase relative to the viral 
genome, thus enabling an efficient reverse transcription process. Because HIV capsid hexamers 
have a pore at the six-fold symmetry axis, they are permeable to small macromolecules such as 
deoxynucleoside triphosphates (dNTPs) and it is believed that HIV reverse transcription is 
triggered by the relatively high concentrations of dNTPs in the cytoplasm that diffuse through 
the inter-ring spacings of the capsid [16, 17]. Uncoating accompanies the formation of a HIV 
pre-integration complex (PIC), which is an integration-competent complex that is formed inside 
the cytoplasm upon viral dsDNA synthesis and can later integrate into the chromosome of the 
target cell and form the long terminal repeat (LTR)-flanked provirus with the assistance of the 
integrase enzyme [3, 13] (Fig. 1.1B). The 5’LTR (long terminal repeat) contains enhancer and 
promoter sequences which serves as the binding sites for host transcription factors that will later 
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Figure 1.2 Schematic of reverse transcription and replication of HIV. The genomic RNA (black 
line) is primed for replication using a host tRNAlys3 primer. Synthesis of the (-)cDNA (bold line) 
generates an RNA/DNA hybrid that is a substrate for RNase H. RNase H degrades the genomic 
RNA strand (hatched line), leaving the nascent (-)cDNA single-stranded. Because both ends of 
the viral RNA genome contain the same repeated sequence (R), this allows the (-)cDNA to 
hybridize with the R sequence at the 3’end of the viral RNA, a step that is called the first strand 
transfer. With the hybridization of (-)cDNA to 3’R, (-)cDNA synthesis resumes along the viral 
RNA and RNase H degrades the RNA strand (hatched line) as the cDNA synthesis proceeds. A 
purine-rich sequence near the 3’end of the viral RNA genome called the polypurine tract or PPT 
is relatively resistant to RNase H degradation and serves as the primer for (+)cDNA synthesis. 
(+)cDNA synthesis proceeds until RT starts to copy the tRNA primer. With the completion of 
the 3’ end tRNA reverse transcription, an RNA/DNA hybrid is created and RNase H removes the 
tRNA primer. This steps exposes a single-stranded portion of the (+)cDNA, which now has the 
same sequence as the 5’ PBS. In a process called the second strand transfer, both the (+) and (-
)cDNA are extended until the entire DNA becomes double-stranded, and eventually creating a 
DNA that has the same sequences (U3-R-U5) at both ends (called the long terminal repeats or 
LTRs). The nucleocapsid protein facilitates the transfer of primers to initiate (-)cDNA and 
genomic strand ((+)cDNA) synthesis. Abbreviations are: R, repeated sequence; U5, unique 5’ 
region; PBS, primer binding site; PPT, polypurine tract; U3, unique 3’ region. It should be noted 
that all retroviruses usually have at least one PPT. HIV has two PPTs, one near the 3’end of the 
RNA genome and the other (the central PPT) resides near the middle of the genome [18]. For 
simplicity, only the 3’ PPT is shown. Figure is adapted from Coffin et al., 1997 [5].  
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position the RNA polymerase II at the correct site for initiating transcription. The viral RNA 
transcribed from the proviral DNA is either packaged into newly-assembly virions as genomic 
RNA or translated in the cytoplasm to form viral proteins [12]. The viral RNA and proteins will 
be transported to the plasma membrane and assembled into progeny virions. Viral maturation 
begins concomitantly with or immediately after budding, and the viral protease processes the 
Gag-pol polyprotein precursors into their mature components and eventually results in the 
production of infectious virus particles [12] (Fig.1.1B).  
Reverse transcription serves as a critical step in retroviral replication, where the viruses 
use a virally encoded RT to convert its RNA genome into DNA [18]. HIV RT is a heterodimer 
that is composed of two subunits: p66 and p51. The p66 and p51 are 560 amino acids and 440 
amno acids in length, respectively [19]. Unlike the p51 subunit which is thought to play a 
structural role, the p66 has a catalytic function and consists of two enzymatic activities: an RNA 
or DNA-dependent DNA polymerase and an RNaseH that cleaves RNA only if the RNA is part 
of an RNA/DNA duplex. The chemical step during the polymerization reaction requires two 
divalent Mg2+ ions [18, 19]. Near the 5’ end of the HIV genome exists an 18 nucleotides long 
sequence named the primer binding site (PBS) and the viral reverse transcription initiates with 
the RNA genome being primed by a host tRNAlys3 at the PBS (Fig. 1.2). The RT synthesizes the 
(-)cDNA while the RNaseH domain of RT catalyzes the degradation of the RNA component of 
the DNA-RNA heteroduplex. HIV nucleocapsid chaperones the first strand transfer of the (-
)cDNA to the 3’ repeated (R) sequence and the polymerization of (-)cDNA continues. With the 
completion of (-)cDNA polymerization, (+)cDNA synthesis is primed by RNaseH-resistant 
polypurine tracts (PPT) of the RNA-DNA heteroduplex [5]. The final product of the reverse 
transcription process is a double-stranded DNA segment with each end of the DNA containing 
the same sequences: U3-R-U5. These are the LTRs that will serve as the substate for integrase 
and be the ends of the provirus after an integration event (Fig. 1.2).  
1.1.2 Current HIV-1 therapies 
The HIV life cycle presents many potential targets for therapeutic intervention. Currently, 
there are thirty nine Food and Drug Administration (FDA)-approved drugs that are available for 
the clinical treatment of HIV infection and they can be categorized into eight classes based on 
their unique molecular mechanisms: nucleoside-analog reverse transcriptase inhibitors, non-
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nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, fusion 
inhibitors, entry inhibitor, pharmacokinetic enhancers, and combination HIV medicines 
(www.aidsinfo.nih.gov). The administration of a cocktail of antiretroviral drugs have seminally 
facilitated the reconstitution of the immune system and reduced the morbidity and mortality 
associated with HIV infection in patients [20]. However, due to the high mutation rate commonly 
associated with RNA virus replication and frequent recombination, the generation of viral 
quasispecies occurs over time in HIV infected individuals. This can result in drug resistant 
isolates that have limited the efficacy of the current antiviral drug regimen and is worsened if 
there is a lack of patience adherence, which can occur due to drug toxicity and high costs. Hence, 
more efficient treatment strategies are required for the advancement of HIV therapy. 
The discoveries of several host cellular proteins in innate immunity that are involved in 
inhibiting a broad range of viral pathogens (so called “restriction factors”) have shed light on the 
development of novel anti-HIV drugs. The rationale behind this therapeutic approach is that 
because successful pathogens have usually developed mechanisms to counteract host defenses to 
establish infection, disrupting the viral counter-restriction mechanisms to fully unleash the 
antiviral potential of these innate host proteins would significantly decrease any possible side-
effects that are associated with the traditional antiviral therapy. A host restriction factor should 
have at least four defining characteristics [21]. First, it must directly and dominantly cause a 
significant decrease in virus infectivity. Second, it must be susceptible to neutralization by viral 
countermeasures. Third, a restriction factor should show signatures of rapid evolution due to 
direct protein-protein interactions that occur through viral-host interaction. Fourth, as part of the 
innate immune response, the expression of a restriction factor should be strongly induced by 
interferons [21]. It should be noted that restriction factors are relatively rare and are different 
from host proteins that can negatively impact viral replication (i.e., dependency factors). 
Examples of the HIV restriction factors include APOBEC3s [22-25], tetherin/BST2 [26, 27], 
Tripartite motif-containing protein 5 alpha (TRIM5α) [28-30], SAM-domain and HD-domain 
containing protein 1 (SAMHD1) [31, 32], and Myxovirus resistance 2 (MX2) [33]. In this 
Chapter, I will focus my review on the current knowledge of the restriction factor family of 
APOBEC3 cytidine deaminases and their viral countermeasure, HIV Vif.  
	 8	
1.2 APOBEC3 family of cytidine deaminases 
1.2.1 Overview 
 Retrotransposons and endogenous retroviruses have been genomic parasites in organisms 
throughout evolution and have contributed to both species evolution and disease [34]. The 
APOBEC (Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide) family of enzymes 
present in their earliest form in bony fish acted as a defense against retroelements [35]. Due to 
expansion of retroelements through evolution there was a corresponding expansion in the 
APOBEC family [36, 37]. The most recent expansion in placental mammals formed the 
Apolipoprotein B mRNA-editing enzyme-catalytic, polypeptide-like 3 (APOBEC3) family in 
response to ancient pathogenic retroviruses [37, 38]. Humans contain seven APOBEC3 (A3) 
enzymes (A3A, A3B, A3C, A3D, A3F, A3G, and A3H) [37, 39]. The A3 enzymes act as host 
restriction factors to inhibit retroelement replication through either RNA binding ability or 
activity as ssDNA cytosine deaminases that catalyze the formation of promutagenic uracils [40-
48]. Currently, A3 enzymes are primarily studied for their ability to restrict the replication of 
retroviruses (such as HIV) [22-25, 45, 49-53] and other viruses that replicate with a ssDNA 
intermediate (such has Hepatitis B Virus) [54, 55]. Restriction of the replication of these present-
day viruses occurs primarily through the deoxycytidine deamination activity of A3 enzymes 
which results in hypermutated and inactivated viral genomes. The gene duplications that resulted 
in the human A3 repertoire formed two general groups of deaminases with different Zinc (Z)-
coordinating domains: A3A, A3C, A3H are enzymes with a single Z-domain and A3B, A3G, 
A3D, and A3F enzymes with two Z-domains (Fig. 1.3A) [37]. For A3 enzymes with two Z-
domains, only one domain is catalytically active, except for A3B, which may have two 
catalytically active domains (Fig. 1.3A) [56-59]. 
 For HIV to successfully infect humans, it must overcome numerous physical and 
immunological barriers [21, 60, 61]. Within cells, HIV must overcome a network of restriction 
factors that are able to block specific replication steps of the virus, including A3 enzymes [21, 
62]. HIV uses Vif to overcome A3 enzymes [23-25, 63, 64]. The Vif protein of simian 
immunodeficiency virus (SIV), the non-human primate form of the virus, has co-evolved with 
species-specific A3s for millions of years [65]. The HIV-1 predecessor, SIVcpz from chimpanzees, 
underwent a key evolutionary event that altered the 3' region of the vif gene that was essential for 
antagonism of human A3 function, along with further evolutionary changes in chimpanzees  
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Figure 1.3 A3s catalyze the formation of promutagenic uracils in DNA through deamination 
reactions. (A) Zinc (Z) coordinating-type domains of human A3 enzymes. A3 enzymes 
coordinate Zinc through the motif H-X-E-X23-28-P-C-X2-4-C. The glutamate activates a water 
molecule to enable Zinc-hydroxide mediated nucleophilic attack to complete the deamination 
reaction. Deamination activity has been demonstrated for all APOBEC3 enzymes. For the 
enzymes with two Z-type domains that restrict HIV in CD4+ T cells (A3D, A3F, and A3G), the 
legend depicts known biochemical functions of each Z-type domain. A common feature of A3 
enzymes with two Z-type domains is the segregation of functions in the N-terminal domain 
(NTD) and C-terminal domain (CTD). The NTD is responsible for encapsidation and the CTD is 
responsible for deamination activity. Both domains can bind nucleic acids. The binding site of 
Vif is in the NTD for A3G and in the CTD for A3D and A3F. (B) The deamination of cytosine to 
uracil. DNA can undergo major structural changes as a result of thermal fluctuation. 
Depurination and deaminations are the two most frequent spontaneous hydrolytic chemical 
reactions known to create DNA damage in cells, if not repaired properly. Major types of 
deamination reactions include the conversion of cytosine and 5-methylcytosine to uracil and 
thymine, respectively, and the conversion of cytosine to uracil is shown here. Aside from 
spontaneous cytosine hydrolysis, uracils can also be introduced into DNA by misincorporation of 
dUTP instead of dTTP and through A3 cytosine deaminase catalyzed deamination of cytosine to 
uracil. A3 enzymes can coordinate a direct nucleophilic attack at position 4 of the pyrimidine 
ring. (C) A3G-catalyzed deamination reaction can lead to C/G→T/A transition mutations. A3G 
deaminates the cytosines on the (-)cDNA from the RNA genome of HIV. A3G prefers to 
deaminate the 3’C in its favored motif, 5’CCC. Upon synthesis of the (+)cDNA, instead of 
inserting a guanine opposite a cytosine, according to Waston-Crick base pairing, reverse 
transcriptase will treat the uracil as a thymine and insert an adenine and this leads to C/G→T/A 
transition mutation on the coding strand. Figure 1.3A is reprinted from Feng et al., 2014 [66]. 
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that adapted simian immunodeficiency virus infecting chimpanzees (SIVcpz) for improved 
infection of humans [67]. To antagonize A3 enzymes, HIV Vif must maintain the ability to 
physically interact with relevant A3s, host protein CBFβ for stability [68, 69], and components 
of the host ubiquitin ligase assembly pathway [70-72]. Ultimately Vif thwarts A3s by inducing 
their polyubiquitination and degradation through the proteasome (Fig. 1.4, A and B). It is thought 
that by disrupting the Vif-host cell interactions through novel pharmaceuticals, A3 enzymes can 
be used to suppress HIV. However, the natural balance of A3 enzymes and HIV must be first 
understood since there is evidence that HIV can take advantage of A3 enzymes to accelerate its 
quasispecies evolution [73, 74], although recent research suggests the inactivation of HIV by A3 
is an “all-or-nothing” phenomenon and concluded that the A3-mediated hypermutation usually 
results in lethal mutagenesis (see below) [75, 76].     
 From cell culture studies, it appears that only A3A, A3D, A3F, A3G, and A3H are relevant 
to HIV restriction [77-81]. A polymorphism in human A3C that changes Serine to Isoleucine at 
amino acid position 188 (S188I) also conveyed strong antiviral activity against HIV [82]. It is 
not surprising that not all seven A3 members restrict HIV replication since they likely evolved to 
restrict different retroelement pathogens [37]. There are two paradigms of how A3 enzymes can 
suppress HIV. A3A present in HIV target myeloid cells can restrict replication of incoming 
virions through low levels of deamination and possibility another mechanism that is not yet fully 
elucidated [77, 79]. In CD4+ T cells, A3D, A3F, A3G, A3H and A3C I188 restrict HIVrvif by 
becoming virion encapsidated in the HIV producer cell and travelling with the virion to the next 
susceptible cell where they catalyze promutagenic deaminations of cytosine to uracil in nascent 
single-stranded HIV (-)DNA (Fig. 1.4A) [78].  
1.2.2 A3s that are relevant to HIV-1 restriction in CD4+T cells 
The A3D, A3F, A3G, A3H and A3C I188 molecules that escape Vif-mediated inhibition 
can restrict HIV by entering the assembling virus particle by binding RNA (HIV genome or 
cellular RNA such as 7SL or Y) that also interacts with the NC portion of the Gag polyprotein 
[83-89]. After the virus enters the next target cell A3 enzymes exert their anti-viral function 
during the reverse transcription process (Fig. 1.4, A and C) [45, 51, 52, 90, 91]. Although A3D, 
A3F, A3G, A3H and A3C I188 are localized to the cytoplasm they require encapsidation to 
restrict HIV and are not able to access the (-)DNA of an incoming virus (Fig. 1.4A) [78]. This 
may be due to the HIV capsid structure or that A3 enzymes can reside in regions of RNA  
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Figure 1.4 Overview of HIV restriction by A3 enzymes. (A) Sketch depicting lifecycles of wild 
type (WT) and ΔVif HIV (ΔVif). Each virion enters a cell that expresses A3 enzymes. In the 
WT virus, Vif is expressed in the cell and recruits host cell CBFβ for stability and an E3 
ubiquitin ligase complex comprised of Elongin B/C (EloB/C), Cullin5 (Cul5) and Rbx2 (inset 
(B)). In this complex Vif acts as the substrate receptor and induces degradation of A3 enzymes. 
As a result, egressing virions do not encapsidate high levels of A3 enzymes and upon infection 
of a target cell the HIV lifecycle continues. The ΔVif HIV encapsidates A3 enzymes through an 
RNA and Gag interaction. In the target cell the A3 enzymes within the capsid of HIV can 
deaminate cytosines to uracils in nascent single stranded (-) DNA during reverse transcription 
(inset (C)). These uracils induce G®A transition mutations upon synthesis of (+) DNA (inset 
(C)). The resulting hypermutated virus can be integrated into the host genome but is functionally 
inactivated. A3 enzymes in the target call cannot enter the HIV capsid and are unable to restrict 
virus replication unless encapsidated into budding virions. (B) Detailed sketch of Vif-mediated 
polyubiquitination of A3G. Vif interacts with Elongin C (EloC), an obligate heterodimer with 
Elongin B (EloB), and Cul5. The transcription cofactor CBFβ stabilizes Vif. Cul5 binds to Rbx2, 
which recruits an E2 ubiquitin conjugating enzyme. Vif is the substrate receptor that recruits A3 
enzymes. The 48K-linked chains result in proteasomal degradation of the A3. (C) Sketch 
demonstrating the limited vulnerability of single-stranded (-) DNA to A3-mediated deamination 
that is imposed from the dynamics of reverse transcription. Reverse transcriptase is abbreviated 
as RT. HIV contains two polypurine tracts (PPT) that are used as a primer for (+)DNA synthesis. 
In the figure, only one PPT is depicted. (D-E) Sketches depicting the stoichiometry of major 
virion components for a (D) WT and (E) ΔVif HIV virion. Figures correspond to insets (D) and 
(E) in panel (A). (D) Low amounts of A3 may escape Vif mediated degradation and become 
virion encapsidated (approximately 1-2 molecules of A3G/virion). (E) A ΔVif HIV cannot 
induce degradation of A3 enzymes which results in the encapsidation of A3 enzymes through an 
interaction with RNA and Gag. Approximately 3-11 molecules of A3G can be encapsidated from 
the virus producer cell. (D-E) Stoichiometry values for virions were obtained from [5, 92-95]. 
Figure reprinted from Feng et al., 2014 [66]. 
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processing, e.g., stress granules or P-bodies, where they may have a role in sequestering human 
retrotransposon RNA to prevent transposition [42, 96-98]. A3 enzymes are Zinc-dependent  
deaminases and they catalyze the conversion of cytosine to uracil in ssDNA substrates. The 
reaction requires the activation of water by a Zn2+ coordinated by the enzyme. A glutamic acid in 
the enzyme active site primes the nucleophilic attack on the C4 position of the pyrimidine ring, 
followed by the removal and protonation of an amino group (NH2) and this leads to the release of 
ammonia (NH3) and formation of uracils as products (for review, see [99]) (Fig. 1.3B). Each 
ssDNA deaminase acts within a preferred di- or tri- nucleotide substrate motif. For A3G this is 
5'CCC or 5'CC (3'-end C preferred for deamination) [91] (Fig. 1.3C). A3D, A3F and A3H and 
A3C I188 deaminate 5’TTC or 5'TC and A3D can also deaminate 5'GC motifs in proviral DNA 
[49, 52, 100].  Since A3 enzymes are ssDNA deaminases, deamination activity is restricted to the 
(-)DNA strand (Fig. 1.3C) [91]. The cytosine (C)→ uracil (U) deaminations catalyzed on the (-
)DNA strand become guanine (G)→adenine (A) mutations when RT uses uracil as a template 
during (+)DNA strand synthesis (Fig. 1.3C) [91]. The resulting ‘hypermutation’ of the provirus 
results in inactivation of HIV (Fig. 1.4A) [22-24]. Although it is known that many proviral 
genomes undergo successful integration with these hypermutations [101], some preintegration 
complexes containing uracils may be degraded by host DNA repair mechanisms, although there 
is no consensus regarding the extent to which this occurs in cells [102, 103]. In cell culture, it has 
been found that the aberrant HIV proteins that may be produced from these proviral genomes can 
act as a source of HIV antigens due to their misfolding and processing through the proteasome, 
which can facilitate immune recognition of HIV [104]. The aberrant HIV protein products 
produced due to A3-induced missense and nonsense mutations could also facilitate the cytotoxic 
T lymphocytes (CTLs) or natural killer cell-mediated clearance of infected cells [104, 105], 
although other reports found that A3-mediated mutations can reduce CTL recognition and induce 
the generation of CTL response escape mutants of HIV [106-109]. 
Although the majority of A3 actions are repressed by Vif in HIV infected individuals (Fig. 
1.4, A,B,D), clinical studies have found that individuals with an inherent ability to express a high 
level of A3G mRNA are less likely to become infected with HIV or progress from HIV to AIDS 
and that the presence of hypermutated proviral genomes correlates with high CD4+ T cell counts 
[110-114]. Other A3 enzymes have not been extensively examined in this regard [100, 115]. 
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However, there is evidence of deaminations in HIV genomes recovered from infected individuals 
due to C/G→T/A mutations in a sequence context that indicates deaminations by A3 enzymes 
other than A3G do occur [100, 111, 113, 114]. For example, a study found that in HIV infected 
individuals suggests there is approximately an equal split between mutations occurring in the 
5'TC and 5'CC contexts on (-) DNA [100]. However, there is difficulty parsing out the effect of 
A3F, A3D, and A3H based on their mutation patterns since they all recognize the minimal 
dinucleotide 5'TC and are more promiscuous than A3G in regards to trinucleotide target site 
preference [49, 52, 78]. Nonetheless, it has become clear that despite some evidence that A3G 
has more mutagenic potential than other A3 deaminases, it is not acting alone against HIV [81, 
100, 116] and proviruses with GG and GA mutation signatures most likely result from copacking 
of multiple A3s and comutation of the same viral genomes in a single round of replication [117] 
(see below). The HIV genomes mutated through A3 catalytic activity are also subject to the 
pressure of purifying selection. This selection pressure results in mutated and inactivated 
genomes being highest in integrated proviral DNA and lowest in circulating viral RNA [101], 
which means only a small proportion of hypermutated genomic RNA can be packaged into 
virions. Further, integrated proviruses that are inactivated by stop codons in the gag gene may 
still be rescued by dual infection of a cell by HIV quasispecies and complementation of Gag 
function [101]. Recombination within virions by RT template switching can result in 
“reactivation” of inactivated viral genomes [101, 118]. As a result, A3-mediated mutagenesis is 
effective, but the complete inactivation of HIV in an infected individual is potentially a long term 
process that is likely to require multiple rounds of exposure to viruses [119]. 
HIV populations generally exhibit high levels of genetic variation and this allows the 
virus to easily acquire drug resistance or escape immune surveillance [120]. The viral genome 
diversity is generated due to the fact that HIV RT lacks proofreading activity [121] and that HIV 
copackages two viral RNA genomes per virion and recombination during viral replication occurs 
frequently [122, 123]. The deamination activity of A3 enzymes can also contributes to HIV 
genetic variation through two mechanisms, namely by introducing sublethal levels of G-to-A 
mutations in HIV (i.e., sublethal mutagenesis) and through copackaging and recombination, 
lethally mutated genome can be rescued by superinfecting the hypermutated provirus-containing 
cells with a replication-competent wild-type virus [76]. The effects of A3-induced G-to-A 
mutations on HIV mutation rate, recombination and the emergence of drug resistance are still 
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under debate. Despite several previous studies that reported A3 enzymes contribute to viral 
genetic variantion and evolution through sublethal mutagenesis [73, 74, 118, 124, 125], other 
studies proposed that A3-mediated hypermutations usually lead to lethal mutagenesis [75, 76, 
126-128]. Recently, Delviks-Frankenberry et al. [76] found that the contribution of A3G or A3F 
hypermutation made to HIV sequence variation and evolution is minimal and is significantly 
small when compared to mutations induced by HIV RT. Also, A3G or A3F-mediated mutations 
do not appear to affect the rate of recombination. Their study [76] reconciles that A3-induced 
sublethal mutagenesis being reported by different groups [73, 74, 118, 124, 125] likely exists, 
but occurs at a low level, therefore its contribution to genetic variation will likely get titrated out 
with each successive replication cycle.    
1.3 A3-mediated restriction of HIV-1 
1.3.1 A3G-mediated restriction of HIV-1 
1.3.1.1 Deamination-dependent restriction of HIV-1 by A3G 
Since A3G was the first A3 enzyme discovered it has been more widely studied and there 
is a wealth of information available to explain how A3G enacts its role as a restriction factor 
(over 900 publications in PubMed). There are two key steps that A3G must complete to be an 
efficient restriction factor. First, the enzyme must be available for binding RNA that will become 
virion encapsidated through interaction with the NC portion of Gag [83-89, 129-131]. Second, it 
must have a mechanism to scan the nascent HIV (-)DNA that is available for a finite period of 
time for potential cytosines that it can deaminate (Fig. 1.4C) [93, 132, 133].  
 A3G exists in cells as a high molecular mass that is bound to RNA and other proteins in 
stress granules and P-bodies [42, 96, 98, 134]. However, only newly synthesized A3G that has 
not associated with host RNAs in these cytoplasmic structures appears to bind the RNA that is 
also bound by HIV Gag and therefore encapsidated into virions [135]. A3G requires 
oligomerization to bind these RNAs effectively in cells and become virion encapsidated [136-
138]. In vitro, oligomerization mutants of A3G can bind many RNAs with less than a 3-fold 
difference from wild type A3G [139, 140]. The RNA binding and oligomerization of A3G is 
primarily mediated by the N-terminal domain (NTD) and the NTD is solely responsible for 
virion encapsidation of A3G (Fig. 1.3A) [56, 57, 138, 140]. The NTD residues 124YYFW127 on 
predicted loop 7 mediate the dimerization of A3G (Fig. 1.3A) [138, 140]. A3G is primarily a 
dimer in solution and when A3G binds RNA or DNA it oligomerizes into tetramers and  
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Figure 1.5 Structures of A3 enzymes. A3 enzymes have a basic structure in each Z-type domain 
that is comprised of a five stranded β-sheet core surrounded by six α-helices. Numerical 
assignments to β-strands and α-helices are superimposed in panel (A). Zinc atoms are shown as 
blue spheres. (A) Model of the N-terminal domain (NTD) of A3G. Loop 7 (L7) of the A3G NTD 
is a central structure in its anti-HIV function. Highlighted on L7 are the residues important for 
interaction with Vif (red, 128DPD130), oligomerization/virion encapsidation (green and cyan, 
124YYFW127), and jumping component of A3G processivity (cyan, 126FW127). Helix 6 (h6) is 
adjacent to L7 and contributes to the sliding component of A3G processivity, particularly 186H 
(cyan). The predicted model of the A3G NTD was obtained by using the automated SWISS-
MODEL program using the homologous A3G C-terminal domain (CTD, PDB: 3IQS). (B) The 
A3G CTD (PDB: 2KEM) is the catalytic domain of A3G and has a discontinuous β2 strand 
forming a loop-like buldge between the β2 and β2' strands. A3G tetramerization is mediated by 
L7 residues 313RIYDDQ318 (green). The L7 residues in all A3 enzymes also determines the 
preferred deamination motif. (C) Model of the NTD of A3F was obtained by using the automated 
SWISS-MODEL program using the homologous A3C structure (PDB: 3VM8). The end of h6 
connects the NTD to the CTD and contains an 190NPM192 motif. This NPM motif is found only in 
A3D and A3F. (D) The A3F CTD (PDB: 4IOU) is the catalytic domain of A3F and interacts 
with Vif. Residues that interact with Vif across Helix 2, 3, 4 and β-strand 4 are shown in red. 
Also shown on this structure is the deamination motif specificity loop (L7) and the 190NPM192 
motif. The structure illustrates the kinked orientation introduced by the Pro in the 190NPM192 
motif, which blocks the sliding function of A3F. (E) Model of the CTD of A3D was obtained by 
using the SWISS-MODEL program using the homologous A3F structure (PDB: 4IOU). Residues 
that interact with Vif across Helix 2, 3, 4 and β-strand 4 are shown in red. The 320C residue on L7 
that influences A3D activity is shown in orange. (F) Model of A3H Hap II showing residues that 
interact with Vif and cause haplotype instability. In A3H Hap II, 121D (red) on predicted h4 
mediates an interaction with Vif. In A3H Hap I the R105G mutation induces protein instability 
(magenta). In A3H Hap III and IV, the deletion of 15N induces protein instability (magenta). 
Figures were made using PyMOL (The PyMOL Molecular Graphics System, Version 1.5.05, 
Shrödinger, LLC.). Figure reprinted from Feng et al., 2014 [66].  
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Figure 1.6 Illustration of DNA scanning by facilitated diffusion. (A) Sketch of DNA showing the 
negative charge region of DNA important for facilitated diffusion of A3 enzymes. (B) Sketch 
depicting a 1-dimensional DNA scanning path by sliding. Dotted line indicates path of enzyme. 
Sliding enables an in-depth search of local areas of a substrate. (C) Sketch depicting a 3-
dimensional DNA scanning path by jumping. Dotted line indicates path of enzyme. Jumping 
enables larger translocations on DNA substrates, but lacks a local search process. The 
microdissociations of the enzyme from the DNA that occur when the enzyme jumps does not 
leave the negatively charged domain of the DNA so the enzyme has a higher likelihood of 
reassociating with the same DNA substrate than diffusion into the bulk solution. (D) Sketch 
depicting a 3-dimensional DNA scanning path by intersegmental transfer. Intersegmental 
transfer enables larger translocations on DNA substrates, but lacks a local search process. An 
enzyme with two DNA binding domains binds two regions of DNA simultaneously before 
dissociating from one region to move to another. Figure reprinted from Feng et al., 2014 [66]. 
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higher-order structures through C-terminal domain (CTD) residues 313RIYDDQ318 on loop 7 (Fig. 
1.5B) [140-142]. It is essential for A3G to enter the inner capsid of the virion to restrict HIV. 
Within the capsid, A3G can associate with the ribonucleoprotein complex and access the (-)DNA 
as it is synthesized. A3 enzymes that cannot encapsidate within the HIV capsid, e.g., A3A and 
A3C, are unable to restrict HIV replication in CD4+ T cells [78, 143]. However, accessing the 
ribonucleoprotein complex does not guarantee the ability to restrict HIV. Since the (-) DNA is 
only available for a finite period of time due to HIV containing two polypurine tracts (PPT) that 
are used to prime (+) DNA synthesis, A3 enzymes require an efficient mechanism to search for 
cytosines (Fig. 1.2 and Fig. 1.4C). Complicating the search is that the (-) DNA contains pieces of 
annealed RNA due to the endonuclease activity of the RT associated RNaseH (Fig. 1.2). A3G 
binds RNA/DNA hybrids less well than ssDNA and encountering these obstacles on the 
substrate can induce A3G to dissociate from DNA [141, 144]. 
 Unraveling the mechanism by which A3G locates its target and catalyzes its deamination is 
of pivotal importance for understanding the mechanistic basis of proviral hypermutation. The 
mechanism with which an A3 enzyme scans non-target DNA in search of its deamination motif 
is a determinant in its catalytic efficiency [133, 139]. DNA scanning is described by the term 
processivity and is defined as the ability of an enzyme to catalyze multiple events in a single 
enzyme-DNA substrate encounter. Enzymes that do not use an energy source for movement on 
DNA use a mechanism termed facilitated diffusion to efficiently search DNA [145, 146]. This is 
a mechanism where the enzymes, subject to Brownian motion, move randomly on DNA. Since 
DNA binding proteins are usually positively charged, the negative charge of the DNA facilitates 
the enzyme movement through electrostatic interactions [145, 146]. A3G is a positively charged 
enzyme (charge of +6.5 at pH 7) and processively scans ssDNA by facilitated diffusion (Fig. 1.6) 
[93, 132]. This mode is distinct from an enzyme that acts on DNA distributively, where only one 
catalytic event occurs before the enzyme disengages from the substrate [147]. Facilitated 
diffusion can involve a variety of movements such as 1-dimensional (D) sliding (Fig. 1.6B) or 3-
D movements such as hopping/jumping (Fig. 1.6C) or intersegmental transfer (Fig. 1.6D) [148]. 
Hopping and jumping describe small micro-dissociations and re-associations with the same DNA 
strand without diffusion into the bulk solution (Fig. 1.6C) [146]. Intersegemental transfer 
involves a two-step mechanism where an enzyme with two DNA binding sites binds a second 
site before releasing the first site (Fig. 1.6D) [146]. Facilitated diffusion works best when both 1-
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and 3- D movements are used to enable local scanning of a small segment of DNA by sliding 
(<20 nt) and movement to distal regions to restart the local scanning process [139, 148]. These 
distal movements do not cause the enzyme to leave the DNA and enter into the bulk solution 
because the charged surface of the DNA keeps the enzyme within the domain of the DNA (Fig. 
1.6C) [146]. Using different methods A3G has been found to scan ssDNA by 1-D sliding 
motions and 3-D jumping motion [132, 149, 150]. However, one study has found that A3G 
moves by 3-D intersegmental transfers [93]. The efficiency imparted by a 3-D movement in the 
specific case of A3G during reverse transcription is that it provides a means of overcoming the 
DNA/RNA hybrid barrier [93, 139]. Clusters of A3G-induced deaminations indicative of 
processive sliding movements have been found in integrated proviral genomes [151] and A3G 
mutants unable to undergo a local searching process by 1-D sliding, such as H186R and A3G 
with an 195NPM197 insertion have decreased mutagenesis during in vitro reverse transcription or in 
HIV proviral genomes [133, 139]. Further, an A3G mutant F126A/W127A that cannot jump has 
decreased mutagenesis during in vitro reverse transcription [139]. These data demonstrate that 
neither movement alone can enable high levels of A3G-induced mutagenesis. Interestingly, the 
F126A/W127A mutant is monomeric, suggesting that the oligomeric state of A3G plays a role in 
efficient restriction of HIV not only by facilitating virion encapsidation but also by facilitating 
the DNA scanning process [138-140]. The processivity determinants of A3G reside on predicted 
loop 7 and helix 6 of the noncatalytic NTD (Fig. 1.3A) [139]. Thus, despite a lack of catalytic 
activity, the NTD contributes to A3G deamination activity by mediating the processive scanning 
mechanism. 
1.3.1.2 Deamination-independent restriction of HIV-1 by A3G 
 A3G primarily restricts HIV replication through its deamination activity. However, there 
have been numerous reports of an ability of A3G to physically inhibit other processes of HIV 
such as RT polymerization [152-157], NC strand annealing [158, 159], and proviral DNA 
integration [156, 160]. These processes do not occur in isolation from deamination, nor do they 
restrict HIV better than deamination alone [156, 157]. I will focus the discussion on inhibition of 
RT polymerization since this is the most prevalent mechanism studied.  
 Early studies of A3G-mediated restriction of HIV proposed that transiently overexpressed 
wild type A3G and deamination null mutants of A3G could inhibit HIV proviral DNA formation 
[23, 161]. The initial mechanism proposed was that A3G binds the HIV genomic RNA which 
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impedes RT [152]. This has been confirmed in multiple reports using cellular and biochemical 
experiments [155, 156, 162]. However, the physiological significance of these processes is 
difficult to reconcile since results from cell-based experiments cannot be replicated when A3G is 
stably expressed, suggesting that overexpression of A3G induced experimental artifacts due to 
excessive packaging of A3G in virions [151, 163-165]. Importantly, studies that used 
deamination null mutants of A3G to show that deamination ability is required for restriction of 
HIV [163-165] should be considered in conjunction with data showing that the A3G E259Q 
catalytically inactive mutant is not a true proxy for A3G [153, 155]. A3G E259Q binds RNA less 
well than A3G and this results in less inhibition of RT in vitro and in cells [153, 155]. 
Nonetheless, it is clear that the ability of A3G to inhibit RT is highly dependent on A3G 
concentration and the primer/template [151, 155, 163-165]. The initiation of DNA synthesis 
from an RNA primer on an RNA template is the least efficient type of polymerization activity of 
RT [166]. Accordingly, in vitro, low levels of A3G can best inhibit RT-mediated primer 
initiation at this step by competing for substrate with RT [152, 155]. In contrast, on a DNA 
primer and DNA template, A3G could at most inhibit initiation of synthesis by RT 2-fold under 
single turnover conditions and could not block RT from binding the primer/template, but merely 
lengthened the time RT required to find the free 3'OH [155]. These data are in agreement with a 
computational study that suggests an A3G-mediated deamination-independent mode of HIV 
restriction contributes <1% of the restriction capability of A3G [167]. Although studies have 
shown that a peptide of A3G can interact with RT and inhibit RT-mediated DNA synthesis, it is 
unlikely that this mechanism is a physiological way to inhibit reverse transcription since in rVif 
virions, only approximately 7 A3G molecules are encapsidated whereas there are approximately 
100 RT molecules (Fig. 1.4E) [5, 92, 154]. In the presence of Vif, there is only an estimated 1-2 
molecules of A3G per virion (Fig. 1.4D) [93], emphasizing the importance of deamination over a 
deamination-independent mechanism. A single molecule of A3G could inactivate an HIV 
provirus through cytosine deamination whereas the deamination-independent mechanism is 
much more concentration dependent [151, 155]. Single-molecule studies have brought forth the 
model that A3G oligomers can act as a road-block for HIV [162]. An additional component to 
this “road-block” model is that A3G can change the structure of DNA and RNA, presumably by 
wrapping or bending the substrate which may enable it to compete with RT for substrate binding 
and delay location of primer termini by RT [141]. Notably, existence of a deamination-
	 23	
independent mode of HIV inhibition has been observed ex vivo in primary cells [157], but 
requires further research as to the significance of this mode of inhibition during an HIV infection. 
1.3.2 A3F-mediated restriction of HIV-1 
1.3.2.1 Deamination-dependent restriction of HIV-1 by A3F 
 Approximately 2 years after the discovery of A3G, A3F was discovered to also exhibit 
restriction activity against HIV [49-51]. Sequenced HIV proviral genomes were known to 
contain G/C→A/T transition mutations in 5'CC and 5'TC contexts in the (-)DNA [168-170], and 
A3F was found to contribute to the transition mutations in the 5’TC context. Of these initial 
studies demonstrating A3F activity active against HIV [49-51, 171], all except one [172] found 
that A3F restriction activity was equivalent to A3G restriction activity. It has since been shown 
that overexpression of A3 enzymes can result in excessive packaging into HIV virions and result 
in artifacts of HIV restriction [92, 164, 165]. Yet even after 10 years of studying A3F, multiple 
groups still find different activities of A3F against HIV that cannot be attributable to 
overexpression, but perhaps different experimental systems and techniques [78, 81, 133, 173, 
174]. However, A3F must exert a restriction pressure on HIV since Vif maintains an interaction 
with A3F that is distinct from A3G in order to induce A3F degradation [175]. As with A3G, for 
A3F to be an effective restriction factor against HIV, it must be encapsidated with the 
ribonucleoprotein complex within the capsid and effectively search for cytosines on the 
heterogeneous (-)DNA substrate [133]. 
 A3F encapsidates into HIV virions through an interaction with RNA, but packages more 
efficiently than A3G into the core of HIV particles [131, 172, 176]. By resolving HIV capsids on 
a sucrose gradient to observe whether A3F and A3G partition with the RNA and enzymes or the 
p24 capsid protein, Song et al. [176] found that more A3F specifically associated with the 
ribonucleoprotein complex, in comparison to A3G. A3F binds RNA with 7-fold higher affinity 
than A3G [133], which may enable it to package more specifically within the capsid [176]. 
Furthermore, A3F has been shown to bind double-stranded DNA with a higher affinity than A3G 
and maintain an association with the pre-integration complex of HIV as it enters the nucleus 
through its high affinity nucleic acid binding [177, 178]. The original functions of A3s were 
against unknown retroelements and A3F and A3G may have specifically evolved to inhibit 
different ones where these different nucleic acid binding abilities were beneficial. Although 
some reports show A3F can be less effective than A3G in restricting HIV [81, 133, 173, 174, 
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176], it cannot be concluded that it does not suppress HIV or impose selective pressure on HIV. 
It is not only because of data showing A3F can effectively restrict HIV in spreading infections 
[78, 80], but also because an HIV lab strain with tandem stop codons in Vif (from HIV NL4-3) 
will revert back to expressing a functional Vif  in the presence of A3F [179]. This does not occur 
when A3G is used in the same type of forced evolution experiments [180, 181]. The HIV evolves 
to overcome A3G restriction, but does so by acquiring a 5'UTR mutation to make HIV RNA 
transcription more efficient and altering the cell cycle through a Vpr mutation [180, 181]. 
Together these mutations result in more virus particles being produced. Presumably since A3G 
has less specific packaging in the capsid than A3F, this strategy titrates out the 
ribonucleoprotein-packaged A3G, enabling the HIV to escape high levels of mutagenesis. These 
data illustrate that A3G and A3F exert a distinct selective pressure on HIV due to distinct 
biochemical properties and that A3 packaging into virions is a necessary but insufficient step to 
ensure efficient HIV restriction. 
 To further understand why A3F-mediated restriction of HIV may be different than for A3G, 
Ara et al. [133] undertook a biochemical study of A3F in comparison to A3G to identify 
biochemical differences between these enzymes that could account for differences in restriction 
efficiency. They found that in contrast to A3G, A3F used only 3-D jumping motions to scan 
ssDNA. This made the DNA scanning mechanism inefficient since A3F could translocate 
between many ssDNA regions and overcome intervening RNA/DNA hybrid regions, but lacked 
a local search mechanism to examine ssDNA regions for its 5'TC motif (Fig. 1.6). The A3F 
sliding movement is blocked by a 190NPM192 motif in the connection domain between the NTD 
and CTD since mutagenesis of this motif to 190NGM192 enabled A3F to slide [133]. Bohn et al. 
[182] reported an A3F CTD structure that includes the 190NPM192 sequence and showed that it is a 
kinked region of the loop structure. Since an A3F 90NGM192 mutant was able to slide, the data 
suggest that the rigid 191P residue primarily blocks sliding [133]. However, imparting sliding 
movement to A3F through the 90NGM192 mutant did not increase A3F HIV restriction efficiency 
because the jumping movements of A3F differed from A3G and were dominant over sliding 
which maintained an inefficient search of ssDNA [133]. The differences in DNA scanning 
between A3F and A3G were shown to be relevant to HIV restriction since A3F was 4-fold less 
effective in restriction of HIV than A3G in a single-cycle infectivity assay [133]. Of note, A3F 
was also shown to have a 100-fold lower specific activity than A3G [133] but this was not 
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thought to contribute to differences in restriction efficiency since studies with different A3G and 
A3F mutants showed that mutagenesis efficiency correlated with the efficiency of the ssDNA 
scanning mechanism, not the specific activity. This is likely because RT polymerization and 
RNaseH activity limit the (-)DNA substrate available [183]. The study by Ara et al. [133] is in 
agreement with studies where A3F has not been as effective as A3G in restriction of HIV [81, 
173, 174], although A3F was found to be as restrictive to HIV replication as A3G in other 
reports [78, 80]. Despite A3F being considered in some reports to be less efficient than A3G as 
an HIV restriction factor when considered side by side, this is far from the natural mechanism of 
these enzymes in which they act in concert [80, 100].  
 It is of note that Zennou and Bieniasz reported that per mutation, A3F was less likely to 
inactivate HIV than A3G [172]. This was later found to be because the 5'CC motif of A3G 
overlaps with the only Trp codon (5'TGG/ACC) and results in a stop codon upon deamination of 
either cytosine in the motif. In contrast, A3F induced mutations largely result in missense 
mutations which may or may not inactivate the encoded protein. The A3G 5'CC motif also 
overlaps with Gly codons and in the HIV prot mutations at these Gly results in more 
nonconservative mutations and gene inactivation than A3F-induced missense mutations that 
primarily cause the conservative mutation of Glu to Gln [133]. The determinant for motif 
specificity is loop 7 in the CTD (Fig. 1.5, B and D) [184-187]. This loop can be grafted into 
different A3 enzymes to change site specificity [185]. However, the consequences of 
deamination-mediated restriction can be independent from inducing amino acid changes. A3F 
and A3G may be able to block proviral integration through deoxycytidine deaminations that 
result in aberrant processing of the proviral DNA ends by HIV integrase and inhibition of plus-
strand DNA transfer by reducing the efficiency of primer tRNA removal [163, 177]. 
1.3.2.2. Deamination-independent restriction of HIV-1 by A3F 
 For many years, A3F was thought to have a stronger deamination-independent mode of 
inhibiting HIV than A3G [188, 189]. Unlike A3G, the mechanism of deamination independent 
“activity” was not extensively studied, but was presumed to be due to inhibition of RT 
polymerization. A computational study has found that A3G and A3F rely differentially on their 
deamination independent modes of HIV restriction with A3G only having the deamination 
independent mode contributing to <1% of its restriction activity whereas for A3F this value was 
approximately 30% [167]. However, two studies using stably expressed A3F and A3F catalytic 
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mutants C280S/C283A and E251Q demonstrated no inhibition of RT, suggesting that previous 
results were influenced by A3F overexpression artifacts [173, 190]. Another study showed that 
A3F can inhibit HIV integration by reducing 3' processing of viral DNA at the U5 and U3 ends 
by integrase [177]. Using a catalytic mutant of A3F (E251Q), the study found that inhibition of 
integration was decreased approximately 2-fold from that of wild type A3F suggesting that 
catalytic activity is in part required to produce the aberrant U5 and U3 ends [177]. Thus, there 
appears to be consensus that despite the potentially inefficient mutagenic activity of A3F in some 
studies, the deamination activity of A3F is still dominant over the deamination-independent 
activity. Further, if a deamination-independent mode of HIV inhibition functions in cells, it may 
be the inhibition of integration rather than RT [177].  
1.3.3 A3D-mediated restriction of HIV-1 
 A3D was first characterized in 2006 to restrict HIV replication in single-cycle infectivity 
assays and to be suppressed by Vif, suggesting that it posed a restriction pressure on HIV[52]. 
Further evidence of this was that HIV proviral genomes showed evidence of deaminations in 
both the contexts of 5'CC, 5'TC, and 5'GC [52]. A3D was found to deaminate in the 5'TC and 
5'GC contexts which were unique from A3G and A3F that maintain less promiscuous 
deamination motif preferences [52]. A3D also forms multimers through an RNA intermediate in 
cells with a similar profile as A3G [191]. In a clinical study of HIV infected individuals, A3D 
was found to be upregulated in both Elite Controllers (low viral load) and in Non-Controllers 
(high viral load) but was down-regulated in response to successful anti-retroviral treatment, 
indicating that A3D is indeed part of an immune response to HIV [192]. However, the restrictive 
activity of A3D appears less than A3G and A3F in single cycle infectivity assays in cell lines 
[52, 193] and spreading infections in primary human cells [81]. Further, A3D represents the most 
divergent A3 enzyme in the lineage of chimpanzee to human and the activity of A3D has 
decreased from chimpanzees to humans [47]. Chimpanzee A3D induces more hypermutation of 
HIV than human A3D, despite equivalent packaging into virions [47].  This was attributed to 
differences in loop 7 of the CTD [47, 193]. One report found a single amino acid in the CTD 
loop 7, C320, that suppressed A3D antiviral activity (Fig. 1.5D) [193]. If the C320 was replaced 
with a Tyr, as in A3F, the activity of A3D could be increased by more than 20-fold [193]. In 
contrast, endogenous A3D from the T cell line CEM2n appears to have activity against HIV-1 
that is similar to A3F [80]. Using a series of A3 null backgrounds or A3 knockdowns, Refsland 
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et al. [80] found that the HIV-1 proviral hypermutation pattern at 5'CC and 5'TC sites was 
induced at comparable levels by the combined action of A3G and A3F or A3G and A3D, 
suggesting a redundancy in the HIV-1 restriction mechanism.  
1.3.4 A3H-mediated restriction of HIV-1 
 A3H was originally identified as not being able to restrict HIV replication due to low steady-
state protein levels in cells, despite normal mRNA expression [52, 194]. However, when A3H 
was recombinantly expressed in Escherichia coli (E. coli) it could mutate the E.coli genomic 
DNA. In later studies, it was realized that A3H exists as multiple haplotypes in the human 
population (Hap I-VII) with different stabilities in cells and HIV restriction capabilities (Table 1) 
and the original A3H tested was an unstable form (Hap I) [45, 195]. The unstable Hap I is the 
most prevalent form of A3H in the population (Table 1) [196], but is able to restrict HIV 
infection by approximately 2-fold when transiently overexpressed in cell lines [45, 195, 197, 
198]. Two amino acid polymorphisms, 105G and Δ15N, can independently contribute to the 
instability of A3H (Table 1). A3H Hap I is unstable due to a Gly at position 105 [45]. An A3H 
Hap I G105R mutant (later identified as Haplotype VII, Table 1) renders the A3H stable in cells 
and imparts strong anti-HIV activity [45, 195]. Other unstable A3H haplotypes (III and IV) have 
the Δ15N in combination with another polymorphism (Table 1) [45, 195]. A3H polymorphisms 
have been shown to be associated with HIV susceptibility in different ethnic groups [199, 200], 
as the haplotype frequency of unstable A3H Hap III is low and that of the stable A3H Hap II is 
high in HIV long term non-progressors, indicating the expression of a stable A3H haplotype may 
help in delaying disease progression to AIDS.   
 It is not known biochemically why these A3H haplotypes are unstable, but comparative 
modeling of A3H with the structure of a related family member APOBEC2 shows that amino 
acid 105 is in a β-strand within the enzyme core five stranded β-sheet, suggesting that a R105G 
mutation could destabilize the core structure (Fig. 1.5F). The Δ 15N is predicted to be within a 
loop structure (Fig. 1.5F) so it is difficult to predict the reason for the instability in this undefined 
region, but it is known from studies with A3F that deletions to a loop that connect the NTD and 
CTD cause protein instability [133], suggesting that the A3H loop may need to be of a specific 
length for proper protein folding. Although different haplotypes (II, V and VII) have been 
reported to exist in the population as stable forms that are able to restrict HIV (Table 1), in this 
review we focus only on A3H Hap II (A3H Hap II), which has been the most highly studied.  
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 Table 1. Summary of A3H Haplotype features     
 a[198] 
b [45] 
A3H 
Haplotypes 
Polymorphic amino acid 
residues 
Antiviral 
activity in 
cell 
culture 
Protein 
stability 
Haplotype 
frequency References 
Δ15 18 105 121 178 
Hap I N R G K E Partial No 0.526
a 
0.308b 
[45, 78, 100, 194, 195, 
197, 198, 201] 
Hap II N R R D D Yes Yes 0.061
a 
0.265b 
[45, 78, 100, 197, 198, 
201] 
Hap III Δ R R D D No No 0.070
a 
0.114b [45, 100, 198]  
Hap IV Δ L R D D No No 0.088
a 
0.178b [45, 195, 198] 
Hap V N R R D E Yes Yes 0.202
a 
0.054b [45, 198] 
Hap VI Δ L G K D No No 0.026
a 
0.0004b [45, 198] 
Hap VII N R R K E Yes Yes 0.009
a 
Not Detectedb [45, 198] 
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Notably, A3H Hap II has some variability in its restriction ability which is dependent on 
alternative mRNA spliced forms [195]. A3H Hap II is primarily found in Africans/African 
Americans (~50%) and to a much lesser extent within other cultural populations (prevalence of 
approximately 0-8%) [45, 198]. Furthermore, an inverse correlation between the presence of Hap 
I and Hap II in different human populations has been established [202], where when A3H Hap II 
is common then A3H Hap I is rare (Africa) and when A3H Hap I is common then A3H Hap II is 
rare (Southeast Asia). It has been proposed that A3H evolved to become unstable due to a 
combination of the loss of an ancient pathogen and the ability of an ancestral A3H to induce 
mutagenesis of genomic DNA [36, 45]. Indeed, human A3H Hap I has been identified as an 
endogenous mutagen based on the findings that A3H Hap I has nuclear localization propensity, 
demonstrates enzymatic activity and is associated with the APOBEC mutation signature in breast 
tumours lacking A3B [202]. In accordance with the idea that A3H Hap I contributes to cancer 
mutagenesis, Zhu et al. [203] found that the T allele of rs139293, a SNP on A3H exon 2 that 
resulted in amino acid substitution from Arginine to Leucine at codon 18 and was predicted to 
have a deleterious effect on the structure and function of A3H, was significantly associated with 
reduced risk of lung cancer in Chinese population [203]. Therefore, it appears inactive forms of 
A3H may protect people from developing lung cancer.    
 A3H is the only common A3 enzyme with highly diversified antiviral activities based on 
sequence polymorphisms [197, 204] and appears to be in a category of its own in relation to 
other A3 enzymes regarding two other aspects. First, A3D, A3F, and A3G that also restrict HIV 
replication have two Z-type domains, whereas A3H has only one Z-domain (Fig. 1.3A) [37]. 
Phylogenic analyses have shown that the A3 members have three distinct Z-type domains (Z1, 
Z2, and Z3) and A3H is the only A3 enzyme with a Z3 (Fig. 1.3A) [37]. A3D and A3F have two 
Z2 domains and A3G has a Z1 (CTD) and Z2 (NTD) domain (Fig. 1.3A) [37]. Second, A3H is 
the only single Z-type domain A3 (others are A3A and A3C) that forms oligomers and 
multimers. Structural and biochemical studies have found that A3A and A3C are largely 
monomeric (>90%) in solution and do not multimerize in cells through an RNA intermediate 
[191, 205-209]. In contrast, A3H Hap II was found to multimerize in cells [191]. The A3H Hap 
II multimerization in cells was shown by fluorescence fluctuation spectroscopy and determined 
that multiple A3H Hap II molecules could closely associate on RNA, not that A3H Hap II 
oligomerized through a protein-protein interaction [191]. However, we have found using size 
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exclusion chromatography that A3H Hap II can form a dimer in solution in the absence of RNA 
or DNA [66, 210]. A3G and A3F also form oligomers in the absence of nucleic acid supporting 
the idea that A3 oligomerization ability facilitates the multimerization of A3 enzymes with RNA 
in cells [133, 140, 150]. It has been shown that similar to A3G and A3F, A3H Hap II interacts 
with cellular RNA and the NC portion of Gag to facilitate its encapsidation into HIV particles 
[198, 201]. Studies on A3H Hap II and Hap I have also shown that cytoplasmic localization 
correlates with restriction efficiency since mutation of A3H Hap I to make it cytoplasmic 
(G105R) increases its restriction capacity despite other amino acid differences from A3H Hap II 
[195, 211]. Additionally, virion mislocalization of certain A3H haplotypes may render them less 
active against HIV [212]. For example, despite nuclear localization of A3H Hap I, it can be 
encapsidated into HIV particles, but through an association with the matrix and capsid region of 
Gag, which leads to its primary localization outside the capsid [212]. These data suggest that 
both cellular and virion localization play a role in restriction efficiency.  
 Studies on the biochemical properties of A3H suggests A3H Hap II prefers to deaminate 
ssDNA at 5'TC sites, similar to A3F and A3D [210, 213, 214]. Through biochemical 
characterizations of A3H Hap II and Hap V, it was determined that A3H can utilize both 3-D 
jumping and intersegmental transfer and 1-D sliding during ssDNA scanning, and that the 3-D 
translocation mechanisms of jumping and intersegmental transfer are redundant [210]. A3H 
primarily dimerizes in solution through amino acid residues 44RGY46 on β2 strand and upon 
ssDNA binding it tetramerizes through amino acid residues 112YYHW115 on loop7 [210]. A3H is 
the only Z3-type deaminase [37] and appears to be the only A3 that oligomerizes in this manner. 
The C-terminal domain (Z1-type domain) of the double-domained A3G dimerizes through CTD 
loop7 (Fig. 1.5B) [138, 140] and the Z2-type single-domained A3C, A3F CTD and rhesus 
macaque A3G NTD dimerize through helix 6 [182, 215, 216].   
1.3.5 A3C I188-mediated restriction of HIV-1 
 A3C has the lowest nucleotide diversity amongst all A3 genes [204]. Although the common 
human A3C with a Serine (S) at amino acid position 188 has weak antiviral activity against HIV, 
A3C is polymorphic at this site and I188 is present at around 10% frequency in the African 
population [82, 204]. A3C I188 also demonstrated a 3 to 10-fold more potent antiviral activity as 
compared to the common human A3C [82, 216] and the difference in the anti-HIV activity of the 
A3C S188 and I188 was due to the enzymatic efficiencies of the two A3Cs. The stronger enzyme 
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specific activity and processivity of A3C I188 correlates with its increased dimerization [82, 
216]. 
1.3.6 Restriction of HIV-1 by coordinately expressed A3 enzymes 
 Vif-deficient HIV was found to show replication defects when produced from cell lines such 
as CEM and H9, resulting in their classification as nonpermissive cell lines [217-222]. After 
many years of investigating the function of Vif and trying to understand the dichotomous 
phenomenon of permissive and nonpermissive cell lines for rVif HIV, Sheehy et al. [25] found 
that the nonpermissive CEM cell line expressed A3G. Thereafter, many groups discovered that 
Vif was required to induce degradation of A3G to enable HIV replication [63, 64, 70, 223-225]. 
Later, it was realized by analyzing the mRNA expression levels of A3s using quantitative PCR in 
permissive (CEM-SS, SupT1) and non-permissive (CEM and H9) T cell lines that the classical 
nonpermissive CEM T cell line expressed not only A3G but also A3F and A3D, albeit with 
lower mRNA levels [116].  
 Because different A3s demonstrate unique mutation signatures (see above), evidence for 
multiple A3s mutating the same integrated proviral genome has been obtained when mutation 
sequence contexts indicative of A3-mediated deaminations have been identified [111, 168, 226-
229]. It has been found that A3G can co-package into the same virion with A3F or A3H without 
competing for encapsidation and these A3s also act cooperatively to increase HIV inhibition by 
co-mutating the same genome in a single round of replication in both cell culture and in proviral 
DNA recovered from primary peripheral blood mononuclear cells (PBMCs) of chronically 
infected HIV-1 patients [117]. Ara et al. [230] investigated mechanistically how co-expression 
increases the mutagenic activities of A3G and A3F and they found that one molecule of A3G and 
three molecules of A3F can form hetero-oligomers in the absence of RNA and this A3F/G 
hetero-oligomer has distinct biochemical properties and functionalities from the individual 
enzymes [230]. A3F appears to increase the processive jumping ability of A3G when they form a 
hetero-oligomer and this enhances the ssDNA scanning abilities for the deamination motif, 
which serves as an indicator of A3’s mutagenic potential [133, 230]. On the other hand, that 
A3G increases the amount of mutations being induced by A3F was due to A3G allowing A3F to 
inhibit reverse transcription more efficiently, which provides more time for A3F to search for 
and deaminate the target motif in (-)cDNA [230]. In regards to other A3 enzymes’ abilities to 
cooperate during HIV infection, it has been found that A3D cannot co-mutate the genome along 
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with A3G efficiently because of its low virion encapsidation level [117], A3H activity can be 
increased synergistically in the presence of A3G [117], and that the combination of A3F and 
A3H activities is much weaker than the combination of A3G and A3F activities [229].   
 In primary CD4+ T cells, A3 enzymes relevant to HIV restriction are expressed and further 
induced by mitogens, rather than interferon, indicative of their function in restricting 
retrotransposons [116, 231]. In contrast, in macrophages, monocytes and dendritic cells 
expression of select A3 enzymes is induced by interferon [116, 231]. Although A3 enzymes are 
not individually expressed in cells as shown in many laboratory experiments [80, 116], there is 
an advantage of individual expression of each A3. Individual expression of A3 enzymes enables 
mechanistic information to be obtained about enzyme function and mutational footprints to be 
established. However, A3s with perhaps a lesser restriction efficiency would not be expressed 
alone during an HIV infection suggesting that it may not matter per se which enzyme is most 
effective since they may each contribute cooperatively to HIV restriction. Gillick et al. [157] 
found that in primary human CD4+ T cells the majority of proviral mutations were in a sequence 
context that indicated A3G-induced mutations are dominant (5'CC), but A3F- and A3D- induced 
mutations (5'TC context) were evident at 9-fold less frequency than the 5'CC context in rVif 
HIV. This is in contrast to a study reported by Ooms et al. [100] that used PBMCs to examine 
the hypermutation of HIV in the absence or presence of A3H Hap II. In the absence of A3H Hap 
II it was found using a deep sequencing approach that there was approximately an equal number 
of mutations originating in 5'CC and 5'TC contexts, suggesting that A3F and A3D cooperate to 
induce a equivalent number of mutations to A3G [100], in agreement with results from a CEM2n 
T cell line [80]. In the presence of Vif that could induce degradation of all A3s except A3H Hap 
II, there was a large number of mutations in the 5'TC context demonstrating that A3H when 
present in a stable form is highly active against HIV. 
 Although the use of spreading infections in primary cells or T cell lines support the idea that 
A3s cooperate, there still may be a question of whether they induce HIV evolution. It has been 
proposed that if there is an insufficient amount of A3-induced hypermutation this may benefit 
HIV and contribute to sequence variation by induction of sublethal levels of mutagenesis which 
results in HIV evolution [74, 109, 118, 124]. There is evidence that A3G and A3F hotspots are 
enriched in immunogenic CTL epitopes and that HIV may utilize A3s to induce immune escape 
[109]. In addition, A3G may be able to induce resistance to the RT inhibitor lamivudine (3TC) 
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because its deamination motif overlaps with a codon for Met and results in a M146I mutation in 
the pol gene [74, 118]. However, the frequency of this mutation being induced by A3G versus 
RT activity has been questioned [126]. It is also not known if A3F/A3D/A3H Hap II induce this 
evolution any more than A3G, due to differences in inactivation potential derived from their 
sequence specificities [91, 133, 172, 206] and if this impacts disease progression in infected 
individuals. On the other hand, Vif has been shown to adapt within HIV infected individuals and 
to be less effective in inducing A3 degradation [73, 125, 232]. It is thought that HIV can utilize 
Vif as a mutational rheostat in times of viral stress by allowing low amounts of A3s into viral 
particles to induce sublethal mutagenesis [73, 125]. These types of studies have raised the idea 
that perhaps inducing hypomutation or shutting off A3 enzymes may benefit HIV infected 
individuals [233, 234]. 
1.4 HIV-1 Viral infectivity factor (Vif) 
1.4.1. General properties of Vif 
 The main function of Vif was not fully understood for the first decade of HIV research. It 
was not known why, but the presence of Vif made some cell lines permissive for producing HIV 
particles capable of undergoing another round of infection [235, 236]. Nonpermissive cells 
allowed a rVif HIV to produce virus particles, but they were rendered noninfectious upon 
infection of fresh cells. Two labs discovered that Vif repressed a host factor [221, 222]. It was 
later identified by subtractive hybridization that A3G (originally called CEM15) was the host 
factor that was highly packaged into virions in the absence of Vif and blocked infection in the 
next target cell (Fig. 1.4A) [25]. Although this is clearly a primary role for HIV infectivity, Vif 
was also shown to influence HIV particle morphology and this may relate to its potential role as 
a nucleic acid chaperone [220, 237-239]. Although Vif is expressed by all HIV strains, its 
sequence varies considerably amongst different HIV isolates [240].   
1.4.2 Vif as an E3 ubiquitin ligase substrate receptor 
Canonically, CBFβ functions as a transcription cofactor to the RUNX family of 
transcription factors to regulate the expression of genes involved in T lymphocytes and bone cell 
development [241]. In 2012, it was discovered that Vif interacts with CBFβ for stability in cells 
[68, 69]. The interaction is mediated through Vif amino acids 84GxSIEW89 and 102LADQLI107 (Fig. 
1.7, A and B) [242, 243]. The Vif/CBFβ complex is also required for in vitro stability of Vif  
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Figure 1.7 Structure of Vif and host interacting partners. (A) Domain organization of Vif. Vif 
uses specific motifs to interact with A3G (magenta, 40YRHHY44), A3F/A3C/A3D (red, 
11WQxDRMR17 and 74TGERxW79), and A3H (orange, 39F and 48H). In conjunction with these 
specific motifs, there are shared interaction motifs for A3F and A3G with Vif (pink, 
21WKSLVK26 and 69YWxL72). CBFβ interacts with Vif through two adjacent motifs (cyan, 
84GxSIEW89 and 102LADQLI107). The Zinc finger region (green, amino acids 108-139) 
coordinates the Zinc through an 108H114C133C139H motif and stabilizes Vif structure, which 
indirectly enables an interaction with Cullin 5 (Cul5). Direct interaction of Vif with Cul5 is 
through amino acids 120IRxxL124. The BC box mediates an interaction with Elongin C (green 
144SLQYLA149). Vif oligomerizes through a PPLP motif (grey, 163PPLPx4L169). Slanted lines are 
used to indicate intervening amino acids between the domains. (B) The crystal structure of Vif 
(wheat) shows that it has two domains on either side of a bound Zinc (blue). The N-terminal α/β-
domain consists of a five stranded β-sheet, a discontinuous β-strand and three α-helices. The 
α/β-domain contains the binding interface for CBFβ (cyan, 102LADQLI107, 84GxSIEW89) and A3 
enzymes. The 11WQxDRMR17 motif (red) is used to interact with A3F, A3C, and A3D, the 
40YRHHY44 motif (magenta) is used to interact with A3G, and residues 39F and 48H (orange) are 
used to interact with A3H. The α-domain contains two alpha helices that mediate two separate 
interactions with EloC (green, 144SLQYLA149) and Cul5 (green, 120IRxxL124). (C) Structure of 
HIV Vif (red) in complex with CBFβ (cyan), Elongin C (EloC, yellow), and the N-terminal 
domain of Cullin 5 (nCul5, orange). Elongin B (EloB, magenta) dimerizes with EloC. Figures 
were made using PyMOL (The PyMOL Molecular Graphics System, Version 1.5.05, Shrödinger, 
LLC.). Figure reprinted from Feng et al., 2014 [66].  
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and enables recombinant expression of Vif in a largely soluble form in E. coli that can be 
purified for biochemical studies [244]. In contrast, Vif alone expressed in E. coli accumulates in  
inclusion bodies and must be purified under denaturing conditions [245]. To suppress A3 action 
Vif interacts directly with A3 enzymes and mimics the human protein suppressor of cytokine 
signaling-2 (SOCS2) to become the substrate recognition subunit of a Cullin 5 (Cul5) E3 
ubiquitin ligase complex (Fig. 1.4B).  
Vif interacts with host proteins Elongin C, an obligate heterodimer with Elongin B 
(EloB/C) and Cul5 [70, 246-251]. The interaction of Vif with EloB/C increases the stability of 
Vif in cells and in vitro and promotes recruitment of CBFβ [252]. The interaction of Vif with 
EloC is mediated through a SLQ motif in Vif termed the Elongin B/C (BC) box (Fig. 1.7, A and 
B, 144SLQYLA149) [70, 91], similar to human SOCS proteins [253, 254]. Distinct from human 
proteins is that Vif does not have the highly conserved Cys in the BC box and instead has a 149A 
[253-255]. The data with Vif suggests that it is the short side chain of the amino acid at position 
149 rather than the Cys that is required for the interaction with EloC [70, 250]. Vif also does not 
contain a canonical Cul5 box [248, 249].  In the search for the presence of conserved Cys in the 
BC box, two other Cys (114C, 133C) were identified in Vif upstream of the BC box and were found 
to be involved in binding with Cul5 [70, 247]. These Cys were found to be part of a novel Zinc 
binding HCCH motif (Fig. 1.7, A and B, 108Hx2YFxCFx4IRx2LxGx6CxYx3H139). The Zinc 
coordination in the HCCH was predicted to stabilize a small domain of Vif and indirectly 
support Cul5 binding [248]. The primary Vif amino acids that contact Cul5 are hydrophobic 
amino acids at positions 120 and 123-124 in a helix that is adjacent to the HCCH residues (Fig. 
1.7, A and B, 120IRxxL124) [72, 256]. The Vif/CBFβ/EloB/C heterotetramer undergoes a 
conformational change that promotes binding to Cul5, suggesting that there is a prescribed order 
in the assembly of the E3 CRL5 ligase complex [257]. Accordingly, Cul5 binds less well to 
EloB/C in the absence of Vif/CBFβ [256].  
 A recent structural study of Vif bound to CBFβ/EloB/C/Cul5 shows that Vif has an overall 
elongated cone structure and contains two domains with a Zinc binding domain in the center of 
the two domains (Fig. 1.7C) [256]. CBFβ binds the N-terminal α/β-domain and the EloC and 
Cul5 bind the C-terminal α-domain of Vif (Fig. 1.7C) [256]. Both EloC and Cul5 interact with 
Vif through hydrophobic interfaces on distinct α-helices [249, 256]. The crystal structure also 
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emphasizes the stability that CBFβ imparts to Vif since they have a total interaction surface area 
of 4,797 A2 and form an antiparallel β-sheet with a β-strand from each protein [256]. The side of 
CBFβ that is bound by Vif is the same side that the human CBFβ binding partner, the RUNX1 
transcription factor, binds to, suggesting a mutually exclusive binding [256, 258], although other 
reports show CBFβ can bind Vif and RUNX1 on distinct surfaces [69, 259, 260]. Functionally, 
Vif appears to exclude CBFβ from binding RUNX1 because overexpression of Vif can alter the 
transcription profile of nearly 100 genes that are known to be regulated by RUNX1 in Jurkat T 
cells and suggests that Vif may have multimodal effects in HIV infected cells [258]. In support 
of this, Anderson et al. [261] found that CBFβ interaction with RUNX protein is required for A3 
gene expression in CD4+ T cells, indicating that by hijacking CBFβ, Vif is able to suppress A3 
activity both post-translationally through degradation and transcriptionally by precluding RUNX/ 
CBFβ complex formation. CBFβ is only required by primate-specific pathogens, such as HIV 
and SIV, for Vif to function [259] and CBFβ is dispensable for the activity of non-primate 
lentivral Vif proteins. Lentiviruses that infect cats (feline immunodeficiency virus), cattle 
(bovine immunodeficiency virus) or sheep (maedi-visna virus, MVV) appear to lack an 
analogous cofactor or to have adapted to use a different cellular cofactor. For example, 
Cyclophilin A (CypA) [262] is used for MVV to stabilize Vif [262, 263]. Because mammalian 
hosts of these viruses have simpler A3 repertoires [37], it has been proposed that adaptation to 
hijack CBFβ and overcome A3s at both the transcriptional and post-translational level is a ‘gain-
of-function’ adaptation that Vif adopted in order to conquer the zoonotic barrier created by the 
expanded A3 repertoire of primates during a cross-species virus transmission [261, 263, 264].   
  CBFβ interacts with a hydrophobic region of the Vif α/β-domain, but the rest of the exposed 
α/β-domain surface is highly positively charged and is thought to mediate electrostatic 
interactions with A3 enzymes [256, 265]. To target A3s for proteasomal degradation, Cul5 
interacts with RING box protein 2 (Rbx2) [68] and this results in the assembly of a hexameric 
complex (Fig. 1.4B). Further, a ubiquitin conjugating E2 enzyme interacts with the hexamer 
through Rbx2 and causes polyubiquitination of the A3 enzyme, on multiple lysine residues 
through a 48K linkage signaling it for degradation through the proteasome pathway (Fig. 1.4B). 
Current data for A3G and A3F suggest that the Lys residues that become conjugated to ubiquitin 
are random [266]. 
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1.4.3 Vif: amino acids that interact with A3s 
 Alanine scanning mutagenesis of Vif or comparison of different Vif variants from HIV 
subtypes has enabled the identification of three distinct regions of Vif that interact with A3G, 
A3F/A3D/A3C, or A3H [175, 240, 267]. Vif interacts with A3G on two widely distributed 
motifs. Two positively charged motifs on Vif, 21WxSLVK26 and 40YRHHY44 are involved in the 
interaction with A3G (Fig. 1.7, A and B) [268-272].  In addition, the 69YWxL72 motif is a region 
of Vif that interacts with both A3G and A3F (Fig. 1.7A) [273, 274]. However, for both A3G and 
A3F mutation of the 40YRHHY44 and 14DRMR17 motifs to all alanines are necessary and 
sufficient to block Vif-induced A3G and A3F degradation, respectively, suggesting the other 
domains provide a secondary stabilizing interaction [269]. Of note, A3C and A3D share a 
common binding site on Vif as A3F, with 14DRMR17 shown to be of importance (Fig. 1.7, A and 
B) [205, 274, 275]. Vif interacts with A3H through another unique site that involves amino acids 
39F and 48H (Fig. 1.7, A and B) [240, 276].  
 The Vif amino acids that interact with A3H are not highly conserved among HIV subtypes, 
in contrast to the motifs of Vif that interact with A3G and A3F. It has been suggested that since 
HIV rarely encounters a host with A3H Hap II that is effective against HIV, there has been 
evolutionary drift of Vif to not maintain an interaction site with A3H [100]. As a result, A3H is 
differentially sensitive to Vif variants. For example, A3H Hap II is not sensitive to HIV NL4-3 
Vif (39F, 48N), but is sensitive to HIV LAI Vif (39F, 48H) [276]. The inability of some Vif variants 
to induce degradation of A3H Hap II enabled Ooms et al. [100] to test whether A3H could act as 
an infection barrier to HIV. They found that Vif will adapt in infected individuals to induce 
degradation of A3H Hap II. Importantly, this evolution of Vif affects only A3H and Vif 
maintains the ability to induce degradation of A3G and A3F [100], confirming that Vif indeed 
uses three distinct interfaces to interact with A3 enzymes and supporting the idea that multiple 
A3 enzymes coordinately exert a restriction pressure on HIV. Importantly, treatment naïve HIV- 
infected individuals at the early or primary infection stage that had at least one active A3H allele 
(Hap II) had higher levels of mutations in proviral genomes in a 5′TC context, lower viral loads 
and higher CD4+ T cell counts [100]. Gourraud et al. [277] similarly reported that early stage 
untreated HIV infected individuals that were homozygous for a stable A3H allele demonstrated 
lower HIV RNA over time, but this did not correlate with increased hypermutation of HIV 
proviral genomes. This difference in mutational load between these reports is likely due to the 
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different sequencing strategies used in the two studies [100, 277]. These data are similar to 
clinical data obtained with A3G and A3F that demonstrate in a number of cohorts (but not all), 
A3G or A3F mRNA expression or hypermutation levels correlate with high CD4+ T cell counts 
and low viremia (reviewed in [115]). Based on these studies [100, 277], Refsland et al. [232] 
took a step further and reported that the ability of A3H to restrict HIV depends on both 
polymorphisms in host A3H genes and natural variations in the Vif proteins of the infecting virus.  
They found that due to the selection pressure A3H exerted on HIV, Vif variants that are most 
capable of neutralizing A3H also dominate in areas where stable A3H haplotypes prevail and 
vice versa. Hence, Vif appears to be able to adapt to different A3H haplotypes in a population. 
This means stable A3H may act as a bona fide transmission barrier and lower the rate of virus 
transmission during early infection when a HIV strain from a patient with an unstable haplotype 
(thus carrying a Vif variant unable to neutralize A3H) infect a person with a stable haplotype, as 
Vif needs adaptation to re-gain its ability to neutralize A3H [232].      
1.4.3.1 Vif-A3G interaction 
The Vif-A3G interaction was the first Vif-A3 interaction to be studied and it established 
that Vif inhibits the antiviral activity of A3 enzymes in a species-specific manner [67, 278-282]. 
This means that HIV Vif cannot neutralize A3G from African green monkey (AGM), and AGM 
SIV Vif cannot neutralize A3G from human and this has been recognized as a cross species 
infection barrier [67, 278-282]. Initially, to identify the residues HIV Vif uses to interact with 
human A3G the human A3G amino acids were replaced with those of AGM or rhesus macaque 
A3G. Mutation of human A3G 128D to 128K as found in AGM and rhesus macaque A3G 
abrogated the interaction of HIV Vif with human A3G and its ability to induce degradation of 
human A3G [278-280]. However, when the 128D was mutated to 128A, HIV Vif could still interact 
with and degrade human A3G, demonstrating that the charged interface was more important than 
the amino acid identity [280]. Since mutation of solely 128D to 128K can abrogate the interaction 
between A3G and Vif in co-immunoprecipitation studies it is clearly a determining residue; 
however, Vif mediated degradation can be influenced by mutation of A3G 129P and 130D and Vif 
also interacts with A3G on surrounding motifs such as helix 6 (Fig. 1.5A) [183, 267, 283]. The 
loop 7 and helix 6 region contain more positively charged and neutral amino acids than 
negatively charged amino acids which may explain why 128D is such an important contact point 
for the positively charged Vif, despite a larger A3G interface predicted from biochemical studies. 
	 40	
The A3G-Vif interface identified by Letko et al. [284] through functional assays and molecular 
docking confirmed that A3G loop7 (also known as β4-α4 loop) indeed serves as a core binding 
site of Vif and amino acid residues 125, 128 and 130 fit into a well-defined positively charged 
pocket on the surface of Vif. Other A3G loop7 residues such as 124, 127, 129 and 131 interact 
with Vif residues lining the pocket [284]. Importantly, although primate-specific amino acid 
polymorphisms exist in A3G loop 7, this structure is conserved across different primate species 
and it provides an explanation for why species-specific variation in loop7 determines primate-
species tropism [284]. Nevertheless, these studies with A3G established the principle that a lack 
of Vif-induced degradation correlates with a lack of an interaction between the A3 and Vif.  
1.4.3.2 Vif-A3F/A3D interaction 
 Unlike A3G where the Vif binding and the enzyme catalytic activities reside within the 
NTD and CTD, respectively, both these activities reside in the same domain, CTD, for A3F and 
A3D (Fig. 1.5, D and E) [205, 285]. A3F has been studied more extensively than A3D in this 
regard and will be discussed here. In contrast to A3G, there was no specific single amino acid 
determinant being identified for A3F that clearly mediated both the primary interaction with Vif 
and was a determinant for Vif-mediated degradation. Rather, different groups identified different 
amino acids in A3F that altered its susceptibility to Vif [179, 205, 269, 285, 286]. For example, 
289E has been reported to be critical for A3F sensitivity to Vif [285, 287]. Albin et al. [288] and 
Land et al. [286] identified another residue, 324E, as the key determinant of A3F to Vif-mediated 
degradation. Based on their molecular dynamic (MD) simulation-optimized model, Richards et 
al. [287] found that the A3F-Vif interaction is dominated by a stable electrostatic interaction 
between A3F 289E and Vif 15R and multiple A3F amino acid residues identified through prior 
mutagenesis studies [179, 205, 269, 285, 286] all located on the solvent-exposed surfaces of the 
helix 2,3, and 4 and can be re-grouped into contacts that either directly or indirectly involve in 
the actual A3F-Vif interaction. In agreement with this study [287], a combination of mutagenesis, 
structural modeling and a crystal structure of A3C that shares the same Vif binding interface 
with A3F and A3D, identified a novel type of A3 and Vif interaction [205, 285], where Vif 
interacted with a negatively charged surface of A3F/A3D/A3C that spanned helix 2, 3 and 4 and 
β-strand 4 (Fig. 1.5, D and E) [205, 265], rather than Vif interacting with a loop as in the case of 
A3G (Fig. 1.5A, loop7). This negatively charged surface supports the hypothesis that it is 
primarily electrostatic interactions that mediate the A3 and Vif interaction and provides an 
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explanation for why the A3F and Vif interaction may be more difficult to disrupt than the 
primarily neutral surface present in A3G. Whether this would mediate a tighter interaction of Vif 
with A3F than A3G is not known since there are no quantitative data available for both A3G and 
A3F using the same experimental conditions. Studies with A3F have shown that a lack of Vif-
induced degradation does not necessarily correlate with a lack of a Vif-A3F interaction, 
suggesting that the binding orientation or other factors contribute to successful Vif-mediated 
degradation rather than only the presence of an interaction [288]. 
1.4.3.3 Vif-A3H interaction 
 A3H sensitivity to Vif is haplotype dependent [45, 78, 195, 211, 240, 289]. The A3H Hap I 
is not sensitive to HIV LAI Vif-mediated degradation whereas A3H Hap II is sensitive to HIV 
LAI Vif-mediated degradation [195, 211, 276, 290]. The A3H haplotype polymorphisms only 
occur at three locations (amino acids 105, 121 and 178) (Table 1). A3H Hap I encodes GKE at 
these three positions and A3H Hap II encodes RDD at these positions. It was shown that at 
position 105 the Arg is required for stable expression in cells and that the 178 position had little 
effect on Vif-mediated degradation [45, 195, 211]. Therefore, a single amino acid homologous to 
A3G 128D at position 121 in A3H Hap II was determined to control sensitivity to Vif-mediated 
degradation (Fig. 1.5F) [211, 290]. An A3H Hap II mutant with a 121K is not sensitive to Vif 
mediated degradation and does not interact with Vif [290]. However, a recent study that 
identified the A3H-Vif interface through structure docking using the A3G CTD and Vif crystal 
structure as models [256] [291] suggests instead of a single amino acid 121D, the Vif-A3H 
interaction sites can be mapped to α-helix 3 (involves amino acid position 86, 87, 90 and 94) and 
α-helix 4 (involves amino acid position 121, 125, and 129) in A3H and β2 to β5 strand in Vif 
[292]. Two Vif residues at amino acid position 39 and 48 have been previously identified to be 
important for A3H interaction [100, 240, 276] and have been found to indeed locate at the A3H-
Vif interface. Specifically, Vif F39 interacts with A3H amino acids at position 121, 124 and 125 
and Vif H48 interacts with A3H amino acid at position 90. Interestingly, they also found Vif 
amino acid 40-44 on β2 sheet is important for interaction with both A3G and A3H, which was 
thought to be exclusively used by A3G [175, 229, 284], although the modeling predicts A3G and 
A3H interact with Vif in this area on different sides [292]. Notwithstanding, from the A3H 
structural model (Fig. 1.5F) it appears that the 121D of A3H is not located on loop 7 as in A3G, 
but is on helix 4 and on a different face of the molecule (Fig. 1.5, A and F). Yet, similar to A3G, 
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the region surrounding 121D in A3H contains mainly neutral or positively charged residues, in 
contrast to the negatively charged interface that Vif uses to interact with A3F and A3D [265].  
1.4.4 Degradation-independent inhibition of A3G 
Although the primary mechanism by which Vif inhibits A3 enzymes is through inducing 
their proteasomal degradation, there have been other ways identified in which Vif can inhibit 
A3G encapsidation or function through a degradation-independent route. Vif may not be able to 
completely induce degradation of A3G in the virus producing cell and these degradation-
independent mechanisms may be another line of defense against A3G virion encapsidation. In 
particular, Vif can become the target of A3-mediated hypermutation [73, 126], which may result 
in a Vif unable to interact with the E3 CRL5 ligase complex, but still able to inhibit A3G through 
a degradation-independent mechanism. It is not known if Vif can act in this manner for other A3 
enzymes 
1.4.4.1 Vif decreases translation of A3G mRNA 
Vif can decrease A3G mRNA translation in order to lower the steady state levels of A3G 
through a Vif and A3G mRNA interaction, but the exact mechanism is not understood [223, 225, 
293]. It is known that Vif can decrease the mRNA levels of A3G by 15-40% and this requires 
that Vif interact with the 5'UTR of the A3G mRNA [225, 293] and stem-loop 2 and 3 within the 
5’UTR of A3G mRNA are required for the translation inhibition by Vif [294]. Importantly, 
Guerrero et al. [294] demonstrated that the translational repression of A3G and proteasomal 
degradation of A3G induced by Vif can independently contribute to the overall decrease of A3G 
intracellular and intravirion level and that the importance of the translational control of A3G by 
Vif was overlooked because previous studies have used A3G expression vectors that lack an 
authentic A3G 5’UTR [294]. The ability to translationally inhibit A3G is well conserved 
amongst different Vif variants and interestingly Vif variants from HIV lab strains LAI and NL4-
3 showed weaker inhibition of A3G translation as compared to variants of clinical origin, such as 
A2 and D1[294]. Nevertheless, since Vif has been shown in an immunofluorescence study to co-
localize with A3 enzymes and P-bodies [295], it is possible that Vif shuttles A3G mRNA to P-
bodies to delay or prevent its translation. 
1.4.4.2 Vif inhibits virion encapsidation of A3G 
Studies by Goila-Gaur et al. [296] have shown that A3G synthesized in vitro using a 
rabbit reticulocyte lysate translation system would become immunoprecipitation and packaging 
incompetent in the presence of Vif. Vif was not associated with these high molecular mass A3G 
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forms, but was required for their formation [296]. Although A3G regularly forms high molecular 
mass complexes in cells, which are less likely to be packaged into virions, Vif can induce an 
even higher molecular weight form of A3G [135, 296]. Moreover, studies with an A3G C97A 
mutant that is resistance to Vif-mediated degradation suggested that Vif-mediated degradation 
and inhibition of packaging are two distinct properties of Vif since the A3G C97A mutant was 
encapsidated less well in the presence of Vif [297]. A molecular mechanism for this effect has 
not been described.  
1.4.4.3 Vif inhibits deamination of deoxycytidine by virion-encapsidated A3G 
A3 enzymes are mainly studied for restriction of HIVrvif in order to observe restriction 
in single-cycle infectivity assays, but in infected individuals A3 enzymes must contend with Vif. 
Despite multiple mechanisms that Vif uses to block A3G, it has been shown that A3G is 
encapsidated in the presence of Vif, albeit in lower amounts [93]. Further, per molecule of A3G 
there is less deamination activity (Fig. 1.4E) [298]. This decrease in A3G deamination activity 
occurs even when A3G and Vif are coexpressed in E. coli and mutations are detected with a 
Rifampin reversion assay or in vitro with purified A3G and Vif, demonstrating that other viral 
components are not required for the inhibition to take place [183, 298, 299]. Enzymatic studies 
have shown Vif can cause a decrease in the specific activity of A3G and this is due to a 
combination of Vif competitively binding to the ssDNA substrate and Vif binding directly to 
A3G [183, 298]. These are separable functions of Vif since ssDNA-binding studies of Vif-A3G 
complex in comparison to each of the component binding ssDNA alone supported the hypothesis 
that Vif bound to A3G is unable to bind ssDNA with high affinity [183]. Another consequence 
of Vif binding to A3G is that it disrupts how A3G scans ssDNA in search of cytosine to 
deaminate [183]. Vif interacts with the A3G NTD on loop7, which is required for processive 
jumping movements (Fig. 1.3A) [139]. In a study that used two Vif variants to examine the 
effect of Vif/CBFβ on the deamination activity of A3G it was found that HIV Vif HXB2 
inhibited A3G jumping movements, consistent with an interaction of Vif on loop7 [183]. In 
contrast, HIV NL4-3 Vif inhibited A3G sliding, which is mediated by helix6, providing 
functional evidence that beyond the key loop 7 contact residues, 128DPD130, Vif variants can 
interact with different regions of A3G [183]. This appears to have no functional consequences 
for A3G-mediated degradation [240], but provides insights on how variable the Vif variants can 
be in their extended binding sites on A3 enzymes. This may affect strategies that aim to use 
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small molecule inhibitors of the Vif-A3 interaction as an HIV therapy. Altogether, the data 
suggest the mechanism by which Vif inhibits A3G deamination activity in virions is by altering 
the scanning mechanism used to find cytosine on ssNDA. Inhibition of A3G deamination activity 
by Vif is likely to result in sublethal mutagenesis of HIV and could contribute to the generation 
of viral quasispecies and HIV evolution [124, 183]. 
1.4.4.4 Development of small-molecule inhibitors for A3-based HIV-1 therapeutics 
The Vif-A3 molecular interface between the host and pathogen creates the possibility of 
developing novel therapeutics [115, 300] and high-throughput screening approaches for small-
molecule inhibitors have delivered positive results. There are strategies to induce either A3G-
mediated viral hypermutations by disrupting the Vif-A3G interaction [301-306] or viral 
hypomutation by blocking A3G catalytic activity [307, 308]. For the “therapy by hypermutation” 
strategy, the rationale is to find small-molecule inhibitors that antagonize Vif function and 
increase the cellular level of A3G available for virus restriction. A few candidate molecules that 
recover A3G expression levels and enable HIV restriction in the presence of Vif have been 
discovered [301-306, 309], although there are little biochemical data to understand the 
mechanism of action. For the “therapy by hypomutation” strategy, small-molecule inhibitors 
have been designed that target a key residue in A3G (C321) that inhibits its catalytic activity 
[307, 308]. It is thought that decreasing the viral quasispecies that may arise due to A3-mediated 
mutagenesis can assist in immune clearance of the virus and decrease resistance to antivirals 
[233, 234] 
Inhibitors targeted to Vif may only be successful if administered in a cocktail to cycle 
their use and prevent the development of drug resistance, a long-standing therapy regimen for 
HIV drugs [310]. One strategy to avoid selection of resistant Vif is to utilize the anti-HIV 
potential of each A3 enzyme and design inhibitors that bind different regions of Vif, based on the 
unique interactions that Vif has with A3G, A3F/D and A3H (Fig. 1.7A). However, more study is 
required to determine if all A3 enzymes function equally well as individual restriction factors 
otherwise, the strategy may need to involve inhibiting degradation of all A3 enzymes together to 
enable a strong restriction pressure on HIV. Development of inhibitors that target the A3 
enzymes may be a problematic route when considering A3G since Vif interacts with A3G near 
the amino acid residues needed for virion incorporation, oligomerization and processivity (Fig. 
1.3A) [138, 183, 267]. As a result, the inhibitor molecule may decrease A3G anti-HIV activity. It 
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is unknown whether the activity of A3D, A3H, or A3F would be affected by this type of strategy. 
Furthermore, it has been shown in the case of A3G, that HIV can overcome the restriction  
pressure of A3G by acquiring mutations in genetic sequences other than Vif in order to indirectly 
avoid A3G encapsidation [180, 181]. 
If Vif were unable to interact with E3 CRL5 ligase complex components, the accelerated 
degradation of A3G would be blocked. This strategy has been raised as a potential option [251, 
300, 311] and current structural data on the EloB/C-, Cul5-, and CBFβ- Vif interfaces could 
facilitate development of inhibitors [250, 256]. However, the consequence of targeting the host 
proteins with small molecules remains unknown. In addition, this approach has potential 
drawbacks since Vif may remain bound to the A3 enzymes. For A3G, this has been shown to 
lead to a decrease in mutagenic activity [183, 298]. In vitro, Vif/CBFβ does not affect A3H 
deamination activity [312]. There are no published studies investigating whether Vif would 
affect the mutagenic activity of other A3s. If Vif were unable to interact with CBFβ it would 
become unstable in the host cells and degradation of A3 enzymes would be circumvented [68, 
69]. However, targeting a small molecule to CBFβ may be problematic if this prevents CBFβ 
from functioning as the transcription cofactor for RUNX proteins. Although some reports show 
that Vif and RUNX1 interact with CBFβ on distinct surfaces [69, 259, 260], Kim et al. [258] 
demonstrated that Vif recruitment of CBFβ alters the transcriptional profile of the cell by 
preventing RUNX1 and CBFβ association, suggesting Vif and RUNX1 may share a mutually 
exclusive binding surface on CBFβ [256, 258]. 
1.5. A3s-mediated inhibition of endogenous retroelements 
Endogenous retroelements and their mobility have played a critical role in shaping the 
human genome during speciation and creating genome diversity [313, 314]. However, the 
excessive mobility of retroelement interferes with genome integrity and thus uncontrolled 
transposition events need to be suppressed [34, 315]. A3 enzymes have been defending the 
genomic integrity of their host cells long before HIV was transmitted to the human population, 
based on the evidence of a long history of positive selection recovered on the A3 locus [316-318]. 
It has been suggested that the primitive function of A3s is to restrict the mobilization of 
mammalian endogenous retrotransposons and the selection pressure imposed by these 
retroelements has also helped shaping the complex locus structure of the present day A3s and 
contributed to the diverse functions of A3 family members [35, 319]. 
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Figure 1.8 Schematic overview of the retrotransposition cycle of retroelements. (A) The 
retrotransposition cycle of the LTR-retrotransposons (also known as the endogenous retroviruses, 
ERVs). Individual ERVs comprise two long terminal repeats (LTRs), separated by 
approximately 5-10 kb of sequence encoding the canonical retroviral gag, pol and env genes 
(although env is usually defective). The life cycle of ERVs include the formation of virus-like 
particles (VLPs) that remain intracellular. Reverse transcription of ERVs occurs in the cytoplasm 
in a process called “extrachromosomally-primed reverse transcription (EPRT)”. A structure that 
closely resembles the pre-integration complex (PIC) of exogenous retroviruses will be formed 
after EPRT, followed by an integrase enzyme (vertical box)-assisted integration event in the 
nucleus. The inserted ERV sequence is shown in red and the flanked target sites are shown in 
green. (B) The retrotransposition cycle of the non-LTR retrotransposons. A full-length non-LTR 
retrotransposon, represented by a L1 here, contains two open reading frames (ORFs), a 
5’untranslated region (UTR) with internal promoter sequences and a 3’UTR with 
polyadenylation signals. ORF1 (yellow) encodes a nucleic acid binding protein with nucleic acid 
chaperone activity; ORF2 (green) encodes proteins with endonuclease and reverse transcriptase 
activity. After protein translation, ORF1p protein (ORF1p) and ORF2p preferentially act in cis 
and bind to their encoding mRNA, giving rise to the L1 ribonuclear protein (RNP) complex, an 
important L1 retrotransposition intermediate. The RNP complex then shuttles to nucleus for L1 
replication and integration event. L1 propagates using a “copy and paste” mechanism and its 
DNA synthesis is based on a process named “target-primed reverse transcription (TPRT)”, 
during which an ORF2p nicks the target DNA and exposes 3’OH, followed by polymerization of 
cDNA (blue) using L1 RNA (red) as a template. After integration, the entire L1 element is 
usually flanked by target site duplications (TSD), with the duplicated target sites shown in green.    
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Endogenous retroelements, including the LTR and non-LTR retrotransposons, represent a 
class of the mobile genetic elements that replicate through an RNA intermediate (for review, see 
[320, 321]) (Fig. 1.8). LTR retrotransposons are also called endogenous retroviruses (ERVs) and 
they account for ~10% of the mammalian genome [322]. The replication of LTR 
retrotransposons is also called extrachromosomally-primed retrotransposition [323] and the 
reverse transcription process occurs exclusively in the cytoplasm of the infected cells (Fig.1.8A). 
LTR retrotransposons structurally resemble exogenous retroviruses such as HIV, except they 
usually lack a functional envelope (env) gene, which means they can only propagate by 
integrating into the genome at a new site within their host cell of origin and thus are transmitted 
vertically. Non-LTR retrotransposons, on the other hand, are also called target-primed 
retrotransposons (Fig. 1.8B) [323] and the reverse transcription predominantly takes place in the 
nucleus using a process named “target primed reverse transcription (TPRT)”, during which the 
endonuclease activity of ORF2 protein nicks the target DNA and the exposed 3’OH primes the 
polymerization reaction using L1 RNA as a template [322] (Fig. 1.9). Non-LRT retrotransposon 
sequences account for ~35% of the mammalian genome, including the long interspersed nuclear 
element (LINE) and short interspersed nuclear element (SINE). LINE-1 (L1) is the most 
common LINE and it alone comprises ~17% of the genomic DNA [324]. L1 is able to replicate 
autonomously and it also facilitates in trans the mobilization of SINEs and some cellular RNAs 
to produce processed pseudogenes (i.e. copies of genes that have lost their protein-coding ability). 
Here, I will review the general knowledge of A3 proteins as restriction factors against LTR and 
non-LTR retrotransposons.   
1.5.1. A3-mediated restriction of LTR retrotransposons 
 Following the discovery of the anti-viral activity of A3 proteins against HIV, similar 
restrictive activities against murine ERVs, such as MusD and intracisternal A particle (IAP), 
have been reported [40, 165, 325, 326]. Similar to the paradigm of HIV restriction by A3s, where 
A3s need to get encapsidated into the budding virion through a RNA-dependent interaction with 
HIV Gag protein, direct interactions between A3 proteins and IAP Gag have been reported [326]. 
It is has been generally accepted that the inhibition of ERV requires the deaminase activity of 
A3s, as the characteristic G-to-A deamination footprints from A3G and A3F have been found in 
various recovered ERV genomes [328-330]. 
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Figure 1.9 Schematic for target primed reverse transcription (TPRT) of L1. L1-encoded 
endonuclease generates a single-stranded nick on the genomic DNA at a degenerate concensus 
sequence (usually 5’-TTTT/A-3’, with / represents the cleavage site). The exposed 3’OH is used 
by the L1 reverse transcriptase to prime L1 cDNA synthesis by paring the L1 RNA 3’ polyA tail 
sequence from L1 RNA (blue) with a AT-rich sequence from the genomic DNA target site 
(wheat). L1 RNA is reverse transcribed by a L1-encoded reverse transcriptase to generate a 
cDNA copy (red). A second cleavage event is required to open the other strand of DNA, and 
microhomology between newly synthesized LINE-1 (-)cDNA and genomic DNA will prime 
(+)cDNA synthesis. TPRT ultimately leads to L1 integration at the new genomic location with 
the following structural hallmarks:  target site duplications (TSDs), integration at an L1 
endonuclease consensus cleave site and frequent 5’ truncation in L1 sequences. This figure is re-
drawn based on a figure in a review by Cordaux and Batzer [322]. 
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Figure 1.10 Repairing an uracil lesion in the DNA. The base excision repair (BER) pathway 
repairs small base distortions in the DNA helix structure, such as DNA damage from alkylation, 
oxidation and deamination. This schematic demonstrates how uracil lesion generated from A3’s 
deamination activity is repaired. BER is initiated by uracil DNA glycosylase that recognizes and 
removes the uracil base. Uracil DNA glycosylase produces an abasic site on DNA by cleaving 
the bond between uracils and deoxyribose (i.e., the N-glycosidic bond). The abasic site is further 
processed by an apurinic/apyrimidinic (AP) endonuclease, a DNA polymerase and a ligase. The 
AP endonuclease cleaves the phosphodiester bond 5’ to the abasic site, producing 3’OH and 5’ 
deoxyribose phosphate (5’dRP) ends. The phosphodiesterase activity of Polβ, a major gap-filling 
family X polymerase, then cleaves the phosphodiester bond 3’ to the lesion and removes 5’dRP 
and subsequently insert the correct nucleotide (a cytosine). The last step in BER is ligation of the 
nick after gap filling and DNA ligase1 is considered the major ligase to be involved in this 
process [327].     
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1.5.2. A3-mediated restriction of non-LTR retrotransposons 
By overexpressing A3s in cell culture experiments, several studies have reported that 
different A3 family members are able to inhibit L1 to varying degrees, with A3A and A3B being 
the most potent at restriction [35, 42, 326, 331-334]. In general, a deamination-independent L1 
restriction model has been proposed, as no G-to-A mutations related to A3-mediated 
deamination events have been detected. For a deamination-independent mechanism of L1 
restriction, the A3s have been reported to interact with L1 mRNA and sequester L1 
ribonucleoprotein (RNP) complex to a cytoplasmic compartment such as stress granules or 
physically interact with L1 RT and inhibit polymerization during L1 reverse transcription [42, 
335, 336]. That the L1 restriction by A3 proteins does not seem to strictly correlate with their 
cellular localization to the nuclear compartment where L1 reverse transcription occurs supports 
the idea that A3s could inhibit various stages of the L1 life cycle [333]. It has been speculated 
that A3-mediated deaminations could still play a major role during L1 restriction, because the 
unsuccessful attempts to uncover A3-induced mutations were likely due to the degradation of 
uracil-containing cDNA intermediates by the uracil DNA glycosylase (UNG) and 
Apurinic/apyrimidinic (AP) endonuclease (APE)-mediated base excision repair machinery [103] 
[337] (for review, see [327]) (Fig. 1.10). Richardson et al. [337] proposed that the annealed L1 
RNA normally protects the L1 (-)cDNA from deamination, but transiently exposed ssDNA 
would become accessible to A3A-mediated deamination during TPRT. The authors were able to 
recover G-to-A mutations in L1 replication intermediates in the presence of A3A when UDG 
was blocked [337]. Altogether, these data suggest the mechanisms of L1 restriction by A3s may 
involve both deaminase-dependent and independent activities.  
 
 
 
 
 
 
 
 
	 52	
2.0 Hypothesis and Objectives 
2.1 Rationales and Hypothesis 
Arthur Kornberg once said, “cell biologists look; geneticists count; biochemists clean”.  
The A3 field is no exception to this, as the restrictive abilities of A3 proteins against HIV were 
originally discovered by a group of virologists and cell biologists across the world and it was not 
until careful inspection of the HIV genomic sequences did some interesting biochemical 
characteristics belonging to the cytidine deaminase activities of A3 enzymes become recognized. 
Building on the hypothesis that HIV Vif has developed a unique interaction with each A3 
enzyme due to the different selection pressures A3s impose on HIV, we have characterized the 
biochemical activities of the single-domain A3H enzyme and compared that to the double-
domain A3G, which has traditionally been the enzyme family representative. Based on this 
knowledge, we have also investigated the molecular mechanism of degradation-independent Vif-
mediated inhibition of A3G and A3H deamination activity and the mechanisms that govern an 
efficient degradation-dependent Vif-mediated inhibition of these two enzymes. The central 
hypothesis of my Ph.D thesis is that knowledge gained on the inherent biochemical properties  
that enable A3G and A3H to locate and catalyze their deamination motifs would lead to a better 
understanding of the mechanistic basis of proviral hypermutations and the cellular activities of 
A3G and A3H as restriction factors against retroviruses (such as HIV) and retrotransposons 
(such as L1).  
2.2 Objectives 
The objectives of my Ph.D thesis include: 
1. Investigation of the degradation-independent mode of inhibition imposed by Vif towards A3 
enzymes through examination of the interaction between A3G and Vif and how Vif inhibits the 
deaminase activity of A3G.   
2. Characterization and comparison of the interaction between A3G and A3H and different Vif 
variants and identification of common features that result in Vif-mediated degradation, which 
contribute to defining the determinants required for efficient Vif-mediated degradation of A3 
enzymes.  
3. Biochemical characterization and comparison of two stable A3H haplotypes and comparison 
of the oligomerization models for Z1, Z2 and Z3-type A3 enzymes.    
4. Identification of the mechanisms A3H uses to restrict the replication of L1. 
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3.1 Abstract 
APOBEC3G is a retroviral restriction factor that can inhibit the replication of HIV-1 in the 
absence of the viral infectivity factor (Vif) protein. Virion encapsidated APOBEC3G can 
deaminate cytosine to uracil in viral (-) DNA which leads to hypermutation and inactivation of 
the provirus. APOBEC3G catalyzes these deaminations processively on single-stranded DNA 
using sliding and jumping movements. Vif is thought to primarily overcome APOBEC3G 
through an interaction that mediates APOBEC3G ubiquitination and results in its proteasomal 
degradation. However, Vif may also inhibit APOBEC3G mRNA translation, virion 
encapsidation, and deamination activity. Here we investigate the molecular mechanism of VifIIIB- 
and VifHXB2- mediated inhibition of APOBEC3G deamination activity. Biochemical assays using 
a model HIV-1 replication assay and synthetic single-stranded or partially double-stranded DNA 
substrates demonstrate that APOBEC3G has an altered processive mechanism in the presence of 
Vif. Specifically, VifHXB2 inhibited the jumping and VifIIIB inhibited the sliding movements of 
APOBEC3G. The absence of such an effect by Vif on degradation resistant APOBEC3G D128K 
indicates that a Vif-APOBEC3G interaction mediates this effect. That the partially processive 
APOBEC3G was less effective at inducing mutagenesis in a model HIV-1 replication assay 
suggests that Vif co-encapsidation with APOBEC3G can promote sublethal mutagenesis of HIV-
1 proviral DNA. 
3.2 Introduction 
 APOBEC3G (A3G) is a single-stranded DNA (ssDNA) deoxycytidine deaminase that 
functions as a potent host restriction factor to inhibit HIV-1 replication in strains that lack the 
viral infectivity factor (Vif) [22-25]. In the absence of Vif, sufficient amounts of A3G are able to 
become incorporated into budding virions by binding to the viral genomic (+)RNA or 7SL 
cellular RNA, and/or nucleocapsid portion of the Gag [130]. Subsequently, A3G catalyzes the 
deamination of cytosine to uracil (C→U) on nascently formed viral (-)DNA in the target cell [90, 
91]. HIV-1 reverse transcriptase (RT) uses these uracils as a template thereby creating G→A 
mutations on the viral genomic strand, resulting in hypermutation and inactivation of proviral 
DNA [22-24]. Synthesis of the (-)DNA is initiated from a host tRNALys,3 primer that binds the 
HIV-1 primer binding site near the 5'-end of the viral genome [5]. Two polypurine tracts (PPT) 
that reside in the center and the 3'-end of the HIV-1 RNA genome are responsible for priming (+) 
DNA synthesis by virtue of their resistance to RNase H degradation [338]. The multiple priming 
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sites for (+) DNA synthesis allow for conversion of the single-stranded (-) DNA to a double-
stranded (ds)DNA provirus as rapidly as possible and influences the distribution of A3G-induced 
mutations [339, 340]. 
 A3G is able to search for its preferred 5'CCC or 5'CC deamination motif (underlined C is 
deaminated) using a processive scanning mechanism [132]. The scanning appears to be through 
facilitated diffusion [146, 148, 341] and involves sliding and microscopic jumping movements 
that enable a 3-dimensional search of the ssDNA without A3G diffusing into the bulk solution 
[132, 149, 150]. This searching mechanism gives enzymes the potential to increase their target 
searching efficiency [146, 148] and results in A3G-catalyzed deaminations occurring in a 
stochastic manner [342]. Further, since A3G must scan viral (-)DNA in the presence of short 
RNA/DNA hybrid regions that result from incomplete processing by the RT RNase H domain, 
the 3-dimensional search enables an efficient scan of the heterogenous substrate [139].  
 A3G contains two zinc-binding domains. The C-terminal domain (CTD) contains the 
catalytically active domain that is directly responsible for deaminase activity of A3G [56, 57] 
and can contribute to oligomerization [140, 343, 344]. The N-terminal domain (NTD) is 
catalytically inactive, but this half of the enzyme is responsible for processivity, virion 
encapsidation, and can also mediate oligomerization of A3G [56, 57, 137-139, 345]. The 
residues that appear to contribute to these N-terminal half functions are located on predicted loop 
7, residues 124-130 [137-139] (Fig. 3.1).   
 A3G-mediated restriction of HIV-1 is for the most part inhibited by HIV-1 Vif [63, 70, 225, 
246, 346]. Vif is thought to primarily accomplish this through triggering A3G degradation [63, 
70, 225, 246]. Among the seven APOBEC3 family members (A3A, A3B, A3C, A3D, A3F, A3G 
and A3H), A3G appears to be the most potent at restricting HIV-1 [81, 171, 172], but also the 
most sensitive to Vif [295]. Specifically, Vif binds to A3G [63, 225, 246], is stabilized in host 
cells by binding the transcription cofactor core binding factor β (CBFβ) [68, 69], and recruits a 
cellular ubiquitin ligase complex [70]. This results in the polyubiquitination and degradation of 
A3G through the 26S proteasome pathway [247, 347]. Vif inhibits the antiviral activity of A3G 
in a species-specific manner [64]. For example, HIV-1 Vif fails to neutralize A3G from African 
green monkey or rhesus macaque and conversely simian immunodeficiency virus (SIV) Vif is 
incapable of neutralizing human A3G [64]. This species-specific type of A3G restriction has  
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loop7
helix 6
 
Figure 3.1 Model of the N-terminal half of A3G. Model (grey) shows loop 7 and helix 6 (both in 
red). The central residue that mediates the interaction with Vif, Asp128 is shown (green). Zinc 
atom is a dark grey sphere. The predicted model of A3G NTD was obtained by using the 
automated SWISS-MODEL program using the homologous A3G CTD (PDB: 3IQS) structure as 
a template. Figure was made using PyMOL (The PyMOL Molecular Graphics System, Version 
1.5.0.5, Schrödinger, LLC.). 
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 been correlated with the ability of Vif to physically associate with A3G and is centrally 
mediated by Asp128 of A3G [280]. Mutating human A3G Asp128 to Lys, as is found in African 
green monkey A3G, abrogates the effect of HIV-1 Vif on human A3G [278-280]. The Asp128 is 
predicted to be located on loop 7 in the N-terminal half of A3G (Fig. 3.1) near the determinants 
for dimerization, processivity, and virion incorporation (124YYFW127) [137-139]. 
 Additionally, Vif has been shown to inhibit A3G function in two other ways that appear to 
involve the RNA binding ability of Vif. First, Vif has been reported to promote A3G virion 
exclusion in a degradation-independent manner [346, 348, 349]. A3G needs to bind to the viral 
genomic RNA or cellular 7SL RNA, and/or nucleocapsid portion of HIV-1 Gag in order to be 
encapsidated in the budding virus [130]. It has been suggested that Vif recruits A3G into high 
molecular weight RNA/protein masses that are unable to be encapsidated, but the exact 
mechanism has not been identified [296]. Vif may exert this function as a secondary effect of its 
own attempt to be encapsidated into budding virions, although the amount of Vif estimated in 
virions ranges widely from about 7 to 80 molecules [94, 95, 223, 350]. Second, there is evidence 
to suggest that Vif depletes the intracellular pool of A3G by downregulating its mRNA 
translation and stability [223, 225, 293, 294]. It is thought that Vif can directly bind A3G mRNA 
to exert this function [293, 294]. 
 Despite the multiple ways Vif attempts to inhibit A3G virion encapsidation, Vif 
neutralization of A3G may not be absolute. A3G may be capable of escaping Vif inhibition in 
the virus producing cell, resulting in A3G encapsidation into budding virions [124, 223]. 
Nowarski et al. reported that a range of 0.3-0.8 molecules of A3G can be found in wild type (wt) 
HIV-1 virions, far less than the 4-9 molecules of A3G found in Vif-deficient virions [93]. 
Further, the residual A3G encapsidated with Vif in the virion was found to be less catalytically 
active than A3G encapsidated in its absence [298]. The explanation of this observation is that 
virus encapsidated Vif inhibits A3G deamination activity [298]. This is supported by an earlier 
report which characterized this phenomenon when A3G and Vif were co-expressed in E. coli 
[299]. The mechanism by which Vif inhibits A3G deamination activity is not fully understood. 
Yet, this mode of Vif-mediated inhibition has implications for design of Vif-based HIV-1 
therapeutics that exclude Vif from interacting with ubiquitin ligase components [300, 311] but 
allow it to remain in contact with A3G and the relationship between A3G deamination activity 
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and sublethal mutagenesis of HIV-1 [73, 124, 126, 351]. Vif-mediated partial inhibition of A3G 
deamination activity could potentially lead to viral evolution rather than viral inactivation. 
  Here we investigate the molecular mechanism of degradation-independent Vif-mediated 
inhibition of A3G deamination activity. Two Vif variants, VifHXB2 and VifIIIB have been applied 
to our study. We used VifIIIB as a standard variant from a widely used HIV-1 lab isolate and we 
used VifHXB2 since it has been reported to be more potent at Vif-mediated degradation of 
APOBEC3 enzymes [295]. The data indicate that the Vif variants inhibit A3G deamination 
activity by primarily altering its processive scanning mechanism, which decreases the ability of 
A3G to induce mutations in nascently reverse transcribed cDNA. Each Vif variant can inhibit 
A3G processive scanning in a unique way suggesting that there are variant specific interactions 
that underlie the differential potency of VifHXB2 and VifIIIB against APOBEC3 enzymes.  
3.3 Results 
3.3.1 Decreased A3G-induced mutagenesis in the presence of Vif. A reconstituted model HIV-1  
replication system was used to determine whether Vif could inhibit the deamination ability of 
A3G. In this assay, we used an RNA construct that contains (from the 5'- to 3'-end) a PPT, 120 nt 
of the HIV-1 prot active site, and the lacZα gene. The PPT enables second strand synthesis to 
occur. The prot and lacZα sequences are used to characterize the spectra of mutations. The prot 
sequence is further used to gauge the ability of A3G-induced deaminations to inactivate the 
protease enzyme. As such, the sequence is analyzed in the (+) strand orientation where C→U 
deaminations are detected as G→A mutations. A3G is able to cause approximately a 17-fold 
increase in the population mutation frequency and 11-fold increase in the clone mutation 
frequency as compared to RT alone (compare Table 3.1 and Table 3.2). 
 A plot of the distribution of A3G-induced mutations recovered from the sequenced clones 
demonstrates a mutational gradient in the 5'→3' orientation, meaning that deaminations were 
biased towards the 5'-end of the nascently synthesized cDNA (Fig. 3.2A). This has been 
previously observed for A3G in vivo due to HIV-1 replication dynamics in which (-)DNA 
furthest from the PPT is single-stranded the longest and incurs the most deaminations [91, 339, 
340]. To determine if Vif could influence the deamination activity of A3G we added Vif at 
excess (~2-fold more than A3G). It can be seen by visual inspection of the mutation spectra that 
addition of VifIIIB or VifHXB2 causes a decrease in A3G-induced mutagenesis (Fig 3.2A), with 
VifHXB2 (Fig. 3.2B) having a greater inhibitory effect than VifIIIB (Fig. 3.2C). The decrease in the  
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Table 3.1 A3G-mediated mutation frequencies in a model HIV replication system in the absence 
and presence of VifHXB2 and VifIIIB. 
 
Reaction condition Population mutation frequency Clone mutation frequency (x10-2) 
A3G  0.87 2.2 
A3G + VifHXB2  0.63a 0.9a 
A3G + VifIIIB 0.90 1.5b 
 
The ratio of white colonies to total colonies is defined as the population mutation frequency. The 
average number of G→A mutations per base pair in the 368 nt prot-lacZα construct is defined as 
the clone mutation frequency.  
a Significant difference was designed as p≤0.001 versus A3G values. 
b Significant difference was designed as p≤0.01 versus A3G values. 
c Significant difference was designed as p≤0.05 versus A3G values. 
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Table 3.2 Mutation frequencies in a model HIV replication system in the absence of A3G 
 
Reaction condition Population mutation frequency Clone mutation frequency (x10-2) 
No A3G 0.05 0.2 
 
The ratio of white colonies to total colonies is defined as the population mutation frequency. The 
average number of mutations (substitutions, insertions or deletions) per base pair in the 368 nt 
prot-lacZα construct is defined as the clone mutation frequency.  
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A3G + VifIIIB
A3G + VifHXB2
A3G
prot lacZα
A
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D E F
A3G + VifIIIBA3G + VifHXB2A3G
 
 
Figure 3.2  A3G-induced mutagenesis is inhibited by VifHXB2 and VifIIIB in a model HIV 
replication system.	A-C, spectra of mutations incurred in 368 nt prot-lacZα construct are plotted 
as percent of clones containing a mutation at a particular location (nt) for (A) A3G, (B) A3G in 
the presence of VifHXB2 and (C) A3G in the presence of VifIIIB. D-F, histograms were generated to 
illustrate the population distribution of mutations per prot-lacZα construct for (D) A3G, (E) A3G 
in the presence of VifHXB2 and (F) A3G in the presence of VifIIIB.	
	 62	
A3G-induced mutations when VifHXB2 (Fig. 3.2B) or VifIIIB (Fig. 3.2C) is present is greater in the 
prot, likely owing to the shorter time that this region is single stranded in comparison to the 
lacZα due to the proximity to the PPT. 
The clones were also binned for analysis based on the number of mutations per prot-
lacZα (Fig. 3.2, D-F). A3G is able to induce a widespread number of mutations (Fig. 3.2D). We 
found a range of 3 to 12 mutations per prot-lacZα occurring for A3G. The data are far less 
spread when A3G-induced mutagenesis occurs in the presence of VifHXB2 where we find there are 
only 3-5 mutations per prot-lacZα ~55% of the time and 0-2 mutations per prot-lacZα ~35% of 
the time (Fig. 3.2E). For VifIIIB the reduction in A3G-induced mutations is demonstrated by a 
shift of mutations down to 3 to 8 mutations per prot-lacZα (Fig. 3.2F). The data were analyzed 
further by comparing the frequency of mutations in heavily mutated sites in the presence of A3G 
and the absence and presence of Vif (Table 3.3). From this analysis we found that VifHXB2 causes 
6 of the 8 heavily mutated sites to be mutated at a lower level (Table 3.3, A3G + VifHXB2). The 
detrimental effect of VifIIIB on A3G-induced mutagenesis was only significant in the prot region 
(Table 3.3, A3G + VifIIIB). 
The more potent effect of VifHXB2 is further evident when the mutation frequencies are 
examined. Here we scored the number of white colonies in the population (population mutation  
frequency) or the number of mutations per base pair (clone mutation frequency) (Table 3.1). We 
found that VifHXB2 causes a significant decrease in both the population (1.4-fold) and clone 
mutation frequency (2-fold) from A3G alone (Table 3.1). The influence of VifIIIB was not as large 
with the population mutation frequency remaining the same as for A3G alone and the clone 
mutation frequency decreasing 1.5-fold (Table 3.1). Altogether, the data indicate that both Vif 
variants we tested can inhibit A3G-induced mutagenesis, consistent with previous results which 
tested VifIIIB [299] or VifHXB2 [298]. Further, the effect of VifHXB2 on A3G is more potent than 
VifIIIB, which is consistent with how these Vif variants function with respect to inducing 
degradation of A3G and other APOBEC3 enzymes [295].  
3.3.2 Vif-mediated inhibition of A3G can promote sublethal mutagenesis in a model HIV-1 
replication system. Here we assessed the potential ability of each Vif variant to cause A3G to 
induce a sublethal amount of mutagenesis in the prot (Table 3.4). After determining the protease 
amino acid sequence of the mutated clones we can infer whether the protease would retain 
activity or be inactivated by drawing on data from Loeb et al. [352]. in which an extensive  
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Table 3.3 Frequency of A3G hot-spot mutations in the prot-lacZα. 
 
Site (nt) Frequency of mutation 
A3G A3G + VifHXB2 A3G + VifIIIB 
 85 
 
0.44 
 
0.00a 
 
0.16b 
111 0.24 0.04b 0.16c 
114 0.24 0.12c 0.00b 
166 0.56 0.36b 0.60 
184 0.56 0.64c 0.60 
216 0.60 0.24b 0.64 
219 0.76 0.32a 0.72 
244 0.92 1.00 0.96 
 
A hot-spot was defined as occurring in at least 20% of clones for the prot region (1 - 120 nt) and 
at least 50% of clones for the lacZα region (121 - 368 nt). 
a Significant difference was designed as p≤0.001 versus A3G values. 
b Significant difference was designed as p≤0.01 versus A3G values. 
c Significant difference was designed as p≤0.05 versus A3G values. 
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Table 3.4 Amino acid changes to the HIV-1 protease resulting from A3G-mediated deaminations 
in the absence and presence of VifHXB2 and VifIIIB. 
 
Amino 
acid Codon change 
Amino acid 
change 
Predicted 
protease  
activity 
Mutated clones (%) 
A3G A3G + VifHXB2 
A3G + 
VifIIIB 
21 GAA → AAA E → R + 0 0 4 
25 GAT → AAT D → N + 8 0 8 
27 GGA → AGA G → R - 12 0 12 
30 GAT → AAT D → N + 0 0 4 
34 GAA → AAA E → K + 4 0 0 
38 TTG → TTA L → L + 0 4 0 
40 
GGG → AGG G → R - 12 4 20 
GGG → GAG G → E - 8 8 0 
GGG →GGA  G →G + 0 4 0 
42 TGG → TAG W → stop - 44 0 16 
46 ATG → ATA M → I + 0 0 4 
48 
GGG → AGG G → R + 4 0 0 
GGG → AGA G → R + 4 0 0 
GGG → GGA G  →G + 12 0 4 
49 GGA → AGA G → R - 4 0 0 
51 
GGA → AGA G → R - 24 4 16 
GGA → GAA G → E - 4 0 4 
52 GGT → AGT G → S - 24 12 0 
Predicted protease activity is determined from a mutagenesis study conducted by Loeb et al[352]. 
An active protease is denoted with a + and an inactive protease is denoted with a -. 
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Figure 3.3 VifHXB2 and VifIIIB have a different effect on the decrease in A3G-induced mutations in 
the prot sequence. Individual analysis of each prot clone enabled determination of the percent of 
clones that would result in an unmutated (no mutations, red), mutated and active (black), or 
mutated and inactive (green) prot. A, A3G was able to inactivate the prot in 60% of clones and 
left an active prot in 8% of mutated clones. A3G did not induce any mutations in the prot in 32% 
of clones. B, A3G-induced mutagenesis in the presence of VifHXB2 resulted less mutations 
overall. There were 68% of clones with no mutations, 24% of clones were mutated and inactive, 
and 8% of clones were mutated but retained prot activity.  C, the effect of VifIIIB on A3G-induced 
mutagenesis was less than VifHXB2 and resulted in 40% of clones with no mutations, 52% of 
clones with inactive prot, and 8% of clones with mutated but active prot. 
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mutagenesis of the protease was conducted. Concomitant with the site to site decreases in 
mutation frequency (Table 3.3), we saw a decrease in the number of clones with amino acid 
changes of the protease in the presence of the Vif variants (Table 3.4). 
When A3G-catalyzed deaminations occurred in the presence of VifHXB2, the types of 
mutations incurred were not changed, but rather decreased with most mutations seen with A3G 
alone being absent in the presence of VifHXB2 (Table 3.4). In the presence of VifIIIB there were 
decreases in mutations at 9 of the 13 sites mutated for A3G alone and changes in the mutation 
frequency, i.e., increased mutation or novel site in 4 of the 13 sites mutated for A3G alone (Table 
3.4). For example, the most heavily mutated site for native A3G is at amino acid 42 (Trp to stop; 
44%). However, in the presence of VifHXB2 and VifIIIB, the frequency of this mutation drops to 
0 % and 16%, respectively (Table 3.4). It is interesting that some of the sites that were mutated 
only in the presence of VifIIIB, albeit at a low level, cause protease inhibitor resistance (Table 3.4, 
4% for D30N and M46I). 
 To determine if each individual model provirus synthesized in our assay would code for 
an active or inactive protease we analyzed each clone individually (Fig. 3.3). A3G-induced 
mutagenesis is able to cause inactivation of the prot 60% of the time and leaves the prot active 
only 8% of the time (Fig. 3.3A). A significant amount of clones (32%) had no mutations in the  
prot region. A3G–induced mutagenesis in the presence of VifHXB2 changes this distribution so 
that 68% of clones had no mutations in the prot and 24% had mutations that inactivated the prot 
(Fig. 3.3B). Again, 8% of clones were mutated but still coded for an active prot (Fig. 3.3B). The 
same trend was found for A3G in the presence of VifIIIB where slightly more clones were not 
mutated (Fig. 3.3C, 40%) in comparison to A3G alone (Fig. 3.3A, 32%). These results are in 
agreement with the analysis of the total population of mutations (Table 3.4) where there was an 
overall decrease in mutations, rather than an alteration of the mutational hot spots.  
3.3.3 Vif alters the processive scanning mechanism of A3G. To investigate how VifIIIB and 
VifHXB2 inhibit A3G-induced mutagenesis and why these variants differ in their effect (Fig. 3.3, 
Table 3.1 and 3.3), we conducted assays measuring A3G-catalyzed deaminations on synthetic 
DNA substrates. Specifically, the assay can measure the processive scanning behavior of A3G 
by using a 118 nt ssDNA substrate with two 5'CCC deamination motifs spaced 61 nt apart (Fig. 
3.4A, schematic). Figure 3.3A shows a characteristic result of A3G in this assay. A3G 
deaminates both the 5'- and 3'- proximal CCC motifs, but there is a 2-fold preference for the 5'-  
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Figure 3.4 Processivity of A3G in the absence and presence of VifHXB2 and VifIIIB. A, deamination 
of a 118 nt F-labeled ssDNA substrate by A3G. Two CCC motifs within the ssDNA sequence 
are spaced 61 nt apart. Single deaminations of the 5'C and 3'C are detected as the appearance of 
labeled 100- and 81- nt fragments, respectively; double deamination of both C residues on the 
same molecule results in a 63 nt labeled fragment (5'C & 3'C). A3G processivity is decreased by 
~2-fold in the presence of VifHXB2 (+VifHXB2) and VifIIIB (+VifIIIB). B, deamination of the substrate 
described for (A), but with a 20 nt ssDNA annealed between the two CCC motifs which can 
block the sliding component of A3G processivity. This results in a 2-fold decrease in A3G 
processivity. Processive deaminations are still observed due to the jumping component of A3G 
processive movement. In the presence of VifHXB2 the processivity of A3G is nearly absent 
indicating that the jumping component of A3G has been inhibited. This is in contrast to the VifIIIB 
that has no effect on A3G jumping movement. C, deamination of the substrate described for (B) 
but with a 20 nt RNA annealed between the two CCC motifs. Processive scanning of A3G on 
this substrate in the absence and presence of VifHXB2 and VifIIIB was similar to that observed for 
(B). The measurements of processivity (Processivity factor) are shown below the gel. Values are 
an average from at least three independent experiments and the SEM for the processivity factors 
are (A) A3G, 1.90; +VifHXB2, 0.03; +VifIIIB, 0.65 (B) A3G, 0.80; +VifHXB2, 0.20; +VifIIIB, 0.76; (C) 
A3G, 1.20; +VifHXB2, 0.16; +VifIIIB, 0.40.  
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motif due to an inherent catalytic orientation specificity of the active site [141]. Of importance is 
the presence of a double deamination band which indicates that a deamination occurred at both 
the 5'C and 3'C on the same ssDNA (Fig. 3.4A, 63 nt). The processivity factor is calculated as a  
ratio of the intensity of this band to the calculated expected value of deaminations that would 
occur at both 5'- and 3'- proximal motifs if the enzyme were not processive (see Material and 
Methods). The processivity factor of 9.1 (Fig. 3.4A, below gel) means that A3G is 9 times more 
likely to undergo a processive deamination of both CCC motifs than deaminate each of the 
motifs in separate enzyme-ssDNA encounters. VifHXB2 and VifIIIB are able to decrease the 
processivity of A3G by at least 1.5-fold from 9.1 to 4.1 or 5.6, respectively (Fig. 3.4A).  
 To discern how the Vif variants are able to decrease the processivity of A3G we used an 
assay that can make a distinction between the two scanning modes of A3G. A3G has been shown 
to scan ssDNA by sliding and microscopic dissociations and reassociations termed jumping [132, 
139]. This bifunctional processive mode was identified using an experiment where a 
complementary DNA oligonucleotide is annealed between two CCC motifs on an ssDNA 
substrate (Fig. 3.4B, schematic). The partially dsDNA, to which the enzyme cannot effectively 
bind, acts as a block to the sliding component of A3G processivity [132, 141]. However, A3G 
can still transverse the block by jumping. As such, A3G incurs a ~2-fold decrease in processivity 
(compare Fig. 3.4A and 3.4B, processivity factors of 9.1 and 4.5, respectively). When VifHXB2 is 
added to the reaction with the partially dsDNA substrate, the processivity factor of A3G 
decreases another 2-fold, from 4.1 to 1.1 (Fig. 3.4, A and B, processivity factor) and there is a 
visible decrease of the double deaminations to almost none (Fig. 3.4B, 63 nt). This indicates that 
VifHXB2 can inhibit the jumping component of A3G so that it is no longer able to transverse the 
dsDNA. A3G is still able to slide since processive deaminations occurred on fully ssDNA (Fig. 
3.3A). VifIIIB does not affect the ability of A3G to jump since the processivity factor in the 
presence of the dsDNA is 5.5 (Fig. 3.4B, processivity factor), which is similar to the processivity 
of A3G in the presence of VifIIIB on fully ssDNA (Fig. 3.4A, processivity factor of 5.6). However, 
VifIIIB does appear to affect A3G processivity since it decreased the processivity factor on 
ssDNA 1.5-fold (Fig. 3.4A, processivity factor decreased from 9.1 to 5.6), suggesting that VifIIIB 
may inhibit A3G sliding. Similar results were found when we used a complimentary RNA 
oligonucleotide as a block (Fig. 3.4C). An RNA/DNA hybrid block would be what A3G  
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Figure 3.5 Mutation cluster frequency of A3G is decreased in the presence of VifIIIB but not 
VifHXB2. Sliding movement of A3G is inferred from clustered mutations. Jumping movement of 
A3G is inferred from distantly spaced mutations. Frequency of clustered mutations was scored in 
eight regions of the prot-lacZα that contain three to six G residues. Horizontal bars represent the 
average mutation cluster frequency. The data show that A3G alone and in the presence of VifHXB2 
induce a similar frequency of clustered mutations (p value 0.32). However, A3G in the presence 
of VifIIIB induced significantly less clustered mutations (p value 0.02). 
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encounters on HIV-1 (-)DNA during viral replication and suggests that the decrease in A3G-
induced mutagenesis seen in the HIV-1 replication assay (Fig. 3.2) was due to a partial inhibition 
of A3G processivity by the Vif variants (Fig. 3.4, A-C). 
 To further test this hypothesis, we examined the sequences of clones from the HIV-1  
replication assay. We can analyze the spatial proximity of mutations in the clones and relate it to 
processivity where clustered mutations are indicative of scanning by local sliding and distantly 
spaced singleton mutations are indicative of scanning by jumping [139]. Areas of the 368 nt 
(+)DNA sequence (contains prot and lacZα), which contain multiple G residues were used to 
analyze the frequency of clustered A3G-induced G→A mutations. If the sliding component of 
A3G ssDNA scanning mechanism is retained, A3G should be able to induce mutagenesis at 
multiple G residues in a close region, i.e., 10 nt or less. The mean clustered mutation frequency 
for A3G alone (Fig. 3.5, 0.48) is similar to the situation when VifHXB2 is present (Fig. 3.5, 0.33, p 
value 0.32). These data are consistent with Fig. 3.4 A-C, which shows that A3G retains the 
ability to slide, but not jump, in the presence of VifHXB2. In the presence of VifIIIB, A3G is less 
capable of inducing mutations that are closely spaced (Fig. 3.5, 0.14, p value 0.02). This 
indicates A3G is less able to scan ssDNA by sliding when VifIIIB is present and is in agreement 
with processivity data obtained from synthetic substrates (Fig. 3.4, A-C).  
3.3.4 Inhibitory mechanism of Vif is mediated by an interaction with A3G. A3G is known to 
physically interact with Vif [63, 225, 246], which suggests that Vif could alter the processivity of 
A3G through a protein-protein interaction. That the two Vif variants affect A3G processivity 
differently supports this notion (Fig. 3.4 and Fig. 3.5). To investigate this possibility, we used the 
A3G D128K mutant (referred to as D128K) which is insensitive to Vif-mediated degradation and 
has been shown to have a disrupted physical interaction with Vif [353]. Our rotational anisotropy 
data confirm the previous findings as we found no detectable interaction between fluorescein (F) 
labeled D128K and the Vif variants (Table 3.5). However, using F-A3G we found that VifHXB2 
and VifIIIB interact similarly with F-A3G. The measured apparent Kd values of 90 nM (VifHXB2) 
and 78 nM (VifIIIB) for F-A3G indicate a strong interaction can occur between these proteins 
(Table 3.5). 
We tested the ability of D128K to induce mutations in a model HIV-1 replication system 
in the absence and presence of the Vif variants. The mutational spectrum for D128K alone shows  
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Table 3.5 Apparent dissociation constants (Kd) of A3G, D128K, and Vif variants. 
 
      
Apparent dissociation constant (Kd), nM 
F-A3G F-D128K prot (-) ssDNA 118 nt ssDNA 
Enzyme 
A3G   270 ± 59 203 ± 18 
D128K    183 ± 13 
VifHXB2 90 ± 15 no binding detected 27 ± 1 67 ± 18 
VifIIIB 78 ± 10 no binding detected 92 ± 13 79 ± 15 
A3G + VifHXB2    158 ± 20 
A3G + VifIIIB    135 ± 11 
D128K + VifHXB2    72 ± 10 
D128K + VifIIIB    51 ± 19 
 
The apparent Kd values are shown with the standard error of the mean that was calculated from 
three independent experiments. No value indicates that the experiment was not conducted.  
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Table 3.6 D128K-mediated mutation frequencies in a model HIV replication system in the 
absence and presence of VifHXB2 and VifIIIB. 
 
Reaction condition Population mutation frequency Clone mutation frequency (x10-2) 
D128K  0.96 2.2 
D128K + VifHXB2  0.93 2.3 
D128K + VifIIIB 0.90  2.6c 
 
The ratio of white colonies to total colonies is defined as the population mutation frequency. The 
average number of G→A mutations per base pair in the 368 nt prot-lacZα construct is defined as 
the clone mutation frequency  
a Significant difference was designed as p≤0.001 versus D128K values. 
b Significant difference was designed as p≤0.01 versus D128K values. 
c Significant difference was designed as p≤0.05 versus D128K values. 
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Figure 3.6 A3G D128K-induced mutagenesis is unaffected by VifHXB2 and VifIIIB in a model HIV 
replication system. A-C, spectra of mutations incurred in 368 nt prot-lacZα construct are plotted 
as percent of clones containing a mutation at a particular location (nt) for (A) D128K, (B) 
D128K in the presence of VifHXB2 and (C) D128K in the presence of VifIIIB. D-F, histograms 
illustrate that the population distribution of mutations per prot-lacZα construct for (D) D128K 
which is not decreased in the presence of (E) VifHXB2 or (F) VifIIIB. 
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peaks for highly mutated sites in the same locations as for A3G (compare Fig. 3.2A and Fig. 
3.6A). The intensity of the mutations among the sites differs slightly, likely owing to the 
stochastic nature of A3G deamination. The mutation frequencies are nearly identical for D128K 
and A3G at the population level (Table 3.6, D128K, 0.96; Table 3.1, A3G, 0.87) and clone level 
(Table 3.6, D128K, 2.2 x 10-2; Table 3.1, A3G, 2.2 x 10-2). Overall, the results are consistent with 
D128K behaving similar to A3G in this assay. When both VifIIIB and Vif HXB2 are added to the 
reaction with D128K we observe no decrease in the mutagenic ability of D128K (Fig. 3.6, A-F 
and Table 3.6), in contrast to A3G (Fig. 3.2, A-F and Table 3.1). In addition, we found no effects 
on D128K processive scanning by sliding by the addition of VifHXB2 or VifIIIB to the model HIV-1 
replication assay as the mutation cluster frequency (Fig. 3.7) and frequency of mutations (Fig 3.6 
and Table 3.6) remained constant in all three experimental conditions. This observation is in 
agreement with data obtained on the 118 nt substrate where neither VifHXB2 or VifIIIB were found 
to change D128K processivity (data not shown). Altogether, the data support a model in which 
an alteration in the processivity of A3G in the presence of Vif is caused by a Vif-A3G interaction. 
3.3.5 Vif affects the specific activity of A3G and D128K. Despite evidence that a Vif-A3G 
interaction is responsible for the observed decrease in A3G-induced mutagenesis (Table 3.4 and 
compare Fig. 3.5 and Fig. 3.2), Vif has been shown to bind DNA and RNA molecules [293, 354, 
355]. Therefore, we assessed whether the Vif variants could additionally alter A3G deamination 
activity, i.e., decrease specific activity, by binding to the ssDNA substrate. Rotational anisotropy 
data show that A3G could bind to the substrate used in the processivity assays (Fig. 3.4A, 118 nt  
substrate) with an apparent Kd of 203 nM (Table 3.5), which is approximately 3-fold higher than 
the apparent Kd values of the Vif variants for this substrate (Table 3.5, Kd of VifHXB2, 67 nM; Kd 
of VifIIIB, 79nM). We also examined the binding of A3G and Vif to the prot (-)DNA which was 
part of the deamination substrate for the HIV-1 replication assay (Fig. 3.2). We observed A3G 
binding to the prot (-)DNA (Table 3.5, Kd of A3G, 270 nM) with an apparent Kd that was 10-fold 
(Table 3.5, Kd of VifHXB2, 27 nM) or 3-fold (Table 3.5, Kd of VifIIIB, 92 nM) higher than the Vif 
variants binding to this substrate. Therefore, in both our experimental systems, the apparent Kd 
values of Vif for DNA and F-A3G (Table 3.5, Kd of F-A3G from VifHXB2 and VifIIIB is 90 nM and 
78 nM, respectively) are similar, giving the possibility that Vif could compete with A3G for the 
ssDNA substrate and decrease the specific activity of A3G. 
 To test this hypothesis, we used D128K, which does not interact with Vif (Table 3.5).  
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Figure 3.7 VifIIIB and VifHXB2 do not decrease the mutation cluster frequency of D128K. Analysis 
of sequenced clones obtained from HIV replication assay conducted for D128K in the absence 
and presence of VifHXB2 and VifIIIB. Frequency of clustered mutations was scored in eight regions 
of the prot-lacZα that contain three to six G residues. Inferred sliding and jumping movement 
from clustered and distantly spaced mutations, respectively, are unchanged by the presence of 
VifHXB2 or VifIIIB. Horizontal bars represent the average mutation cluster frequency. The data 
show that D128K alone and in the presence of VifHXB2 or VifIIIB induce a similar frequency of 
clustered mutations (p value 0.96 and 0.75, respectively).  
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Table 3.7 Specific activities of A3G and D128K in the absence and presence of Vif variants.  
 
Reaction condition Specific Activity (pmol/µg/min) 
A3G 10 ± 0.3 
A3G + VifHXB2 1.2 ± 0.3 
A3G + VifIIIB 1.8 ± 0.9 
D128K 40 ± 9 
D128K + VifHXB2 0.5 ± 0.2 
D128K + VifIIIB 0.8 ± 0.4 
 
The specific activity was determined using the 118 nt substrate and the values are shown with the 
standard error of the mean that was calculated from three independent experiments.  
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There was no effect of Vif on D128K-induced mutagenesis (Fig. 3.7), suggesting that Vif 
interactions with the DNA in the HIV-1 replication assay are inconsequential with regards to 
processivity (Fig. 3.6). Notwithstanding, a decrease in specific activity could be occurring, but 
cannot be observed in the HIV-1 replication assay because deamination events are dependent on 
and limited by other factors such as the rates of RNA degradation and (+)DNA synthesis. To 
determine if Vif can decrease the specific activity of A3G or D128K, we used the 118 nt ssDNA 
substrate previously used for the processive deamination assay (Fig. 3.4). The experiment 
involved Vif and D128K or A3G being preincubated together and then the reaction was started 
by the addition of the 118 nt ssDNA substrate. On the 118 nt ssDNA substrate, D128K has a 4-
fold higher specific activity (Table 3.7, 40 pmol/µg/min) than A3G (Table 3.7, 10 pmol/µg/min). 
However, Vif (HXB2 and IIIB) can decrease D128K specific activity 80-fold (Table 3.7, D128K 
+ VifHXB2, 0.5 pmol/µg/min) or 50-fold (Table 3.6, D128K + VifIIIB, 0.8 pmol/µg/min) in 
comparison to an 8-fold (Table 3.7, A3G + VifHXB2, 1.2 pmol/µg/min) or 6-fold (Table 3.7, A3G 
+ VifIIIB, 1.8 pmol/µg/min) decrease in A3G activity. These data suggest that there is a significant 
amount of Vif binding the 118 nt ssDNA substrate in the presence of D128K, causing a large 
decrease in specific activity. To investigate this further we determined the apparent Kd of a 
D128K and VifHXB2 mixture and found the value (Table 3.5, Kd of 72 nM) was almost identical to 
that of VifHXB2 alone (Table 3.5, Kd of 67 nM). These data support the hypothesis that Vif has a 
dominant role in ssDNA binding in the presence of D128K that has an approximately 3-fold 
higher apparent Kd than Vif (Table 3.5, Kd of 183 nM). Similar results were found with a D128K 
and VifIIIB mixture binding to the 118 nt ssDNA substrate (Table 3.5, Kd of 51 nM). In contrast, 
an A3G and VifHXB2 or A3G and VifIIIB complex had an apparent Kd (Table 3.5, A3G and VifHXB2, 
Kd of 158 nM; A3G and VifIIIB, Kd of 135 nM ) that was above that of VifHXB2 or VifIIIB alone 
(Table 3.5, VifHXB2, Kd of 67 nM; VifIIIB, Kd of 79 nM). Based on these data, it appears that Vif 
molecules that interact with A3G may not be able to bind the ssDNA substrate efficiently 
through the Vif DNA binding domain since it is near the A3G interaction residues. This would 
lower the effective DNA binding concentration of Vif and result in an increase in the apparent Kd 
value (Table 3.5). However, the Vif variants may still contact the ssDNA since the A3G/Vif 
complex apparent Kd values are slightly below that of A3G alone (Table 3.5, Kd of 203 nM). 
 In contrast to A3G, which has a decrease in processivity in the presence of Vif (Fig. 3.4), 
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we do not observe a decrease in D128K processivity on the 118 nt substrate (data not shown) or 
in the HIV-1 replication assay (Fig. 3.6 and Fig. 3.7) in the presence of the Vif variants, despite 
the decrease in specific activity (Table 3.7). Together with binding data (Table 3.5), the results 
indicate that Vif can bind ssDNA and compete with D128K for substrate access, which results in 
a decrease in D128K specific activity (Table 3.7). This activity is lessened in the presence of 
A3G (Table 3.7) which binds Vif with high affinity (Table 3.5). Therefore, the data support a 
model where the inhibition of processivity and specific activity by Vif are two different functions 
mediated by an A3G-Vif or ssDNA-Vif interaction, respectively.  
3.4 Discussion  
 Although Vif induces polyubiquitination and degradation of A3G in HIV-1 infected cells 
[70, 225, 246], the clearance of A3G from the host cell may not be complete [93, 124]. Vif can 
use alternate ways of inhibiting A3G activity such as suppressing A3G mRNA translation, 
blocking virus encapsidation of A3G, and inhibiting A3G deamination activity [64, 223, 298, 
299, 348, 349]. Here we examined the mechanism by which Vif can inhibit A3G deamination 
activity. Our data demonstrate that Vif changes the processive scanning mechanism of A3G (Fig. 
3.4) and this appears to account for the observed decrease in A3G-induced mutagenesis 
occurring in a model HIV-1 replication system (Fig. 3.2). The data indicate that the change in 
A3G processivity by the Vif variants is due to a protein-protein interaction since A3G D128K-
induced mutagenesis is unaffected by Vif (Fig. 3.6). The implications of the data are that any 
residual A3G that escapes Vif-mediated degradation and becomes encapsidated into HIV-1 
virions in the presence of Vif is likely to be ineffective at restricting HIV-1 replication [93, 124]. 
Vif and A3G co-encapsidation could also be induced by a therapeutic option that prevents Vif 
interaction with ubiquitin ligase components, but retains Vif interaction with A3G [311]. Of note, 
while this work was being completed it was discovered that CBF-β stabilizes Vif in cells [68, 69]. 
We confirmed that a CBF-β/Vif complex similarly affects A3G processivity and specific activity 
as the GST-Vif used in our study (Fig. 3.8, Table 3.8, and see Material and Methods), which 
provides additional evidence that Vif is likely to affect A3G deamination ability in vivo. The 
results of the model HIV-1 replication assay for A3G (Fig. 3.2 and Fig. 3.5) and D128K (Fig. 3.6 
and Fig. 3.7) in the presence of the Vif variants supports a model in which a Vif-A3G complex 
results in a decreased ability of A3G to deaminate C→U processively, resulting in a decrease in 
mutagenesis. However, we examined if there were additional effects caused by Vif binding  
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Figure 3.8 Determination of processivity of A3G in the absence and presence of CBFβ/VifHXB2 
and CBFβ/VifIIIB. CBFβ/VifHXB2 and CBFβ/VifIIIB demonstrate a similar effect on A3G as GST-
VifHXB2 and GST-VifIIIB (Fig.3, A-B). A, deamination of a 118 nt F-labeled ssDNA substrate by 
A3G. Two CCC motifs within the ssDNA sequence are spaced 61 nt apart. Single deaminations 
of the 5'C and 3'C are detected as the appearance of labeled 100- and 81 nt fragments, 
respectively; double deamination of both C residues on the same molecule results in a 63 nt 
labeled fragment (5'C & 3'C). A3G processivity is decreased by ~1.7-fold in the presence of 
CBF-β/VifHXB2 (+ CBF-β/VifHXB2) and   CBF-β/VifIIIB (+ CBF-β/VifIIIB). B, deamination of the 
substrate described for (A), but with a 20 nt ssDNA annealed between the two CCC motifs 
which can block the sliding component of A3G processivity. This results in a ~2-fold decrease in 
A3G processivity. Processive deaminations are still observed due to the jumping component of 
A3G processive movement. In the presence of CBF-β/VifHXB2 the processivity of A3G is nearly 
absent indicating that the jumping component of A3G has been inhibited. This is in contrast to 
the VifIIIB that has no effect on A3G jumping movement. The measurements of processivity 
(Processivity factor) are shown below the gel. The standard deviation for the processivity factors 
are (A) A3G, 1.4; + CBFβ/VifHXB2, 0.6; + CBFβ/VifIIIB, 0.3 (B) A3G, 0.8; + CBFβ/VifHXB2, 0.9; + 
CBFβ/VifIIIB, 0.7.  
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Table 3.8 Specific activities of A3G the absence and presence of CBF-β/Vif variants.  
 
Reaction condition Specific Activity (pmol/µg/min) 
A3G 8.0 ± 0.8 
A3G + CBF-β/VifHXB2 1.2 ± 0.5 
A3G + CBF-β/VifIIIB 1.3 ± 0.7 
 
The specific activity was determined using the 118 nt substrate and the values are shown with the 
standard error of the mean that was calculated from three independent experiments. The specific 
activities of A3G the absence and presence of CBF-β/Vif variants are similar to those obtained 
with the GST-Vif variants (Table 3.7). 
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ssDNA. We reasoned that the ssDNA binding effects of Vif would manifest as a decrease in 
specific activity of A3G or D128K due to competition for substrate binding. This cannot be 
observed in the HIV-1 replication assay due to substrate access being limited by RNA 
degradation and (+)DNA synthesis. While this alone argues that the inhibition of A3G 
processivity by Vif is of primary importance, we examined the effect of Vif binding a synthetic 
ssDNA substrate to fully characterize the mechanisms by which Vif can affect A3G deamination 
activity. We hypothesized that because the residues of Vif that interact with A3G are near the Vif 
RNA/DNA binding domain [355], the A3G-Vif complex may contact ssDNA more efficiently 
through A3G DNA binding residues. This would argue that there is a minimal effect of Vif on 
A3G specific activity. Consistent with the model is the observed smaller decrease in A3G 
specific activity (Table 3.7, 6- to 8-fold) than D128K specific activity (Table 3.7, 50- to 80-fold) 
in the presence of the Vif variants. As such, our data are in agreement with previously published 
literature that Vif can decrease A3G deamination activity [298, 299], but here we find that the 
mechanism by which this occurs is Vif affecting primarily the processive scanning (Fig. 3.4, A-C 
and Fig. 3.5) rather than the specific activity (Table 3.7) of A3G. This is also supported by 
rotational anisotropy data where Vif variants bind ssDNA with the same apparent Kd in the 
absence or presence of D128K, but have an increase in the apparent Kd in the presence of A3G 
(Table 3.5). Based on the data obtained with D128K where we observed a decrease in specific 
activity (Table 3.7), but not processivity (Fig. 3.6 and Fig. 3.7), it appears that these two 
inhibitory functions are implemented by free Vif and A3G bound Vif, respectively (Table 3.5 
and 3.7). The Vif-bound A3G does not efficiently induce mutagenesis of (-)DNA suggesting that 
both processive jumping and sliding movements are required, in agreement with other reports 
[133, 139]. 
Vif is known to physically interact with A3G and Asp128 is a key residue that mediates 
this interaction [280]. The Asp128 is predicted to be located on loop 7 of the N-terminal half of 
A3G (Fig. 3.1). The predicted loop 7 is functionally important because the amino acids 
124YYFW127 located in this region mediate virion incorporation [137, 138], oligomerization [138, 
140] and the jumping component of A3G processivity [139]. The proximity of Asp128 to the key 
processivity residues, 126FW127, which mediate A3G jumping movements [139], provides a 
logical explanation of how VifHXB2 can block the jumping ability of A3G (Fig. 3.4, A-C). 
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Together with the high affinity of A3G for binding VifHXB2 (Table 3.5), the data support that 
VifHXB2 inhibition of A3G deamination ability is primarily through a protein-protein interaction. 
It has been demonstrated that a loss of jumping ability in the A3G F126A/W127A mutant 
resulted in a large decrease of A3G-induced mutations in the HIV-1 replication assay [139] and 
we observe the same phenomenon here (Fig. 3.2, A-B and D-E). The decreased mutagenesis 
observed in the HIV-1 replication assay is likely to correlate with a decrease in HIV-1 infectivity 
since virion encapsidated F126L or W127A mutants are less effective at restricting HIV-1 in 
single cycle infectivity assays [137]. We have hypothesized that this is because A3G requires the 
jumping component of its processive mechanism to effectively transverse the RNA/DNA hybrid 
regions left by RT RNase H activity [139]. In the presence of VifHXB2, A3G is capable of sliding, 
but any surrounding RNA/DNA hybrid regions would essentially lock the A3G into an isolated 
area of (-)DNA. Due to the extended residence time A3G has on ssDNA, a half-life of ~4 min 
[141], remaining in a confined (-)DNA region would result in an ineffective search over the 
whole (-)DNA (Fig. 3.2, compare A and B and D and E).  
Interestingly, VifIIIB has a different effect on A3G processivity than VifHXB2 and inhibits 
A3G sliding (Fig. 3.2, A-C, Fig. 3.4). Based on phylogenic analysis, VifIIIB is less similar to 
VifHXB2 than other variants, such as VifELI-1 or VifYU-2 (Fig. 3.9) providing a rationale for the 
difference in their effect on A3G and suggests that the inhibition of A3G jumping rather than 
sliding is more likely to be observed in other variants. It has been suggested that the sliding 
component of A3G is mediated by helix 6 [139]. Helix 6 is predicted to be adjacent to loop 7 
(Fig. 3.1). The contacts of Vif with A3G have been shown to encompass 128DPD130 on loop 7 and 
hypothesized to also extend beyond loop 7 [267], which is supported by a mutagenesis study 
[356]. However, the A3G-Vif interface identified by Letko et al. [284] through functional assays 
and molecular docking did not recognize helix 6 to be involved in A3G-Vif interaction. This may 
explain why the addition of VifIIIB does not cause a more severe effect on A3G than VifHXB2 in the 
model HIV replication system (Table 3.1). VifIIIB may stabilize itself on A3G primarily by 
interacting with loop 7 and subsequently establish an unstable interaction with helix 6. 
Conformational change and structural flexibility in A3G could be induced upon VifIIIB binding to 
A3G (presumably through loop 7) [312], which allows VifIIIB to contact helix 6 and affect the 
sliding motion of A3G. Nevertheless, random mutagenesis identified residues in the N-terminal 
domain predicted helices 3, 4, and 6 and predicted loops 1 and 3 that interact with VifIIIB [356].  
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VifIIIB
VifHXB2
VifYU-2
VifELI-1
VifJR-CSF  
Figure 3.9 Phylogram of Vif variants. The GenBank accession numbers for the Vif variants are: 
M19921 (VifIIIB), K03455 (VifHXB2), K03454 (VifELI-1), M38429 (VifJR-CSF), and AY569174 
(VifYU-2). Phylogram was made using Clustal W. 
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This may be due to a charged surface on A3G that interacts with Vif through multiple structural 
components. This appears to be the case for A3F, which interacts with Vif through its C-terminal 
half, where a negatively charged surface surrounding predicted C-terminal helices 2, 3, and 4 
may interact with Vif in addition to a key residue, Glu 289 [205, 285, 287, 288]. These reports 
provide a supporting rationale for how A3G sliding, which is mediated by helix 6 [139], could be 
affected in our study by VifIIIB. Furthermore, VifIIIB and VifHXB2 have been found to differentially 
mediate the extent of APOBEC3 enzyme degradation [295], which implies they may interact 
with A3G differently beyond residues 128DPD130. Since A3G and VifIIIB interact with high affinity 
(Table 3.5, Kd of 78 nM), the data support the conclusion that VifIIIB inhibition of A3G activity is 
primarily through a protein-protein interaction that disrupts the sliding component of the 
processive ssDNA scanning mechanism.  
It has previously been reported that any type of small molecules that could be designed to 
bind A3G and block its interaction with Vif may not be a relevant therapeutic option if A3G 
functions imparted by the residues adjacent to Asp128, such as virion encapsidation, are also 
affected [267, 300]. For this reason, alternate therapeutic options have been put forward such as 
small molecules that bind Vif [301] or the ubiquitin ligase complex [309, 311] to inhibit 
degradation of A3G. The latter therapeutic option would presumably allow a maintained 
interaction between Vif and A3G. Based on our data, a therapeutic option that left Vif in the cell 
allowing it to form a Vif-A3G complex would not enable virion encapsidated Vif-A3G to 
reliably restrict HIV-1 replication (Fig. 3.2, A-F and Fig. 3.3). Because the number of A3G-
induced mutations has been correlated with HIV-1 inactivation [124, 151],  an implication of our 
results is that the Vif-A3G complex could lead to sublethal mutagenesis of HIV-1. However, 
reports published recently suggest that A3G-induced sublethal mutagenesis is likely to be an rare 
event and it does not promote HIV-1 evolution more than RT replication errors [75, 76], which 
indicates A3G can act in the host’s favor and irretrievably inactivate HIV-1 through lethal 
mutagenesis, regardless of the presence of Vif inside virions. Nevertheless, our data indicate that 
Vif can make virion encapsidated A3G less effective and small molecular inhibitors that disrupt 
Vif-mediated degradation pathway of A3G thus allowing the co-packaging of Vif-A3G could be 
provide a potential avenue for therapeutic intervention.   
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Table 3.9 Primers and DNA substrates. 
 
Name Sequence 
VifIIIB Forward  ATG GAG AAC CGG TGG CAG GTG ATG 
VifIIIB Reverse  CTA GTG TCC ATT CAT TGT ATG GCT CCC 
VifHXB2 Forward  ATG GAA AAC AGA TGG CAG GTG 
VifHXB2 Reverse  C TA GTG TCC ATT CAT TGT GTG 
CBF-β Forward  ATG CCG CGC GTC GTG CCC GAC CAG A 
CBF-β Reverse  CTA GGG TCT TGT TGT CTT CTT GCC AGT TAC TGC CAG 
D128K SDM Forward CC CGC CTC TAC TAC TTC TGG AAG CCA GAT TAC CAG 
GAG GCG CTT C 
D128K SDM Reverse GA AGC GCC TCC TGG TAA TCT GGC TTC CAG AAG TAG 
TAG AGG CGG G 
L60 (deamination assay 
and anisotropy) 
GAA TAT ATG TTG AGA CCC AAA GTA ATG AGA GAT 
TGA [dT-Fam] TAG ATG AGT GTA ATG TGA TAT ATG TGT 
ATG AAA GAT ATA AGA CCC AAA GAG TAA AGT TGT 
TAA TGT GTG TAG ATA TGT TAA 
L60 complementary DNA CTT TCA TAC ACA TAT ATC AC 
L60 complementary RNA CUU UCA UAC ACA UAU AUC AC 
Protease (-) DNA 
(anisotropy) 
[5'-Fam] GAT AAA ACC TCC AAT TCC CCC TAT CAT TTT 
TGG TTT CCA TTT CCC TGG CAA ATT TAT ATC TTC TAA 
TAC TGT ATC ATC TGC TCC TGT ATC TAA TAG  AGC TTC 
TTT CAG TTG TCC TCC TAT 
 
Abbreviations are: SDM, site directed mutagenesis; Fam, fluorescein. 
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3.5 Material and Methods 
3.5.1 Protein Expression and Purification. Recombinant baculovirus production for expression 
of GST-A3G, GST-A3G D128K, GST-VifIIIB, GST-VifHXB2 or GST-nucleocapsid protein (NC) in 
Sf9 cells was carried out using the transfer vector pAcG2T (BD Biosciences), as previously 
described [132, 139]. VifNL4-3 was cloned from pcDNA-hVif vector that encodes the Vif protein 
of HIV-1 NL4-3, which was obtained from the NIH AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH from Dr. Stephan Bour and Dr. Klaus Strebel [357]. 
HIV-1 NL4-3 and HIV-1 IIIB have the same Vif sequence and we have referred to Vif from this 
clone as VifIIB. VifHXB2 was cloned from pHIV-gpt(wt), a gift from Dr. David Kabat (Oregon 
Health and Science University). Site directed mutagenesis was used to create the A3G D128K 
clone. Cloning primers for Vif variants and the site directed mutagenesis primers were obtained 
from Integrated DNA Technologies and are listed Table 3.9. Sf9 cells were infected with 
recombinant virus at a multiplicity of infection (MOI) of 1, except for GST-VifIIIB and GST-
VifHXB2 which were infected at an MOI of 4 or 2, respectively. Recombinant baculovirus infected 
Sf9 cells were harvested after 72 h of infection, except for GST-VifIIIB and GST-VifHXB2 which 
were harvested after 48 h of infection. Cells were lysed in the presence of RNase A and the 
proteins (A3G, A3G D128K, and NC) were purified as described previously [140] to obtain 
protein that was cleaved from the GST tag and 95% pure. The Vif variants were eluted from the 
glutathione-sepharose resin (GE Healthcare), as previously described [132], with the GST tag to 
maintain their stability. Eluted GST-Vif variants were dialysed against 100 mM Tris pH 7.5, 250 
mM NaCl, 10% glycerol, and 1 mM DTT and are 85% pure. Protein fractions were stored at -
80 °C. HIV-1 reverse transcriptase p66/p51[358] was generously provided by Dr. Stuart F.J. Le 
Grice (NCI, National Institutes of Health).  
Recombinant expression of VifHXB2 or VifIIIB in the presence of CBF-β was done in E. coli 
using the double expression vector, pET-DUET (Novagen). CBF-β tagged was hexa histidine 
tagged at the N-terminus. VifIIIB was cloned from pcDNA-hVif vector that encodes the Vif 
protein of HIV-1 NL4-3, which was obtained from the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH from Dr. Stephan Bour and Dr. Klaus Strebel 
[357]. VifHXB2 was cloned from pHIV-gpt(wt), a gift from Dr. David Kabat (Oregon Health and 
Science University). CBF-β isoform 2 (Accession number BC018509) was obtained from Open 
Biosystems. Cloning primers were obtained from Integrated DNA Technologies and are listed in 
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Table 3.9. Induction of exponential phase BL21(DE3) E. coli cells with IPTG (0.2 mM) 
proceeded at 16 °C for 18 h. Cells were lysed in lysis buffer containing 20 mM Tris pH 7.5, 150 
mM NaCl, 1 mM DTT, complete protease inhibitor (Roche), 1 mg/mL lysozyme, and 40 µg/mL 
RNAseA in combination with sonication. Cleared lysates were applied to HisTALON beads 
(Clontech) and purification of the protein was done following manufacturer’s instructions. Eluted 
CBF-β/Vif was applied to a HiLoad Superdex 75 (16/600) gel filtration column (GE Healthcare) 
and dimer fractions eluted in running buffer (100 mM Tris pH 7.5, 150 mM NaCl, and 1 mM 
DTT) were adjusted to contain 10% glycerol before storage at -80 °C. Protein preparations 
are >95% pure.  
3.5.2 Model HIV-1 Replication Assay. The model HIV-1 replication assay, which measures 
A3G-induced mutagenesis of ssDNA during reverse transcription of an RNA template, was 
performed as described previously [139]. A synthetic (+) RNA genome is synthesized in vitro 
that contains a PPT, 120 nt of the catalytic domain of the HIV-1 protease (prot), and lacZα (248 
nt). The PPT enabled second strand ((+)DNA) synthesis to occur. The lacZα was used as a 
reporter gene for mutations by blue/white screening. The originating sequence of the HIV-1 
protease gene is from a clone obtained through the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: p93TH253.3 from Dr. Feng Gao and Dr. Beatrice 
Hahn[359]. The RNA template (25 nM) was annealed to a 24 nt DNA primer and incubated with 
NC (1.5 μM), RT (1.2 μM), and dNTPs (500 μM) in RT buffer (50 mM Tris pH 7.4, 40 mM KCl, 
10 mM MgCl2, 1 mM DTT) in the presence or absence of 100 nM of A3G or A3G D128K. A3G, 
RT and NC are added to the reaction at ratios to the RNA that are estimated to be found in 
virions [5, 92, 360, 361]. Reactions containing A3G or A3G D128K were conducted in the 
presence or absence of 175 nM VifIIIB or VifHXB2. Synthesized DNA was PCR amplified using 
Pfu Turbo Cx (Agilent Technologies) and cloned into a pET-Blue vector backbone that would 
allow the experimentally synthesized lacZα to be used for α-complementation[139]. Twenty-five 
mutated clones for each condition tested were analyzed. DNA sequencing was carried out at the 
National Research Council of Canada (Saskatoon, Saskatchewan). A t-test was used for 
statistical analysis of sequences.  
3.5.3 Deamination Assays. The 118 nt ssDNA substrate was obtained from Tri-Link 
Biotechnologies and the sequence is Table 3.9. A3G and A3G D128K (10-20 nM) were 
incubated with 100 nM fluorescein (F)-labeled ssDNA and 700 nM Vif (IIIB or HXB2) in RT 
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buffer. The substrate to A3G ratio is kept high to ensure reactions were carried out under single-
hit conditions, i.e., < 15% substrate consumed, where a single A3G could interact with a 
particular ssDNA substrate at most once[362]. Reactions were incubated at 37°C for 2.5 - 40 min. 
Deaminations were detected by resolving DNA that had been treated with Uracil DNA 
Glycosylase and heated under alkaline conditions on a 10% v/v denaturing polyacrylamide gel, 
as described previously[132]. Gel pictures were obtained using a Typhoon Trio (GE Healthcare) 
multipurpose scanner and analysis of integrated gel band intensities used ImageQuant software 
(GE Healthcare). Under these conditions, a processivity factor can be determined by comparing 
the total number of deaminations occurring at two sites on the same DNA substrate to a 
calculated theoretical value of the expected deaminations that would occur at those two sites if 
the events were uncorrelated, i.e., not processive [139]. The specific activity was calculated from 
single-hit condition reactions by determining the picomoles of substrate consumed per minute for 
a microgram of enzyme. The addition of DNA was used to start the deamination reactions. Prior 
to the addition of DNA the reaction components were prewarmed to 37°C. 
3.5.4 Steady State Rotational Anisotropy Assays. Steady state fluorescence depolarization 
(rotational anisotropy) was used to measure protein-nucleic acid and protein-protein binding 
affinities using a F-labelled binding partner. A QuantaMaster QM-4 spectrofluorometer (Photon 
Technology International) with a dual emission channel was used to collect data and calculate 
anisotropy. Measurements were made at 21°C. Samples were excited with vertically polarized 
light at 495 nm (6 nm band pass) and vertical and horizontal emissions were measured at 520 nm 
(6 nm band pass). Apparent dissociation constants (Kd) were obtained by fitting to a rectangular 
hyperbola or sigmoidal curve using Sigma Plot 11.2 software. 
 A3G, A3G D128K, VifIIIB, and VifHXB2 were tested for their ability to bind a 118 nt ssDNA 
substrate, which is listed in Table 3.9 and described in the text. Reactions were 50 μL and 
contained F-labelled ssDNA (50 nM) in RT buffer and A3G (0 - 700 nM) or Vif (0 - 200 nM) 
were titrated into the reaction. Alternatively, A3G or D128K were mixed with a Vif variant at an 
equimolar ratio before titration (0-350 nM) in to the reaction. 
 For protein-protein binding, A3G or A3G D128K were labeled with fluorescein using the 
Fluorescein-EX Protein Labeling Kit (Life Technologies). The F-A3G or F-D128K (50 nM) was 
used in a reaction mixture (50 µL) which contained RT buffer and a titration of VifIIIB or VifHXB2 
(0 - 200 nM). 
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4.0 Investigation of the degradation-independent and-dependent 
functions of Vif against A3s  
Two landmark papers published in late 2012 reported the core binding factor beta 
(CBFβ) acts as a pivotal Vif regulator by being part of the E3 ubiquitin ligase complex that is 
involved in polyubiquitinating and degrading Vif [68, 69] and these findings have prompted 
many questions to be revisited, including the physiological form of Vif that participates in the 
non-degradative Vif-mediated inhibition of A3 proteins. Understanding the physiologically 
active form of Vif allows the development of more relevant model system to study Vif-A3 
interactions in vitro. Vif needs to bind HIV-1 5’UTR to achieve virion encapsidation [363] and 
we have found that both forms of Vif, namely Vif/CBFβ heterodimer and Vif/CBFβ/EloB/C 
heterotetramer, are able to bind 5’UTR with high affinity, as the apparent Kd falls into the 
nanomolar range (Table 4.1), albeit some Vif variants-specific differences in binding affinities 
were observed. Whether the differences in RNA binding leads to different virion encapsidation 
efficiencies of the Vif forms was tested by examining the form of Vif encapsidated into HIV 
virions using western blot and antibodies against each native protein. The preliminary results 
indicate that Vif encapsidates in virions without CBFβ and EloB/C (Fig. 4.0). It may be that 
RNA binding stabilizes Vif and displaces CBFβ and the EloB/C complex. 
Through the investigation of the degradation-independent inhibition of A3G by Vif (see 
Chapter 3) [183], we used A3G D128K to help dissecting whether Vif inhibits A3G’s 
deamination activity through a protein-protein or protein-DNA interaction. We observed that 
upon mutating 128D to an alanine, instead of lysine, Vif could still cause a decrease in D128A-
induced mutagenesis in our reconstituted HIV replication system (Table 4.2), in contrast to what 
was observed for D128K [183] (Fig. 3.6). This data has made us realize that not just amino acids 
contacts, but the overall charge of the Vif-A3G interface was of importance. In addition, due to 
VifHXB2 and VifIIIB influence A3G DNA scanning and processivity differently (Fig. 3.4), we have 
obtained evidence that different Vif variants could use different amino acid contacts on A3G 
beyond the key 128D amino acid. Based on these findings, we next set out to test whether the 
different A3G-Vif interaction interface would have an impact on the strength of the interaction 
and if this would influence the efficiency of Vif-induced degradation.   
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Table 4.1 Binding affinities of different Vif forms for the HIV-1 5’UTR 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vif form Apparent binding constant 
(Kd), nM 
VifHXB2/CBFβ heterodimer 16 ± 1 
VifIIIB/CBFβ heterodimer 125 ± 18 
VifHXB2/CBFβ/EloB/C 
heterotetramer 
146 ± 20 
VifIIIB/CBFβ/EloB/C 
heterotetramer 
61 ± 9 
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Table 4.2 D128A-mediated mutation frequencies in a model HIV replication system in the 
absence and presence of VifHXB2 and VifIIIB. 
 
Reaction condition Population mutation frequency 
D128A  0.90 
D128A + VifHXB2  0.66b 
D128A + VifIIIB 0.82c 
 
The population mutation frequency is defined as the ratio of white colonies to total colonies. 
a Significant difference was designed as p≤0.001 versus A3G values. 
b Significant difference was designed as p≤0.01 versus A3G values. 
c Significant difference was designed as p≤0.05 versus A3G values. 
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Figure 4.0 Form of Vif in virions. 293T cells infected with HIV was produced in the absence or 
presence of HA-tagged A3G and levels of Elongin B (EloB), Vif, and CBFβ expressed in cells 
and encapsidated into HIV virions were determined using immunoblotting. The expression of 
EloB, Vif and CBFβ were detected using the native antibody. The loading control for cell lysates 
was α-tubulin and for virions was p24. Despite the Vif/CBFβ/EloB/C heterotetramer being 
required for Vif function in cells, in virions we could only detect Vif alone. No Elo B was 
detected in virions. We did not have an appropriate antibody to detect Elongin C (EloC); 
however, that the EloB/C form an obligate heterodimer suggesting that neither is present in the 
virion with Vif. CBFβ was also not present. Thus, the stable form of Vif in cells and virions may 
be different. In virions, RNA binding may stabilize Vif.  
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5.1 Abstract 
The APOBEC3 deoxycytidine deaminases can restrict the replication of HIV-1 in cell culture to 
differing degrees. The effects of APOBEC3 enzymes are largely suppressed by HIV-1 Vif that 
interacts with host proteins to form a Cullin5-Ring E3 ubiquitin ligase that induces 48K-linked 
polyubiquitination (poly-Ub) and proteasomal degradation of APOBEC3 enzymes. Vif variants 
have differing abilities to induce degradation of APOBEC3 enzymes, and the underlying 
biochemical mechanisms for these differences is not fully understood. We hypothesized that by 
characterizing the interaction of multiple APOBEC3 enzymes and Vif variants we could identify 
common features that resulted in Vif-mediated degradation and further define the determinants 
required for efficient Vif-mediated degradation of APOBEC3 enzymes. We used Vifs from HIV-
1 IIIB and HXB2 to characterize their induced degradation of and interaction with APOBEC3G 
and APOBEC3H in 293T cells. We quantified the APOBEC3G-Vif and APOBEC3H-Vif 
interaction strengths in vitro using rotational anisotropy. Our biochemical and cellular analyses 
of the interactions support a model in which the degradation efficiency of VifIIIB and VifHXB2 
correlated with both the binding strength of the APOBEC3-Vif interaction and the APOBEC3-
Vif interface, which differs for APOBEC3G and APOBEC3H.  
5.2 Introduction 
The APOBEC3 (A3) deoxycytidine deaminases can act as intracellular restriction factors 
against replication of HIV-1 (referred to as HIV) [99]. A3 enzymes that are encapsidated into 
budding HIV virions can restrict HIV replication in the next target cell by deaminating cytosine 
in (-) strand single-stranded DNA, which forms mutagenic uracils and results in numerous 
C/G→T/A transition mutations that can inactivate the virus [22-24]. In CD4+ T cells it appears 
that four of the seven A3 members, A3D, A3F, A3G, and A3H Haplotype II (referred to as A3H) 
are primarily responsible for HIV restriction [78]. Nonetheless, HIV can successfully infect cells 
where A3 enzymes are highly expressed due to the viral infectivity factor (Vif) protein [246, 
346]. Vif acts as a substrate receptor for a Cullin5-Ring E3 (Cul5-E3) ubiquitin ligase complex, 
which can induce polyubiquitination (poly-Ub) and degradation of A3 enzymes [70, 248]. This 
process is mediated by Vif binding to host Cullin5 and the Elongin B/C heterodimer (EloB/C) 
through specific motifs in Vif that mimic human SOCS2 [72, 91, 249-251]. Vif also binds with 
the transcription cofactor CBFβ for thermodynamic stability [68, 69]. Within this E3 ligase 
complex, Rbx2 recruits an E2 ubiquitin conjugating enzyme to induce 48K-linked poly-Ub of A3 
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enzymes, which is concomitant with their proteasomal degradation [63, 68, 70, 225, 247]. Vif 
interacts with A3s through its N-terminal domain (NTD) in distinct regions for A3G 
(40YRHHY44), A3H (39F, 48H), or A3C, A3D and A3F (14DRMR17) in conjunction with secondary 
binding sites [240, 265, 269-273, 364]. The positively charged surfaces of Vif interact with 
negatively charged amino acids on the A3 enzyme, with some contribution from hydrophobic 
amino acid interactions, depending on the interface [265]. There are three distinct structural 
motifs on the A3 enzymes that interact with a corresponding Vif region. These can be 
categorized in three classes: A3G-, A3H-, or A3C/A3F/A3D- like [265]. 
 A3G is a double Z-domain enzyme that primarily interacts with Vif through residues 
128DPD130 on predicted loop 7 in the NTD, 128DPD130 [267]. The 128D amino acid was identified as 
essential for Vif-mediated degradation and mediation of a cross-species barrier to simian 
immunodeficiency virus (SIV) by mutating 128D to 128K, as found in African Green Monkey or 
Rhesus Macaque A3G [278-281]. Multiple research groups found that Vif did not interact or 
induce degradation of the A3G D128K mutant. However, if the 128D was mutated to an alanine, 
Vif-mediated degradation occurred, demonstrating that the overall charge of the A3G-Vif 
interface was of importance and not only the amino acid per se [278, 280, 281]. The overall 
interface of A3G that interacts with Vif was studied through a MAPPIT analysis and it was 
found that VifIIIB could interact not only with 128D located on A3G structural loop 7 but also other 
adjacent structures, such as helix 6 [283]. The MAPPIT analysis was in agreement with other 
studies that identified larger regions of Vif binding [131, 175, 183, 284]. Further, a study by our 
group found that VifIIIB and VifHXB2 interacted with different regions of the A3G NTD beyond 
128D [183]. This enabled each Vif variant to cause distinct changes in A3G enzymatic activity 
[183].  
 For A3H, Vif variant differences in the ability to induce A3H degradation are widespread 
and have been extensively studied [240, 276]. Data from cell culture and HIV-1 infected patients 
demonstrates that amino acids 39 and 48 in Vif are important for both the ability of Vif to induce 
degradation of and interact with A3H [240]. For example, VifLAI which contains 48H can induce 
degradation, but not VifIIIB that contains a 48N. It was concluded that VifIIIB is unable to degrade 
A3H due to an inability to efficiently associate with the enzyme [276]. For A3H, the interface 
that interacts with Vif occurs on predicted helix 4 with 121D being the primary determinant in 
Vif-mediated degradation efficiency [195, 211, 265, 290, 292]. Zhen et al. found that a D121K 
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mutant was unable to interact with Vif and concluded that similar to the example of A3G D128K 
a lack of Vif-induced degradation correlates with a lack of a A3-Vif interaction [290].  
 Vif interacts with the A3F/A3D interface through A3 helices 2, 3, 4, and β-strand 4 [205, 
285, 287, 288, 365, 366]. For A3F and A3D that contain two Z-domains, the structural motif is at 
their C-terminal domain (CTD). Extensive mutagenesis studies by several groups on A3F 
demonstrated that mutation of conserved residues on these helices cause less or abolish Vif-
mediated A3F degradation [205, 285, 288]. Mutation of A3F 263L, 264S or 324E that are involved in 
Vif-mediated degradation [205] did not decrease the binding affinity of Vif for A3F [365, 367], 
suggesting that for A3F the larger Vif binding interface is not as easily disrupted as for A3G and 
A3H [366]. However, Kitamura et al. and Richards et al. found that an A3F E324K mutant had a 
partial decrease in the A3F-Vif interaction [205, 287] and Siu et al. found no interaction of an 
E324Q mutant with Vif [365], demonstrating that there is experimental variability between labs 
and the relationship between a lack of Vif-mediated degradation and the A3-Vif interaction still 
requires further investigation.  
 Despite a large amount of data regarding A3 and Vif interactions, the biochemical basis 
of how Vif induces A3 substrate poly-Ub and degradation remains to be determined. Studies 
which examined differences in Vif variants and found specific nonconserved amino acids that 
were responsible for the ability to induce degradation suggest that the interaction strength with 
Vif is a primary determining factor in successful Vif-mediated degradation [240, 276]. However, 
these studies used qualitative co-immunoprecipitations to characterize these interactions. 
Therefore, to better understand the mechanistic role of Vif as the Cul5-E3 ubiquitin ligase 
substrate receptor we undertook a study to define the parameters for efficient Vif-induced 
degradation of an A3 enzyme, using both biochemical and cellular experiments. We 
hypothesized that the interaction strength between the A3 and Vif was not the sole determinant 
of degradation efficiency and that the A3-Vif interface also plays a role. To test this hypothesis, 
we used Vif variants from HIV NL4-3 (IIIB) and HXB2 and A3 enzymes that are either 
efficiently degraded by these Vifs (A3G) or not efficiently degraded by both Vifs (A3G D128K, 
A3H) [211, 240, 267, 278-281, 295]. We used cellular experiments to determine Vif-induced 
degradation efficiency and A3-Vif interactions in cells in conjunction with an in vitro 
quantitative method to determine the binding strength of A3G, A3G D128K and A3H with Vif 
variant heterotetramers (Vif/CBFβ/EloB/C), the most stable form of Vif [244, 252, 368]. Our 
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biochemical and cellular analyses of the interactions support a model in which the degradation 
efficiency of Vifs correlated with the both the A3-Vif binding strength and A3-Vif interface.  
5.3 Results 
5.3.1 Interaction of A3G with HIV-1 VifIIIB and VifHXB2.  A3G degradation is induced by all HIV 
Vif variants (referred to as Vif) tested in the literature [211, 240, 295, 369], including VifIIIB and 
VifHXB2 used in our study (Fig. 5.1). In Baig et al. [312], we have demonstrated the almost 
equivalent abilities of VifIIIB and VifHXB2 to induce proteasomal degradation of A3G in a 
degradation assay where A3G and partially codon optimized Vif expression plasmids were 
cotransfected into 293T cells. However, VifIIIB could induce slightly less degradation of A3G 
than VifHXB2 [312]. Evidence of the ability of VifHXB2 and VifIIIB to use different amino acid 
contacts on A3G beyond the key 128D amino acid exists from biochemical studies that examined 
the effect of Vif on A3G DNA scanning and processivity [183]. This biochemical data prompted 
us to test whether the different A3G-Vif interactions have an impact on the strength of the 
interaction and if this influenced the efficiency of Vif-induced degradation.  
To obtain a quantitative value for A3G interacting with VifHXB2 and VifIIIB we used 
rotational anisotropy. Rotational anisotropy measures the apparent change in rotation speed of a 
fluorescently labeled molecule due to a change in shape and/or molar mass of the molecule upon 
binding an unlabeled partner [370]. We fluorescently labeled A3G and titrated Vif 
heterotetramer (Vif/CBFβ/EloB/C) into the binding reaction. The binding of the fluorescently 
labeled A3G to the Vif heterotetramer will result in a change in rotation speed (anisotropy) until 
the fluorescently labeled A3G population is saturated with its binding partner. From these 
measurements an apparent dissociation constant (Kd) can be calculated. Since Vif must be 
coexpressed with CBFβ for stability [244], we would be unable to specifically label the Vif and 
therefore chose to fluorescently label A3G. Usually, upon a fluorescently labeled molecule 
interacting with a binding partner the increase in size of the complex causes the rotation speed to 
decrease, which results in an increase in rotational anisotropy. However, with A3G we found that 
there was a decrease in anisotropy, indicative of an increase in rotation speed (Fig. 5.2A). We 
hypothesized that this was due to Vif disrupting the dimers of A3G [140, 142] and interacting 
with a monomer of A3G since the key residues for A3G dimerization (126FW127) are adjacent to 
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Figure 5.1 Purity of enzymes used for in vitro biochemical assays. The purity of A3G, A3H 
(haplotype II), VifHXB2/CBFβ/EloB/C, VifIIIB/CBFβ/EloB/C was assessed by resolving 3.5 μg of 
purified recombinant proteins using 15% SDS-PAGE and staining with Coomassie blue. 
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Figure 5.2 Degradation efficiency and interaction of VifIIIB and VifHXB2 with A3G. (A) Steady 
state rotational anisotropy (fluorescence depolarization) was used to measure the binding 
strength between A3G and VifIIIB/CBFβ/EloB/C or VifHXB2/CBFβ/EloB/C (labeled as VifIIIB or 
VifHXB2). Anisotropy results were normalized to a start value of 0.14 and end value of zero for 
comparison. The actual anisotropy start value was between 0.14 and 0.12. The Vif variant 
heterotetramer was titrated into a binding reaction with fluorescently labeled A3G to determine 
an apparent dissociation constant (Kd). A change in anisotropy indicates an interaction between 
A3G and the Vif heterotetramer. The decrease in anisotropy indicated that the initial 
fluorescently labeled complex had decreased in size and/or undergone a conformational change 
that increased the speed of rotation (see sketch above panel A). The VifIIIB (apparent Kd 46 ± 7 
nM) and VifHXB2 (apparent Kd 11 ± 2 nM) heterotetramers efficiently interacted with A3G. Error 
bars represent the standard deviation of the mean from three independent experiments. (B) Size 
exclusion chromatography was used to determine the oligomerization state of an A3G-
Vif/CBFβ/EloB/C complex. For comparison, A3G alone and the Vif/CBFβ/EloB/C 
heterotetramer alone were resolved by size exclusion chromatography. Peak fractions were 
identified by the UV absorbance of the chromatogram and confirmed by resolving samples by 
SDS-PAGE. The graph represents the quantification of the coomassie stained bands shown in the 
SDS-PAGE gels. Comparison to molecular weight standards was used to calculate apparent 
molecular masses of peak fractions. The Vif/CBFβ/EloB/C heterotetramer resolved as a 
stoichiometric complex with an apparent molecular mass of 67 kDa (Fractions 26-27). A3G 
resolved as a dimer with an apparent molecular mass of 74 kDa in the peak fraction (Fraction 25). 
The A3G-Vif/CBFβ/EloB/C complex resolved in fractions 22-24 which gave an apparent 
molecular mass range of 157-96 kD. The presence of EloB/C in fractions containing Vif/CBFβ 
was confirmed by staining with Bio-rad Oriole stain (gel not shown).  
 
	 103	
 
128D [138, 140]. The existence of this stoichiometric complex (A3G/Vif/CBFβ/EloB/C) was 
confirmed with size exclusion chromatography (Fig. 5.2B). First, A3G and VifHXB2 
heterotetramer were run individually on the size exclusion column. Consistent with previous 
studies, A3G had an apparent molecular mass of a dimer (Fig. 5.2B, Fraction 25, 74 kDa) and the 
VifHXB2 heterotetramer was a 1:1:1:1 complex (Fig. 5.2B, Fraction 26, 67 kDa) [140, 258]. The 
A3G-VifHXB2 heterotetramer complex resolved in three peak fractions with apparent molecular 
masses ranging from 157– 96 kDa (Fig. 5.2B, Fractions 22-24). If a VifHXB2 heterotetramer were 
to interact with a monomer of A3G, the expected apparent molecular mass would be 111 kDa, 
which is within the range of the peak fractions (Fig. 5.2B, Fraction 23-24). Equivalent results 
were found with VifIIIB (data not shown). As a result, the apparent dissociation constants obtained 
were a measure of the ability of the Vif heterotetramer to disrupt A3G oligomerization, which 
was simultaneous with an interaction between the two proteins. A proportion of the VifHXB2 
heterotetramer interacts with a dimer of A3G (Fig. 5.2B, expected apparent molecular mass of 
141 kDa, Fraction 22). This is due to the size exclusion chromatography being run with a 1:1 
ratio of A3G:Vif heterotetramer to enable resolution of the different species. According to the 
rotational anisotropy data, we would require a 2-fold excess of Vif heterotetramer to completely 
disrupt the A3G dimer population in steady-state (Fig. 5.2A, 50 nM A3G saturates at 100 nM Vif 
heterotetramer).  
Consistent with efficient degradation by both Vifs, the apparent Kd of the A3G and Vif 
heterotetramer complexes were in the low nanomolar range (Fig 5.2A, VifIIIB, apparent Kd 46 ± 7 
nM; VifHXB2, apparent Kd 11 ± 2 nM). However, the apparent Kd of VifIIIB and A3G was 
approximately 4-fold higher than the apparent Kd of VifHXB2 and A3G (Fig. 5.2A). This 
difference, albeit only subtle, is consistent with results from the degradation assays where more 
residual A3G in the presence of VifIIIB than VifHXB2 was observed (data not shown and [312]) and 
suggests that small changes in the binding strength influence degradation efficiency. All together 
these data are consistent with other studies that demonstrated that the determining factor for the 
ability of Vif to degrade an A3 enzyme is a physical interaction.  
5.3.2. HIV-1 VifIIIB maintains an interaction with A3H in the absence of inducing degradation.  
To examine if determinants of the A3-Vif interaction are similar for other A3s, we studied A3H 
for comparison. A3H has been shown to interact with different amino acids on Vif than A3G and 
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is differentially sensitive to Vif variants from HIV NL4-3 (IIIB) and LAI [100, 240, 284, 292]. 
The VifHXB2 used in our study and VifLAI sequences are identical. Baig et al. [312] has shown that 
A3H was not sensitive to VifIIIB-mediated degradation, but was sensitive to VifHXB2 degradation 
and co-immunoprecipitation suggests both VifIIIB and VifHXB2 could co-immunoprecipitate with 
A3H-HA, suggesting that a lack of Vif-induced degradation did not always correlate with a lack 
of an interaction. To quantify this interaction, we used rotational anisotropy. First, we 
determined the oligomerization state of A3H by size exclusion chromatography. In contrast to 
other single Z-domain A3 enzymes [205, 206], we found that A3H existed as polydisperse forms 
in solution (Fig. 5.3A). Based on apparent molecular masses, A3H can exist as a monomer 
(apparent molecular mass of 22 kDa), dimer (apparent molecular mass of 44 kDa), and 
trimer/tetramer (apparent molecular mass of 67 kDa). The dimeric A3H was the most 
predominant form (Fig. 5.3A, Fraction 28). Similar to A3G, we found that the rotational 
anisotropy of fluorescently labeled A3H decreased upon the addition of the Vif heterotetramer 
(Fig. 5.3B), suggesting that Vif disrupted A3H oligomerization. We found that in the presence of 
the VifHXB2 heterotetramer, the A3H peak shifted from Fraction 28 to Fractions 22-24 (Fig. 5.3C). 
The A3H in Fractions 22, 23, and 24 was approximately equal suggesting that VifHXB2 interacted 
with A3H monomers (Fraction 24), A3H dimers (Fractions 23 and 24) and A3H tetramers 
(Fraction 22). Thus, the observed decrease in rotational anisotropy (Fig. 5.3C) may be a 
combination of a change in A3H oligomerization and structural conformation, both of which can 
cause the molecules to rotate faster [370]. Notably, the apparent Kd of VifHXB2 for A3H was ~60-
fold lower than that of VifIIIB for A3H (Fig. 5.3B, VifHXB2, apparent Kd 7 ± 2; VifIIIB, apparent Kd 
442 ± 89). Binka et al. [240] showed amino acid at position 39 and 48 in Vif are important for 
interacting with A3H, as mutations F39S and H48N disrupt the interaction of VifLAI with A3H. 
Since both VifHXB2 and VifIIIB have 39F, but lacks a histidine at position 48 and instead encodes an 
asparagine at position 48 (Fig. 5.3D), the binding data essentially measure the contribution of Vif 
amino acid 48 in the binding strength of the A3H-Vif interaction [276]. A3H exemplified that 
although VifHXB2 bound A3H with higher affinity than VifIIIB, both Vifs bound A3H in the low 
nanomolar range, but this was not sufficient for complete Vif-mediated degradation of A3H. 
Therefore, the interaction strength appeared not to be the only determinant.  
5.3.3 VifHXB2 can induce degradation of A3G D128K. To further test if the difference in Vif-
mediated degradation efficiency is influenced by the A3-Vif interface, we used the A3G D128K  
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Figure 5.3 A3H interacts with both VifIIIB and VifHXB2  in vitro. (A) By comparison to a standard 
curve, size exclusion chromatography was used to determine the oligomerization state of A3H. 
A3H resolved primarily as a dimer with an apparent molecular mass of 44 kDa with minor 
trimer/tetramer (67 kDa) and monomer (22 kDa) fractions (open triangles). (B) Steady state 
rotational anisotropy (fluorescence depolarization) was used to measure the binding strength 
between A3H and VifIIIB/CBFβ/EloB/C or VifHXB2/CBFβ/EloB/C (labeled as VifIIIB or VifHXB2). 
The Vif variant heterotetramer was titrated into a binding reaction with fluorescently labeled 
A3H to determine an apparent dissociation constant (Kd). The VifHXB2 heterotetramer (apparent 
Kd 7 ± 2 nM) interaction with A3H was of ~60-fold higher affinity than the VifIIIB heterotetramer 
(apparent Kd 442 ± 89 nM). Error bars represent the standard deviation of the mean from three 
independent experiments. (C) Size exclusion chromatography was used to determine the 
oligomerization state of an A3H-Vif/CBFβ/EloB/C complex. For comparison, A3H alone and 
the Vif/CBFβ/EloB/C heterotetramer alone were resolved by size exclusion chromatography. 
Peak fractions were determined by the UV absorbance of the chromatogram and confirmed by 
resolving samples by SDS-PAGE. The graph represents the quantification of the coomassie 
stained bands shown in the SDS-PAGE gels. Comparison to molecular weight standards was 
used to calculate apparent molecular masses of peak fractions. A3H resolved primarily as a 
dimer (44 kDa, Fraction 28). The Vif/CBFβ/EloB/C heterotetramer resolved as a stoichiometric 
complex with an apparent molecular mass of 74 kDa in the peak fraction (Fraction 25). The 
A3H-Vif/CBFβ/EloB/C complex resolved in Fractions 22-24 which gave an apparent molecular 
mass range of 157-96 kDa. The presence of EloB/C in fractions containing Vif/CBFβ was 
confirmed by staining with Bio-rad Oriole stain (gel not shown). (D) Alignment of VifIIIB and 
VifHXB2 amino acid sequences from amino acids 16 to 53. Residues that differ between the Vif 
variants are shown in lower case. The 40YRHHY44 motif highlighted in blue is the A3G 
interaction motif. Amino acids 39 and 48 are important for both the ability of Vif to induced 
degradation of and interact with A3H. 
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Vif IIIB
VifHXB2, Kd 1347 ± 125 nM
 
Figure 5.4 D128K interacts with Vif variants. Steady state rotational anisotropy (fluorescence 
depolarization) was used to measure the binding strength between D128K and 
VifIIIB/CBFβ/EloB/C or VifHXB2/CBFβ/EloB/C (labeled as VifIIIB or VifHXB2). The Vif variant 
heterotetramer was titrated into a binding reaction with fluorescently labeled D128K to 
determine an apparent dissociation constant (Kd). The VifIIIB heterotetramer was unable to 
interact with A3G D128K, in contrast to the VifHXB2 heterotetramer (apparent Kd 1347 ± 125 nM). 
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mutant. D128K is resistant to transiently overexpressed VifIIIB-mediated degradation [278, 280, 
281], but only partially resistant to transiently overexpressed VifHXB2-mediated degradation. 
Specifically, VifHXB2 can induce degradation of ~ 40% of the transiently overexpressed D128K 
[312]. That the degradation was not strong was consistent with results from others [279] and the 
co-imunoprecipitation data by Baig et al. in which neither VifIIIB nor VifHXB2 could co-
immunoprecipitate with the D128K-HA [312]. However, using rotational anisotropy, which is a 
more sensitive method we found that D128K and VifHXB2 did interact with each other, albeit at 
low affinity (Fig. 5.4, apparent Kd of 1347 ± 125 nM).  The interaction strength of Vif and 
D128K was ~120-fold less than with A3G, thus necessitating titration of 4-fold more Vif 
heterotetramer to determine the apparent Kd (compare x-axis, Fig. 5.4 and Fig. 5.2A) and 
consistent with the suboptimal-induced degradation of D128K by VifHXB2. There was no 
interaction detected when A3G D128K was incubated with increasing amounts of VifIIIB 
heterotetramer (Fig. 5.4). Altogether, these data demonstrate D128K could be degraded by 
VifHXB2 despite an interaction in the micromolar range (Fig. 5.4) [312], whereas A3H could not 
be degraded by VifIIIB and was degraded by VifHXB2 only 2-fold more than D128K [312], despite 
a low nanomolar binding affinity (Fig. 5.3B), further indicating that mechanistically the different 
interfaces of A3G/D128K and VifHXB2 and A3H and VifHXB2 influences degradation efficiency.  
5.3.4 Degradation-independent effects of Vif on A3H.  For A3H and VifIIIB, the interaction 
maintained in the absence of A3H degradation may be a consequence of maintaining a lower 
affinity interaction to decrease the evolutionary barrier when HIV adapts to rare hosts that 
express a stable A3H haplotype [100]. Alternatively or in addition to this, VifIIIB may exert 
degradation-independent inhibitory effects on A3H through this interaction. Degradation-
independent effects of Vif on A3G have been characterized such as inhibition of virion 
encapsidation, depression of A3G mRNA translation, and inhibition of deamination activity of 
virion encapsidated A3G molecules that escape Vif-mediated suppression [183, 223, 225, 296, 
298, 299, 348, 349]. We did not find that VifIIIB/CBFβ or VifHXB2/CBFβ could alter the 
deamination activity or processive scanning of A3H (Fig. 5.5), as was previously found for A3G 
(Fig. 3.8) [139].  This may be because the primary interaction residue of A3H (121D) is predicted 
to be located on helix 4, not on loop 7 as for A3G and is on a face of A3H distal to the amino 
acids predicted to be involved in A3 enzyme processivity [139, 265].  
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Figure 5.5 Degradation-independent effects of Vif on A3H. Processivity of A3H was tested on a 
118 nt single-stranded DNA substrate (100 nM) that contained an internal fluorescein (F)-label 
(yellow star) and two deamination motifs separated by different distances. The A3H substrates 
had 5′CTC motifs. The two target cytosines were spaced 63 nt apart. Single deaminations of the 
5′C and 3′C were detected as the appearance of labeled 100- and 81- nt fragments, respectively; 
double deamination of both C residues on the same molecule resulted in a 63 nt labeled fragment 
(5′C & 3′C). A processivity factor (P.f.) above 1 indicates that the enzyme can catalyze 
deaminations of both motifs on the substrate in a single enzyme-substrate encounter. VifIIIB and 
VifHXB2 cannot decrease the processivity of A3H, in contrast to A3G (see Fig. 3.8) [183]. Due to 
different specific activities, 50 nM of A3H was used in reactions. The standard deviation of the 
mean (S.D.) was calculated from three independent experiments. 
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5.4 Discussion 
Due to evidence that different Vif variants have different abilities to degrade specific A3 
enzymes [240, 295], we undertook an analysis of various A3-Vif interactions to identify the 
determinants of an optimal Vif substrate and how the Vif variants differ in their ability to induce  
A3 degradation. This study is a step towards a better understanding of the A3-Vif relationship at 
a biochemical level. Based on the enzymes used in our study, we found that there was no clear 
relationship between the absence of Vif-induced degradation correlating with a lack of an A3-Vif 
interaction, except for D128K. Rather, the data support a model in which the strength of the 
interaction between the Vif variant and the A3 enzyme in addition to the A3-Vif binding 
interface are determinants in Vif-induced degradation efficiency. 
Overall, VifHXB2 appears to maintain higher affinity interactions than VifIIIB. For example, 
in the absence of the 128D residue, VifHXB2 could maintain an interaction with D128K where VifIIIB 
could not (Fig. 5.4). VifHXB2 could interact with A3G and A3H with a 4-fold and 60-fold higher 
affinity than VifIIIB, respectively (Fig. 5.2A and Fig. 5.3B). These differences in VifIIIB and 
VifHXB2 may relate to the extended A3 binding interface beyond the primary residues important 
for inducing A3 degradation. The extended A3G binding interface was found to be different for 
VifIIIB and VifHXB2 [183]. Experiments examining how Vif variants affected A3G processivity 
showed that VifHXB2 primarily interacts with loop 7 and VifIIIB interacts with loop 7 and helix 6 
[183]. Therefore, it is conceivable that VifHXB2 could interact with D128K due to stronger 
interactions with the 129PD130 residues on loop 7 than VifIIIB, which maintained the ability of 
VifHXB2 to induce degradation. The Vif from SIV of Sooty Mangabey Monkeys is able to interact 
with A3G primarily through 129P [282]. VifIIIB could not maintain a measurable interaction with 
D128K (Fig. 5.4) suggesting that it stabilizes itself on A3G through low affinity interactions with 
helix 6.  
The data with A3H and D128K demonstrated that the A3-Vif interface influences 
degradation efficiency. D128K degradation occurred despite an apparent Kd for VifHXB2 
heterotetramer in the micromolar range (Fig. 5.4 and [312]). In contrast, VifHXB2 degradation of 
A3H was only 2-fold more than for D128K despite a nanomolar range Kd (Fig. 5.3B and [312]). 
Notably, previously both Vif variants were found to not interact with D128K in a similar in vitro 
assay that used GST-Vif (Table 3.4) [183]. However, our current data with the Vif 
heterotetramer (Vif/CBFβ/EloB/C) suggests that in the previous study the GST tag 
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nonspecifically disrupted the VifHXB2 and D128K interaction or further stabilization of Vif with 
CBFβ/EloB/C was required for the interaction with D128K. However, the GST-Vif produced 
similar results when interacting with A3G as those obtained here [183], presumably due to the 
tighter interaction of Vif with wild type A3G (Fig. 5.2A). 
5.5 Material and Methods 
5.5.1 Protein expression and purification. The GST-A3H was produced using recombinant 
baculovirus infected Sf9 cells. The recombinant baculovirus was constructed using the pAcG2T 
transfer vector (BD Biosciences) as described in Chelico et al [132]. The A3H Haplotype II 
template used for PCR and subcloning was identical to that used for the pcDNA3.1 vector. The 
plasmid construction of GST-A3G and GST-D128K has been previously described [132, 139]. 
The GST-A3H, GST-A3G, and GST-A3G D128K were expressed and purified as described 
previously to obtain protein that was cleaved from the GST tag and 95% pure (Fig. 5.1) [140].  
The Vif heterotetramer (Vif/CBFβ/EloB/C) was obtained by coexpression of all 
components in Escherichia coli. The Vif heterodimer (Vif/CBFβ) was obtained by coexpression 
of Vif and CBFβ in E. coli. The Elongin B (residues 1-187) and Elongin C (residues 17-112) 
cloned in the pACYC-Duet plasmid were a gift from Dr. Alex Bullock (University of Oxford). 
The CBFβ isoform 2 (residues 1-182, NCBI Accession NP_001746) was cloned into MCS1 of 
pET-Duet at BamHI and HindIII sites. VifHXB2 and VifIIIB, carried in a pAcG2T baculovirus 
transfer vector as described previously [139] were subcloned into the BglII and XhoI sites of the 
MCS2 of pET-DUET (Novagen). The codon-optimized sequences of VifHXB2 and VifIIIB were also 
cloned into the NcoI and HindIII sites of the MCS1 of pRSF-Duet and pCDF-Duet, respectively, 
to supplement Vif expression. Protein expression in E. coli BL21 cells (DE3) cells was induced 
with 0.2 mM isopropyl-D-thiogalactopyranoside (IPTG) for 16 h at 16 °C. Cells were lysed by 
sonication in ice-cold lysis buffer (20 mM Tris-Cl, pH 8.0, 300 mM NaCl, RNaseA (80 µg/mL, 
Qiagen), EDTA-free protease inhibitor (Roche) and lysozyme (1mg/mL, EMD chemicals). 
Clarified supernatants were transferred to TALON Metal affinity Resin (Clontech Laboratories) 
and incubated for 45min at 4 °C. The affinity resin was then extensively washed with buffer 
containing increasing amounts of imidazole (20 mM Tris-Cl, pH 8.0, 300 mM NaCl and 5-10 
mM Imidazole). Affinity resin bound proteins were eluted with elution buffer (20 mM Tris-HCl, 
pH 8.0, 300 mM NaCl, 200 mM Imidazole, and 10% glycerol). The eluted proteins were loaded 
onto a Superdex 200 Increase (10/300) column (GE Healthcare) equilibrated with buffer 
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containing 20 mM Tris-Cl, pH8.0, 300mM NaCl, 10% glycerol and 1mM DTT. Peak fractions 
corresponding to the Vif/CBFβ/EloB/C heterotetramer or Vif/CBFβ heterodimer were identified 
based on comparison to molecular weight standards (Bio-Rad) and confirmed with SDS-PAGE. 
The Vif heterotetramer was further purified using a DEAE Fast Flow column (GE Healthcare). 
The proteins were loaded onto the column in low salt buffer (20 mM HEPES, pH 7.0, 75 mM 
NaCl, 10% glycerol, 1 mM DTT) and eluted using a salt gradient. The Vif heterotetramer eluted 
from the column at approximately 500 mM NaCl. The complexes were estimated to be 95% pure 
by SDS-PAGE (Fig. 5.1). 
To determine the oligomerization state of A3G, A3H, and VifHXB2 heterotetramer, 100-
150 µg of purified enzyme was loaded onto a Superdex 200 Increase (10/300) column (GE 
Healthcare) equilibrated with buffer containing 20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 10% 
(v/v) glycerol, 1 mM DTT. For determination of the A3G- or A3H- VifHXB2 heterotetramer 
complex, 100 μg of each A3G or A3H and the VifHXB2 heterotetramer were premixed and 
incubated at room temperature for 3 min before loading on the column. The Bio-Rad gel 
filtration standard set was used to generate a standard curve from which the molecular masses 
and oligomerization state was calculated. 
5.5.2 Steady state fluorescence depolarization. The affinity of the interaction between A3G, A3G 
D128K or A3H and Vif/CBFβ/EloB/C was determined using steady state fluorescence 
depolarization (rotational anisotropy). The purified A3G, A3G D128K or A3H was labeled with 
fluorescein using the Fluorescein-EX Protein Labeling kit (Invitrogen) and used as the binding 
substrate for Vif/CBFβ/EloB/C. Reactions (50μl) were conducted in buffer (50 mM Tris, pH 7.5, 
40 mM KCl, 10 mM MgCl2, 1mM DTT) and contained 50 nM fluorescein labeled A3 enzyme 
and increasing amounts of Vif/CBFβ/EloB/C (0-2800 nM). A QuantaMaster QM-4 
spectrofluorometer (Photo Technology International) with a dual emission channel was used to 
collect data and calculate anisotropy. Measurements were made at 21°C. Samples were excited 
with vertically polarized light at 495 nm (6-nm band pass) and vertical and horizontal emissions 
were measured at 520 nm (6-nm band pass). An apparent dissociation constant (Kd) was obtained 
by fitting to a hyperbolic decay or sigmoidal curve equation using SigmaPlot 11.2 software. 
5.5.3 In vitro deamination assay. The 118 nt ssDNA substrates were obtained from Tri-Link 
Biotechnologies and are listed in Table 5. Substrates containing two 5′CTC motifs (A3H) were 
used at 100 nM and a fluorescein labeled thymidine was placed in between the motifs.  
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Table 5 Primers and DNA substrates. 
 
Name Sequence 
VifIIIB Forward  
pETDuet MCS2 
TTTTAGATCTATGGAGAACCGGTGGCAGGTG 
VifIIIB Reverse  
pETDuet MCS2 
TTTTCTCGAGCTAGTGTCCATTCATTGTATGGCTC 
VifHXB2  Forward 
pETDuet MCS2  
TTTTAGATCTATGGAAAACAGATGGCAGGT 
VifHXB2 Reverse  
pETDuet MCS2 
TTTTCTCGAGCTAGTGTCCATTCATTGTGTG 
CBF-β Forward  
pETDuet MCS1 
TTTTGGATCCATGCCGCGCGTCGTGCCCGACCAGA 
CBF-β Reverse  
pETDuet MCS1 
TTTTAAGCTTCTAGGGTCTTGTTGTCTTCTTGCCAGTTACTGCCAG 
A3G-D128K SDM 
Forward 
CC CGC CTC TAC TAC TTC TGG AAG CCA GAT TAC CAG GAG 
GCG CTT C 
A3G-D128K SDM 
Reverse 
GA AGC GCC TCC TGG TAA TCT GGC TTC CAG AAG TAG TAG 
AGG CGG G 
VifHXB2 Forward 
pRSFDuet MCS1 
TTTTCCATGGAAAACCGCTGGCAAGTTATGAT 
VifHXB2 Reverse 
pRSFDuet MCS1 
TTTTAAGCTTTCAATGGCCGTTCATCGTAT 
VifIIIB Forward  
pCDFDuet MCS1 
TTTTCCATGGAAAACCGCTGGCAAGTTATGATT 
VifIIIB Reverse  
pCDFDuet MCS1 
TTTTAAGCTTCCAATGGCCGTTCATCGTATG 
A3H 118 nt 
substrate 
GAA TAT AGT TTT TAG CTC AAA GTA AGT GAA 
GAT AAT [Fam-dT] TAG AGA GTT GTA ATG 
TGA TAT ATG TGT ATG AAA GAT ATA AGA CTC 
AAA GTG AAA AGT TGT TAA TGT GTG TAG ATA 
TGT TAA 
A3G 118 nt 
substrate 
GAA TAT ATG TTG AGA CCC AAA GTA ATG AGA GAT TGA [dT-
Fam]  TAG ATG AGT GTA ATG TGA TAT ATG TGT ATG AAA GAT 
ATA AGA CCC AAA GAG TAA AGT TGT TAA TGT GTG TAG ATA 
TGT TAA 
 
Abbreviations are: SDM, site directed mutagenesis; Fam, fluorescein. 
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For A3H, 50nM of enzyme was incubated with 1750 nM Vif (IIIB or HXB2) during the reaction 
and the molar ratio of Vif:A3 enzyme was maintained at 35:1. The reaction buffer used was 
identical to that used for steady state fluorescence depolarization. All reactions were carried out 
under single hit conditions (~10% substrate consumed) where a single A3 could interact with a 
particular ssDNA substrate once at most [362]. Reactions were incubated at 37 °C for 1.5 to 30 
min. Deaminations were detected by resolving DNA that had been treated with Uracil-DNA 
Glycosylase and heated under alkaline conditions on a 10% (v/v) denaturing polyacrylamide gel. 
Gel pictures were obtained using a Typhoon Trio (GE Healthcare) multipurpose scanner, and 
analysis of integrated gel band intensities was performed using ImageQuant software (GE 
Healthcare). Under these conditions, a processivity factor can be determined by comparing the 
total number of deaminations occurring at two sites on the same DNA substrate with a calculated 
theoretical value of the expected deaminations that would occur at those two sites if the events 
were uncorrelated, i.e. not processive [132].  
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6.0 Biochemical characterization of the single-domain A3H enzyme 
provides insights for oligomerization models within A3 family 
members 
  Although A3G has taken center stage among all seven A3 proteins for a long time due to 
its potent HIV restriction ability, through a few seminal studies the importance of A3H during 
HIV infection was eventually recognized [45, 100, 232]. A3H is the most polymorphic amongst 
all human A3 proteins with at least 7 haplotypes (hap I-VII) being reported (Table 7.1). The role 
each amino acid polymorphism played in the cellular functions of A3H has been examined over 
the years. Specifically, polymorphic changes at amino acid position 15 and 105 have been 
reported to be the determinants for the cellular stability of the protein [45, 371]. Amino acid 
polymorphism of K/D at position 121 determines the sensitivity of A3H to Vif [195, 197, 290]. 
In this biochemical characterization, I investigated the function of A3H amino acid 178 
polymorphism as the polymorphism at this position had no prior ascribed functions [197]. 
 The three stable haplotype (hap II, V and VII) all have N15, R18, R105 and vary at the 
121 and 178 positions [45, 198] (Table 1), where A3H hap II, V and VII have a DD, DE and KE 
sequence at positions 121 and 178, respectively [100, 213, 232]. During the process of 
biochemically characterizing the determinants required for efficient Vif-mediated degradation of 
A3G and A3H enzymes (Chapter 5), we have examined the oligomerization states for all three 
stable haplotypes (hapII, V and VII) and unexpectedly found that the three stable haplotypes 
demonstrate different oligomeric states in solution. Specifically, A3H hap II and hap V exhibited 
a similar oligomerization profile as they both primarily form dimers in solution (Fig. 7.5), 
suggesting amino acid D/E at position 178 on predicted helix 6 was not responsible for 
mediating dimerization; however, A3H hap VII was able to form an equilibrium of 
tetamers/pentamers and higher-order oligomers in solution (Fig. 6.0), suggesting amino acid D/K 
at position 121 near the predicted loop 7 might be involved in larger molecular weight complex 
formation. Altogether, these results indicate that unlike double-domain A3G which dimerizes 
through the NTD loop 7 [140] or single-domain Z2-type A3C which dimerizes through helix 6 
[205, 216], A3H may dimerize in solution using an interface that is completely distinct from the 
other A3 family members. Driven by this hypothesis, in Chapter 7 we set out to understand the 
biochemical basis of A3H oligomerization and to explore how its oligomeric state transitions 
upon substrate binding. 
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Figure 6.0  Size exclusion chromatography profiles of stable A3H haplotypes. A3H haplotype II 
(hap II), haplotype VII (hap VII) and haplotype V (hap V) obtained from a 25-mL G200 
Superdex Increase column. Hap VII exhibits a different oligomerization profile as compared to 
hapII and hap V, with dimer (D, 38.2kDa), pentamer (P, 100kDa) and higher order oligomer (H, 
163kDa) forming an equilibrium in solution. A3H hap II and hap V demonstrate a similar 
oligomeric state, as they both mainly form dimers (42 kDa) in the solution, with monomers (22 
kDa) and tetramers (94kDa) also been observed. The size exclusion chromatography profile of 
A3H hap VII, hap V and hap II (300 μg) was used to calculate the oligomerization state of the 
enzymes from a standard calibration curve (Fig. 7.5, A and B).  
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The experiments in Chapter 7 were carried out by Y.F., with the following exceptions: 
experiments in Figure 3 and Table 4 were performed by R.P.L. and A.A., experiments for A3H 
haplotype 5 data in Figure 1 were performed by T.T.B., and experiments for A3H haplotype II 
and A3G binding data in Table 2 were performed by M.B.A.. Y.F., R.P.L., and L.C. conceived 
and designed the experiments. Y.F., R.P.L., A.A., M.B.A., T.T.B., and L.C. analyzed the data. 
Y.F. and L.C. wrote the paper. Y.F., R.P.L., A.A., M.B.A., T.T.B., and L.C. revised the article.  
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7.1 Abstract 
APOBEC3H is a deoxycytidine deaminase that can restrict the replication of HIV-1 in 
the absence of the viral protein Vif that induces APOBEC3H degradation in cells. APOBEC3H 
exists in humans as seven haplotypes (I-VII) with different cellular stabilities. Of the three stable 
APOBEC3H haplotypes (II, V, and VII), haplotypes II and V occur most frequently in the 
population. Despite APOBEC3H being a bona fide restriction factor, there has been no 
comparative biochemical characterization of APOBEC3H haplotypes. We characterized the 
single-stranded (ss)DNA scanning mechanisms that haplotypes II and V use to search their 
ssDNA substrate for cytosine containing deamination motifs. APOBEC3H haplotype II was able 
to processively deaminate multiple cytosines in a single enzyme-substrate encounter by using 
sliding, jumping, and intersegmental transfer movements. In contrast, APOBEC3H haplotype V 
exhibited diminished sliding and intersegmental transfer abilities, but was able to jump along 
ssDNA. Due to an Asp or Glu at amino acid 178 differentiating these APOBEC3H haplotypes, 
the data indicated that this amino acid on helix 6 contributes to processivity. The diminished 
processivity of APOBEC3H haplotype V did not result in a reduced efficiency to restrict HIV-1 
replication in single-cycle infectivity assays, suggesting a redundancy in the contributions of 
jumping and intersegmental transfer to mutagenic efficiency. Optimal processivity on ssDNA 
also required dimerization of APOBEC3H through the β2 strands. The findings support a model 
in which jumping can compensate for deficiencies in intersegmental transfer and suggest that 
APOBEC3H haplotypes II and V induce HIV-1 mutagenesis efficiently, but by different 
mechanisms.  
7.2 Introduction 
The human APOBEC3 (A3) family contains seven deoxycytidine deaminases that act as 
cellular restriction factors for a number of retrotransposons, retroviruses, and DNA viruses [66, 
319]. Excluding A3 polymorphisms, only four of the human A3 enzymes, A3D, A3F, A3G, and 
A3H are able to restrict the replication of HIV by becoming encapsidated into budding virions 
and deaminating cytosines to uracils on the nascent (-)DNA synthesized by HIV reverse 
transcriptase [78, 80](2017 NAR ref). The uracil lesions result in transition mutations upon using 
the (-) DNA as a template to synthesize the (+) DNA [22-24]. This results in decreases in HIV 
infectivity that are dependent on the number of mutations and the effect of the mutations on the 
viral proteins. Each deaminase has a preferred sequence context for deamination, but the 
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minimal dinucleotides for recognition are 5'CC for A3G and 5'TC for A3D, A3F, and A3H [49-
52, 91, 195]. 
The number of mutations that an A3 can introduce into the HIV proviral genome is 
mediated by the level of encapsidation into the viral capsid and the biochemical properties of the 
A3 [21, 66]. The primary factor mediating A3 restriction ability is the HIV viral infectivity factor 
(Vif) protein [25]. Vif acts as the substrate receptor of a Cullin RING ligase-5 (CRL5) E3 ligase 
complex to induce polyubiquitination and degradation of A3s relevant to HIV restriction [24, 63, 
64, 70, 223, 225, 246]. This greatly decreases the encapsidation levels of A3s into HIV virions, 
but does not completely block A3 virion encapsidation since G to A mutations in a sequence 
context indicating the action of A3 enzymes are present in HIV genomes recovered from infected 
individuals [115, 119]. In the absence of Vif and despite equal encapsidation of some A3s into 
virions, there are differences in their efficiency of HIV restriction, e.g., A3G and A3F [133, 176]. 
These data demonstrate that there are biochemical differences in the enzymes that influence their 
activities as restriction factors [133]. We have determined that the mechanisms that A3G and 
A3F use to scan the single-stranded (ss) DNA substrate in search of the deamination motifs 
affects the number of induced mutations [133, 139]. Synthesis of the proviral double-stranded 
(ds) DNA is a dynamic process concurrently involving (-) DNA synthesis, RNA degradation, 
and synthesis of (+) DNA that blocks A3 access to its single-stranded (-) DNA substrate [4, 91]. 
As a result, the enzymes require an efficient search process to locate the deamination motifs [66]. 
A3 enzymes studied thus far have been found to scan ssDNA by facilitated diffusion [93, 132, 
133, 206]. Facilitated diffusion can involve 1-dimensional (1-D) sliding movements or 3-D 
jumping/hopping or intersegmental transfer movements on ssDNA [145, 146]. The most efficient 
search on ssDNA would involve a combination of 1-D and 3-D scanning movements [66, 139, 
372]. The 1-D sliding motions allow for an in-depth local search, i.e., < 20 nt, of the substrate for 
the deamination motif. The 3-D jumping/hopping or intersegmental transfer movements mediate 
larger translocations on the DNA substrate [148]. Each type of movement provides a superficial 
scanning mechanism by itself, but together the enzyme is able to transition between an in-depth 
search (sliding) for the catalytic sequence to random relocation (jumping/hopping or 
intersegmental transfer) on the DNA substrate to restart the search process [133, 139]. 
Jumping/hopping are differentiated from intersegmental transfer by the type of association the 
enzyme has with the DNA. Jumping/hopping involves microscopic dissociation and re-
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association of the enzyme with the same DNA without diffusion into the bulk solution. 
Intersegment transfer involves an enzyme with two DNA binding domains engaging in a doubly-
bound state with the DNA substrate before moving to one of the bound sites [146]. Facilitated 
diffusion movements enable enzyme processivity where an enzyme can catalyze multiple 
reactions before dissociating from the substrate and diffusing back into the bulk solution [66]. 
Of the A3 enzymes most effective against HIV, A3H is of special interest since it occurs 
with the highest number of haplotypes in the A3 family [45, 195, 198]. A3H exists as at least 
seven haplotypes in humans, with three of the haplotypes being stable forms of A3H that can 
suppress HIV (Table 7.1). The A3H haplotypes that are unstable and inactive against HIV 
contain two single nucleotide polymorphisms that occur in different combinations with other 
polymorphisms. Unstable A3H haplotypes (haplotypes I, III, IV, and VI) carry either a G105, Δ
N15, or both in combination with other possible polymorphisms at positions 18, 121, and 178 
(Table 7.1) [45, 198]. Unstable A3H haplotype I occurs at the highest population frequency 
(0.308-0.526) [45, 198]. A R105 and N15 are required for a stable A3H in cells [45]. The three 
stable haplotypes all have a N15, R18, R105 and vary at the 121 and 178 positions (Table 7.1) 
[45, 198]. A3H haplotype II has been the most widely studied and has a DD sequence at 
positions 121 and 178 [100, 213, 232]. A3H haplotype V has a DE sequence at positions 121 and 
178 [195, 198]. A3H haplotype II and V comprise the majority of the stable A3H alleles 
(haplotype II, frequency of 0.061-0.265; haplotype V, frequency of 0.054-0.202) [45, 198]. A3H 
haplotype VII has been identified only from one individual (frequency of 0.009) and has a KE 
sequence at positions 121 and 178 [198]. The 121 position determines the sensitivity to Vif, 
where a D121 is sensitive and a K121 is not sensitive to Vif-mediated degradation [195, 197, 
290]. There is currently no known function of the polymorphism of D/E at position 178 [197].  
 Despite the several unique aspects of A3H in comparison to the other A3 enzymes, there 
has been no in depth biochemical characterization of the most frequently occurring stable A3H 
haplotypes (II and V). This type of characterization is necessary to fully understand the 
determinants required for HIV restriction since A3H has several distinctive characteristics in the 
A3 family. A3s can be divided into two families based on the number of Zinc coordinating 
domains (Z-domains) [37]. A3B, A3D, A3F and A3G are deaminases with two Z-domains, 
whereas A3A, A3C and A3H are deaminases with a single Z-domain. In addition, A3s have been 
classified into three categories based on the phylogenetic analysis of their Z-domains (Z1, Z2  
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Table 7.1 A3H haplotypes. 
Haplotype Stability 
Polymorphisms 
(amino acids 15, 18, 
105, 121, 178) 
I Unstable NRGKE 
II Stable NRRDD 
III Unstable ΔRRDE 
IV Unstable ΔLRDE 
V Stable NRRDE 
VI Unstable ΔLGKE 
VII Stable NRRKE 
Haplotype data summarized from OhAinle et al. and Wang et al [45, 198]
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and Z3) and A3H is the only Z3-type domain A3 enzyme [37]. Part of the reason why A3H is 
able to restrict HIV is that it is the only wild-type single Z-domain A3 that oligomerizes in 
solution and on cellular RNA, which is generally prerequisite for virion encapsidation [191, 312]. 
Importantly, in another single Z-domain A3, A3C, a rare S188I polymorphism that occurs in 
10% of people of African descent, enables A3C dimerization and this results in A3C S188I being 
able to restrict HIV [216]. Thus, the oligomerization of single Z-domain A3 enzymes appear to 
have a large effect on their ability to contribute to cellular functions.  
We undertook a biochemical characterization of A3H haplotypes II and V in order to 
determine if there are shared biochemical characteristics between single Z-domain and double Z-
domain A3 enzymes for restriction of HIV. The data demonstrate that A3H is a processive 
enzyme. A3H haplotype II uses sliding, jumping and intersegmental transfer to locate 
deamination motifs on ssDNA. The E178 polymorphism of A3H haplotype V causes diminished 
sliding and intersegmental transfer, but does not affect jumping. This differences in processivity 
did not affect HIV restriction ability. Further, we identified that the dimerization interface in 
A3H is mediated by the pairing of β2 strands from two monomers and tetramerization can occur 
through the pairing of loop 7 from two dimers, as predicted could occur from a crystal structure 
of APOBEC2 (A2) with a 40 amino acid N-terminal deletion [373]. The β2-β2 strand 
dimerization of A3H is required for efficient ssDNA scanning. The results demonstrate that A3H 
dimerization and D178 is required for sliding and intersegmental transfer movements on ssDNA. 
The data combine to support a model in which A3H haplotypes II and V both induce HIV 
mutagenesis efficiently, but by different mechanisms and suggest that jumping can compensate 
for deficiencies in intersegmental transfer. 
7.3 Results 
7.3.1 A3H Haplotype II and V processively scan ssDNA. The ssDNA scanning mechanism(s) of 
A3H haplotypes II and V were determined using an in vitro deamination assay that measures the 
processivity of purified A3H. Processivity is defined as the ability of an enzyme to deaminate 
more than one cytosine on an ssDNA substrate in a single enzyme-substrate encounter [132]. 
The processivity was measured using different synthetic ssDNA substrates containing two 
deamination motifs (5'CTC, underlined C being preferentially deaminated) spaced various  
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Figure 7.1 Analysis of A3H haplotypes II and V processivity and ssDNA scanning. Processivity 
of A3H haplotype II (Hap II) and haplotype V (Hap V) was tested on ssDNA substrates that 
contained fluorescein labeled deoxythymidine (yellow star) between two 5'CTC deamination 
motifs separated by different distances.  (A) Deamination of a 60 nt ssDNA substrate with 
deamination motifs spaced 5 nt apart. Single deaminations of the 5'C and 3'C are detected as the 
appearance of labeled 42 nt and 23 nt fragments, respectively; double deamination of both C 
residues on the same molecule results in a 5 nt labeled fragment. (B) Deamination of a 69 nt 
ssDNA substrate with deamination motifs spaced 14 nt apart. Single deaminations of the 5'C and 
3'C are detected as the appearance of labeled 51 nt and 32 nt fragments, respectively; double 
deamination of both C residues on the same molecule results in a 14 nt labeled fragment. (C) 
Deamination of a 118 nt ssDNA substrate with deaminated cytosines spaced 63 nt apart. Single 
deaminations of the 5'C and 3'C are detected as the appearance of labeled 100 nt and 81 nt 
fragments, respectively; double deamination of both C residues on the same molecule results in a 
63 nt labeled fragment. (D). Deamination of the same substrate described for (C), but with a 20 
nt DNA annealed between the two deamination motifs. (E) Deamination of the same substrate 
described for (C), but with a 20 nt RNA annealed between the two deamination motifs. (A-E) 
The A3H: ssDNA ratio was 1:2. The measurements of enzyme processivity (Processivity factor) 
and the Standard Deviation of the mean (S.D.) are shown below the gels. All values are 
calculated from at least three independent experiments. 
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distances apart. This strategy allows the dissection between 1-D sliding and 3-D translocation 
movements since it has been previously shown that substrates with closely spaced motifs, i.e., < 
20 nt, are processively deaminated through 1-D sliding motions [133, 139].  Processive 
deamination of more distantly spaced motifs requires a 3-D translocation mechanism such as 
jumping or intersegmental transfer [66, 133, 139]. All deamination reactions were performed 
under “single-hit” conditions (<15% substrate usage) to ensure any given ssDNA substrate was 
acted upon by at most one enzyme during the reaction. Under these conditions a processivity 
factor can be calculated to determine the likelihood that an enzyme would undergo processive 
deaminations in comparison to a nonprocessive deamination (see Material and Methods and 
[132]). 
On ssDNA substrates with deamination motifs separated by 5- and 14- nt, A3H haplotype 
II had processivity factors of 2.1 and 3.6, respectively (Fig. 7.1, A and B). Thus, depending on 
the distance between the deamination motifs, A3H haplotype II is ~2 to 4 times more likely to 
catalyze a processive deamination of the two deamination motifs than a single nonprocessive 
deamination of one of the deamination motifs. Due to the short distance between the deamination 
motifs, the data show that A3H haplotype II can processively scan the ssDNA by sliding. The 
amino acid sequence of A3H haplotype II and A3H haplotype V differ only at the amino acid at 
position 178 where A3H haplotype II has an Asp and A3H haplotype V has a Glu [195, 198]. 
Because the amino acid at position 178 is located on predicted helix 6, which mediates sliding 
ability in A3G and A3F [133, 139], we tested A3H haplotype V on ssDNA substrates with 
closely spaced deamination motifs to determine if the sliding ability was compromised. On the 
substrate with deamination motifs separated by 5 nt, the processivity factor was 1 (Fig. 7.1A). 
Since the processivity factor is a ratio, the processivity factor of 1 means that A3H haplotype V 
is essentially not processive on this substrate (see Material and Methods), in contrast to A3H 
haplotype II (Fig. 7.1A). On the substrate with cytosines separated by 14 nt, A3H haplotype V is 
processive but has a processivity factor ~2-fold less than A3H haplotype II (compare 
processivity factors of 3.6 and 2.1 (Fig. 7.1B)). The data indicated that in A3H, predicted helix 6 
mediates sliding and that the D/E178 polymorphism between A3H haplotype II and haplotype V 
caused a difference in the ssDNA sliding ability.  
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We also tested if other processive mechanisms were affected by the polymorphism at 
amino acid position 178. On the ssDNA substrate with cytosines separated by 63 nt, A3H 
haplotype V had a processivity factor of 3.8, which is ~1.5-fold less processive as compared to 
A3H haplotype II on the same substrate (compare processivity factors of 5.2 and 3.8 (Fig. 7.1C)). 
That both A3H haplotypes were processive on a substrate with distantly spaced deamination 
motifs suggests that A3H uses a 3-D translocation mechanism to scan ssDNA. To confirm this, 
we annealed a 20 nt complementary DNA between the two deamination motifs (Fig. 7.1D, 
schematic). Since A3H haplotype II does not bind to this dsDNA region (Table 7.2, no binding 
detected) it serves as a block to inhibit the sliding motion of the enzyme. A3H haplotype II can 
still processively deaminate the cytosines on this substrate, (Fig. 7.1D, processivity factor of 2.2), 
which confirms that A3H haplotype II uses a 3-D translocation mechanism to overcome 
obstacles while scanning ssDNA. The approximately 2.5-fold decrease in processivity in 
comparison to the fully ssDNA (compare processivity factors, Fig. 7.1C and 7.1D) is due to 
attempts to slide over the dsDNA region that instead result in dissociation of the enzyme into the 
bulk solution. A3H haplotype V bound to dsDNA with an affinity 10-fold less than ssDNA, 
suggesting that it would also not be able to slide over the dsDNA (Table 7.2, apparent Kd of 7.3 
μM, dsDNA and 0.73 μM, ssDNA). Similar to A3H haplotype II, the dsDNA region caused a 
decrease in the processivity of A3H haplotype V, but the enzyme was still processive (Fig. 7.1D, 
processivity factor of 1.7). Interestingly, we found that A3H haplotype II and V are able to bind 
RNA/DNA hybrids with an apparent dissociation constant that is equivalent to that of ssDNA 
(Table 7.2, A3H haplotype II apparent Kd values of 0.65 μM (RNA/DNA) and 0.72 μM (ssDNA); 
A3H haplotype V apparent Kd values of 0.82 μM (RNA/DNA) and 0.73 μM (ssDNA)). This is in 
contrast to A3G that binds both dsDNA and RNA/DNA hybrids at least 3-fold less than ssDNA 
(Table 7.2, apparent Kd values of 5.70 μM (dsDNA); 0.99 μM (RNA/DNA); and 0.31 μM 
(ssDNA)). These data predict that A3H should be able to slide over RNA/DNA hybrids. To test 
this prediction, we annealed a 20-nt complementary RNA between the two deamination motifs 
(Fig. 7.1E, schematic). The enzyme processivity was not significantly different on this substrate 
in comparison to its analogous ssDNA for both A3H haplotypes II and V (Fig. 7.1, C and E, 
processivity factors). This suggests that during HIV reverse transcription A3H haplotypes II and 
V could slide on RNA/DNA hybrid regions.  
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 Table 7.2 Comparison of apparent dissociation constants (Kd) from DNA of A3H haplotypes II, 
V, and A3G. 
Enzyme Kd, µM  ± S.D. 
 ssDNA               dsDNA RNA/DNA 
A3H haplotype II               0.72 ± 0.14 
No binding 
detected                           0.65 ± 0.09  
A3H haplotype V         0.73 ± 0.07 7.30 ± 2.30 0.82 ± 0.29 
A3G 0.31 ± 0.04 5.70 ± 1.10 0.99 ± 0.11 
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To determine the 3-D translocation mechanism of A3H haplotypes II and V, we tested 
whether the enzyme could move by intersegmental transfer. This mechanism requires that an  
enzyme with two DNA binding domains transfer to distal sites through a “doubly-bound” 
intermediate state [146]. A3H haplotype II has been shown to form dimers in solution [66],  
indicating that it could use intersegmental transfer. To observe intersegmental transfer we 
increased the enzyme and substrate concentrations in the reaction but kept their ratios constant 
(Fig. 7.2). By crowding the reaction in this manner the enzyme will become more likely to 
translocate to a different substrate than to translocate within a single ssDNA as the concentration 
of the reaction components increases [374]. Thus, if intersegmental transfer is occurring, this 
would lead to an apparent decrease in the processivity factor. Intersegmental transfer should also 
result in an increase in the apparent reaction rate since increasing the cycling of the enzyme also 
increases the rate of searching for deamination motifs [374]. The processivity factor of A3H 
haplotype II decreased ~2-fold with increasing reaction components (Fig. 7.2A, processivity 
factor decreases from 5.2 to 3.0) and this was accompanied by a ~2-fold increase in the rate of 
deamination (Fig. 7.2A, rate increases from 0.35 to 0.6%/min), demonstrating that A3H 
haplotype II can use intersegmental transfer to scan ssDNA. However, at the highest level of 
reaction components the processivity plateaued and did not decrease to 1 which would otherwise 
indicate a complete loss of apparent processivity due to the reaction conditions (Fig.7.2A, 
Processivity factor of 3.0). This indicates that A3H haplotype II may also use jumping to 
translocate on ssDNA. Processive ssDNA scanning mediated by jumping is insensitive to the 
crowding of the reaction components since during this movement the enzyme remains within the 
negatively charged region of the ssDNA and out of the bulk solution [66]. All together the results 
indicate that A3H haplotype II uses sliding and both intersegmental transfer and jumping as a 3-
D translocation mechanism to scan ssDNA for its preferred deamination motif. We next 
examined if A3H haplotype V was capable of intersegmental transfer. A3H haplotype V did 
have a 1.5-fold decrease in apparent processivity, similar to A3H haplotype II, but there was no 
increase in the reaction rate observed (Figs. 7.2, compare A and B). Thus, the data indicated that 
although A3H haplotype V could transfer to other ssDNA substrates, there was no corresponding 
increase in cycling between the ssDNAs, suggesting that the Glu-178 polymorphism also 
diminished intersegmental transfer ability. The processivity factor from the intersegmental  
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Figure 7.2 A3H can scan ssDNA using intersegmental transfer. Processivity of A3H haplotype II 
(Hap II) and haplotype V (Hap V) was tested on ssDNA substrates that contained fluorescein 
labeled deoxythymidine (yellow star) between two 5'CTC deamination motifs separated by 
different distances. (A-B) Deamination of a 118 nt ssDNA substrate with deaminated cytosines 
spaced 63 nt apart. Single deaminations of the 5'C and 3'C are detected as the appearance of 
labeled 100 nt and 81 nt fragments, respectively; double deamination of both C residues on the 
same molecule results in a 63 nt labeled fragment. For A3H Hap II (A) and A3H Hap V (B) the 
A3H: ssDNA ratio of 1:2 the reaction components were increased (50 nM: 100 nM; 100 nM: 200 
nM; 150 nM: 300 nM; 200 nM: 400 nM; 250 nM:  500 nM; 300nM: 600 nM; 350 nM: 700 nM). 
These reaction conditions enabled the investigation of whether A3H Hap II and Hap V could 
translocate on ssDNA by intersegment transfer. The measurements of enzyme processivity 
(Processivity factor), Standard Deviation of the mean (S.D.), and rate of deamination (percent 
(%)/min) for each individual reaction condition are shown below the gel. All values are 
calculated from at least three independent experiments.  
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transfer assay at the highest concentration of reaction components where the decrease in 
processivity plateaued was greater than 1, suggested that A3H haplotype V was able to 
processively jump on ssDNA (Fig. 7.2B). Of note, the identity of the amino acid at position 178 
also affected the binding of dsDNA and RNA. Although A3H haplotypes II and V did not differ 
in their ssDNA binding ability as determined by their apparent dissociation constants (Kd) (Table 
7.2, haplotype II Kd of 0.72 μM; haplotype V Kd of 0.73 μM), A3H haplotype V was able to bind 
double-stranded (ds) DNA whereas A3H haplotype II was not able (Table 7.2, haplotype II, no 
binding detected; haplotype V, Kd of 7.3 μM). There were also haplotype differences in RNA 
binding. The apparent Kd of A3H haplotype II binding to HIV 5'UTR RNA was 21-fold lower 
than A3H haplotype V (Table 7.3, haplotype II Kd of 0.22μM; haplotype V Kd of 4.60 μM). This 
difference in RNA binding ability was consistent with binding data for 7SL Alu RNA where 
A3H haplotype II bound with an apparent Kd 9-fold lower than A3H haplotype V (Table 7.3, 
haplotype II Kd of 0.33 μM; haplotype V, Kd of 3.00 μM). Interaction with either HIV or host 
RNAs such as 7SL, in a nucleocapsid dependent manner, have been reported to be required for 
encapsidation of A3G and A3H [83, 86, 89, 130, 136, 172, 198, 375, 376]. Similar to A3G [140] 
and in agreement with previous data [191], A3H bound RNA cooperatively demonstrating the 
ability to oligomerize on RNA (Table 7.3, Hill coefficients).  
7.3.2 A3H Haplotype II and V demonstrate similar HIV-1∆Vif restriction efficiencies. Excluding 
A3 polymorphisms, human A3H is the only single Z-domain A3 enzyme that encapsidates into 
budding HIV virions and restricts the replication of HIV in the subsequent target cell [78]. It has 
been established that A3H haplotype II and haplotype V can similarly restrict the replication of 
HIV in cell culture or infected individuals [45, 100, 195, 199, 232, 289, 377]. In agreement with 
others, our data indicated that in a single-cycle of replication, A3H haplotype II and V suppress 
HIV similarly over a range of A3H expression levels [198, 211, 212, 232] (Fig. 7.3, A and B). 
Despite the 10 to 20-fold differences in RNA binding affinities between A3H haplotypes II and 
V (Table 7.3), their virion encapsidation was comparable (Fig. 7.3B). It has been shown that 
A3G binds cellular or viral RNA indiscriminately to ensure encapsidation into virions in a 
nucleocapsid specific manner[378] [379] and our data suggest that the same encapsidation 
mechanism applies to A3H.  
It has been previously established for A3G and A3F that an efficient processive DNA 
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Cell
HA
α-tubulin
Virus
HA
p24
No 
A3H
A3H Hap II A3H Hap V
HapII_09     TATTAGAAGAAATGAATTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGGAATTGGAG
HapII_07     TATTAGAAAAAATGAATTTGCCAGAAAAATGGAAACCAAAAATAATAGGGGGAATTGGAG
HapV_01      TATTAAAAAAAATGAATTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGAAATTGAAG
HapV_05      TATTAGAAAAAATGAATTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGGAATTGAAG
Reference    TATTAGAAGAAATGAATTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGGAATTGGAG
***** ** *************** ** *************** ******* ***** **
HapII_09     GTTTTATCAAAGTAAGACAGTATGATCAAATACTCATAGAAATCTGCGGACATAAAGCTA
HapII_07     GTTTTATCAAAGTAAGACAGTATAATCAGATACTCATAGAAATCTGCGGACATAAAGCTA
HapV_01      GTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAAAAATCTGCGAACATAAAGCTA
HapV_05      GTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGAAATCTGCGGACATAAAGCTA
Reference    GTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGAAATCTGCGGACATAAAGCTA
*********************** **** ********* ********* ***********
C
		
Figure 7.3 A3H haplotypes II and V demonstrate similar HIVΔVif restriction efficiencies. (A) 
HIV ΔVif infectivity was measured by eGFP expression in 293T cells infected with HIVΔVif 
that was produced in the absence or presence of untagged A3H haplotype II (Hap II) or A3H 
haplotype V (Hap V). A titration of A3H plasmid was used (25, 50, 100, or 200 ng). Results 
normalized to the no A3 condition are shown with the Standard Deviation of the mean calculated 
from at least three independent experiments. (B) The level of HA-tagged A3H Hap II and A3H 
Hap V expressed in cells and encapsidated into HIVΔVif virions was determined using 
immunoblotting. The A3 enzymes were detected through the HA tag. The loading control for cell 
lysates was α-tubulin (α-tub) and for virions was p24. A representative blot from three 
independent experiments is shown. (C) Proviral DNA sequencing data from a subset of clones 
(from 100 ng A3H plasmid transfection) showing the sequence context of mutations induced by 
Hap II or Hap V in the protease region. Asterisks denote homology. Guanine (G) to adenine (A) 
mutations are shown in boldface. 
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Table 7.3 Comparison of apparent dissociation constants (Kd) and Hill coefficients from RNA of 
A3H haplotypes II and V. 
Enzyme Kd, µM ± S.D.  (Hill coefficient) 
 HIV 5′UTR Alu  
A3H haplotype II                            0.22 ± 0.04 (2.1) 0.33 ± 0.05 (3.2)                           
A3H haplotype V               4.60 ± 0.38 (1.8)   3.00 ± 0.60 (2.3) 
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scanning mechanism involving both 1-D sliding and 3-D translocation is required for inducing 
high numbers of deoxycytidine deaminations in HIV (-) DNA [133]. Because we observed that 
A3H haplotypes II and V were encapsidated into virions at similar levels to each other and there 
were no significant differences in suppression of HIV infectivity (Fig. 7.3, A and B), the data  
support that the diminished processivity of A3H haplotype V in comparison to A3H haplotype II 
(Fig. 7.1) is inconsequential to A3H-mediated HIV restriction. This may be because A3H 
haplotype V did not have a complete loss of sliding ability and still maintained jumping as a 3-D 
translocation mechanism (Fig. 7.1). The A3H haplotype II data suggest that the 3-D translocation 
mechanisms are redundant since A3H haplotype II did not restrict HIV replication more than 
A3H haplotype V over a range of cellular expression levels (Fig. 7.3, A and B). We sequenced 
proviral DNA from the transfection conditions that used 100 ng of A3H expression plasmid and 
found no significant differences in the spacing of the A3H haplotype II and V mutations, 
confirming that the diminished processivity of A3H haplotype V did not affect its ability to 
induce mutations in HIV proviral DNA (Fig. 7.3C). Processivity can be inferred from the 
mutational spectra because clustered mutations are indicative of sliding and distantly spaced 
mutations are indicative of jumping or intersegmental transfer [133, 139, 183]. Because there 
were similar distantly spaced mutations for both A3H haplotypes the data support that 
intersegmental transfer and jumping are redundant 3-D processive mechanisms (Fig. 7.3C). Both 
A3H haplotypes II and V also induced closely spaced mutations, indicative of sliding, in 
agreement with the processivity data from ssDNA oligonucleotides (Fig. 7.3C and Fig. 7.1 (A 
and B)). The ~2-fold lower processivity of A3H haplotype V in comparison to A3H haplotype II 
for closely spaced deamination motifs on ssDNA oligonucleotide substrates (Fig. 7.1, A and B) 
did not appear to affect its ability to induce closely spaced mutations during proviral DNA 
synthesis (Fig. 7.3C). At most, there was only a 2-fold difference in the G to A mutation 
frequency of A3H haplotypes II and V and this was observed only at the 100 ng A3H expression 
plasmid condition (Fig. 7.3A and Table 7.4). 
7.3.3. Optimal sliding and intersegmental transfer requires an Asp-178. The A3H haplotypes II 
and V differ by only an Asp/Glu at amino acid position 178. These amino acids have differences 
in side chain rigidity and pKa that could account for the effect on ssDNA scanning ability.  
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Table 7.4 Analysis of A3-induced mutagenesis of prot DNA from integrated HIVrVif. 
 
 
 
 
 
 
The proviral DNA analyzed was obtained from the transfection condition with 100 ng of A3H 
expression plasmid. 
Enzyme 
Base pairs 
sequenced 
Total number of 
G→A mutations 
G→A mutation 
frequency 
(mutations/kb) 
A3H haplotype II 10530 35 3.2 
A3H haplotype V 8424 14 1.7 
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Figure 7.4 A3H D178K is deficient in sliding and intersegmental transfer. Processivity of A3H 
D178K (D178K) was tested on ssDNA substrates that contained fluorescein labeled 
deoxythymidine (yellow star) between two 5'CTC deamination motifs separated by different 
distances. (A) Deamination of a 60 nt ssDNA substrate with deamination motifs spaced 5 nt 
apart. Single deaminations of the 5'C and 3'C are detected as the appearance of labeled 42 nt and 
23 nt fragments, respectively; double deamination of both C residues on the same molecule 
results in a 5 nt labeled fragment. (B) Deamination of a 118 nt ssDNA substrate with deaminated 
cytosines spaced 63 nt apart. Single deaminations of the 5'C and 3'C are detected as the 
appearance of labeled 100 nt and 81 nt fragments, respectively; double deamination of both C 
residues on the same molecule results in a 63 nt labeled fragment. For D178K the A3H: ssDNA 
ratio of 1:2 the reaction components were increased (50 nM: 100 nM; 100 nM: 200 nM; 150 nM: 
300 nM; 200 nM: 400 nM; 250 nM:  500 nM). These reaction conditions enabled the 
investigation of whether A3H Hap II and Hap V could translocate on ssDNA by intersegment 
transfer. The measurements of enzyme processivity (Processivity factor), Standard Deviation of 
the mean (S.D.), and rate of deamination (percent (%)/min) for each individual reaction 
condition are shown below the gel. All values are calculated from at least three independent 
experiments.  
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However, we investigated if a charge reversal or removal mutation could more drastically alter 
the processivity of A3H. The sliding ability of a D178K mutant was tested using a ssDNA 
substrate that had deamination motifs separated by 5 nt (Fig. 7.4A). Similar to A3H haplotype V, 
the A3H D178K mutant was not processive on this substrate, indicating a deficiency in sliding 
ability (compare Fig. 7.4A and Fig. 7.1A, processivity factors of 1). The D178K mutant was 
processive on the ssDNA substrate with deamination motifs separated by 63 nt, indicating that it  
could use a processive 3-D translocation mechanism (Fig. 7.4B). In the assay that tests 
intersegmental transfer ability, the D178K mutant processivity decreased 1.6-fold with 
increasing concentration of enzyme and substrate, but there was no increase in the reaction rate 
(Fig. 7.4B). Thus, the D178K mutant was similar to A3H haplotype V and could transfer to other 
ssDNA substrates but was unable to cycle efficiently (compare Fig. 7.2B and 7.4B). All together 
the data indicated that rather than the amino acid charge, the Asp at amino acid position 178 was 
specifically important for sliding and intersegmental transfer. However, a charged amino acid is 
important at amino acid position 178 for enzyme stability since a D178A mutant was less stable 
than A3H haplotype II and had processivity factors of 1.7 or less on all ssDNA substrates tested 
(data not shown). This suggests that a salt bridge may be formed from the amino acid position at 
178 to stabilize the enzyme and influence interactions with ssDNA.  
7.3.4 The dimer interface of A3H is mediated by predicted β-β strand interactions. The finding 
that an amino acid change on A3H predicted helix 6 affected sliding motions was consistent with 
published data [133, 139], but a role for helix 6 in intersegmental transfer was unexpected. The 
current understanding of intersegmental transfer is that two DNA binding domains are required 
[146, 148]. Additional determinants for this ssDNA scanning mechanism have not been 
previously identified. Yet, there appears to be additional determinants required for A3 enzymes 
since those with two Z-domains in a single polypeptide, i.e., A3F and A3G, are unable to readily 
undergo intersegmental transfer under our assay conditions [133]. Based on intersegmental 
transfer requiring two DNA binding domains [148], the data indicated that since we could not 
completely abolish intersegmental transfer ability by making mutations at the amino acid at 
position 178, the A3H was remaining in its oligomeric state and we had identified an amino acid 
determinant required for intersegmental transfer. To fully characterize the determinants for 
intersegmental transfer in A3H, we characterized the oligomeric interfaces of A3H haplotype II  
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Figure 7.5 β2-β2 strand amino acids mediate A3H dimerization. (A) The size exclusion 
chromatography profiles of A3H haplotype II (Hap II) and A3H haplotype V (Hap V) obtained 
from a 25 mL G200 Superdex Increase column were used to calculate the oligomerization states 
of the enzymes from a (B) standard calibration curve. Analysis demonstrated that both A3H 
haplotype II (Hap II) and A3H haplotype V (Hap V) were able to form monomers (M), dimers 
(D) and tetramers (T) in solution. Both 150 µg and 300 µg (inset graph) of enzyme were resolved 
to investigate whether A3H tetramer formation was concentration-dependent. According the 
calibration curve the apparent molecular weights of peak fractions for A3H Hap II were 24 kDa 
(monomer), 44 kDa (dimer), and 94 kDa (tetramer) and for A3H Hap V were 23 kDa (monomer), 
44 kDa (dimer), and 102 kDa (tetramer). The same data also appeared in Figure 6.1. (C) 
Sequence alignment of A3H Hap II and APOBEC2 (A2) β2 strand amino acid sequences. Amino 
acids that were mutated are indicated in red. (D) The size exclusion chromatography profiles of 
GST-A3H haplotype II (GST-Hap II) and GST-A3H haplotype II R44A/Y46A (GST-
R44A/Y46A) obtained from a 10 mL G200 Superdex column were used to calculate the 
oligomerization states of the enzymes from a (E) standard calibration curve. When 10 µg of 
enzyme was loaded onto the size exclusion column, GST-A3H haplotype II formed dimers in 
solution (apparent molecular weight of 77 kDa in peak fraction). This is in contrast to GST-A3H 
haplotype II R44A/Y46A, which formed monomers (apparent molecular weight of 37 kDa in 
peak fraction). (F) The chromatograms from the 10 mL Sephadex 200 column (panel D) were 
constructed by analyzing the integrated gel band intensities of the protein in each fraction after 
resolution by SDS-PAGE. The gels show the peak fractions of GST-A3H haplotype II and GST-
A3H haplotype II R44A/Y46A with start and end volumes corresponding to the fractions that 
were resolved by SDS-PAGE. (G) The Sephadex 200 column (10 mL bed volume) demonstrates 
that GST is a dimer. The gel shows the peak fractions of GST with start and end volumes 
corresponding to the fractions that were resolved by SDS-PAGE. However, GST tagged A3H 
does not dimerize through the GST tag based on data from GST-A3H haplotype II R44A/Y46A 
(panel D). 
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in order design mutations that would result in an A3H haplotype II monomer to determine the 
effect on intersegmental transfer. 
Using size exclusion chromatography, we observed that A3H haplotype II and V both 
primarily form dimers in solution (apparent molecular mass of 44 kDa, Fig. 7.5, A and B). We 
also observed minor monomer (apparent molecular mass of 24 kDa) and tetramer (apparent 
molecular mass of 98 kDa) peaks (Fig. 7.5, A and B). A dimer and tetramer of A3H are of 
equivalent molecular mass to a monomer and dimer of A3G, respectively [140]. The formation 
of A3H tetramers was not concentration dependent since the chromatograms for 150 μg and 300 
μg enzyme showed that the tetramer fraction remained at only 20% (haplotype II) or 25% 
(haplotype V) of the total population (Fig. 7.5A and inset graph). These data confirmed that 
D178 was not responsible for mediating dimerization and instead the amino acid at position 178 
is a specific determinant that contributes to intersegmental transfer ability. Because helix 6 did 
not mediate oligomerization for A3H (Fig. 7.5, A and B) as may have occurred based on A3C 
crystal structure contacts [205], we performed our structure-guided mutagenesis using another 
single Z-domain oligomerization model, the A2 crystal structure and surrogate mutations made 
in activation-induced cytidine deaminase [373, 380]. The 40 amino acid N-terminal deleted A2 
that was crystallized was found to dimerize through two monomers pairing their β2 strands. 
Through sequence alignment of A2 and A3H and biochemical data from activation-induced 
cytidine deaminase [373, 380],  we generated an A3H mutant with amino acid substitutions 
R44A/Y46A located at this predicted oligomerization interface along the β2 strand (Fig. 7.5C) 
and determined the oligomerization state using size exclusion chromatography.  
The A3H haplotype II predicted β2 strand mutant R44A/Y46A was less stable than A3H 
haplotype II as evidenced by approximately 10-fold less recombinant protein being produced 
from the Sf9 cell system (data not shown). Thus, the GST tag was not cleaved to extend the 
stability of the mutant for size exclusion chromatography since the R44A/Y46A mutant was 
prone to precipitation after extended incubation at 4° C in solution without GST. Only 10 μg of 
GST-A3H wild type and mutant were applied to the column due to the lower yield of GST-A3H 
haplotype II R44A/Y46A mutant during purification and the chromatograms were generated by 
manually quantifying integrated gel band intensities in each fraction from an SDS-PAGE gel. 
Further, the GST-tagged wild type and mutants were analyzed on a 10 mL G200 Superdex 
	 141	
column, in contrast to untagged A3H that was analyzed using a 25 mL G200 Superdex column 
(see Material and Methods). To ensure that the GST tag did not confound our interpretation of 
the results, the GST-tagged R44A/Y46A mutant was compared to GST-tagged A3H haplotype II 
during the size-exclusion chromatography. Due to the 22 kDa GST tag, the predicted GST-A3H 
monomer molecular weight was 46 kDa. Consistent with β2-β2 strand dimerization, the GST-
A3H haplotype II R44A/Y46A mutant eluted predominantly as a monomer (apparent molecular 
weight 37 kDa, Fig. 7.5, D-F). Although GST alone forms a dimer (apparent molecular weight 
51 kDa, Fig. 7.5G), the GST appears to be unable to dimerize when attached to the A3H protein 
(Fig. 7.5D), otherwise we would be unable to resolve GST-A3H haplotype II R44A/Y46A at a 
molecular weight of 37 kDa. GST-A3H haplotype II resolved as a dimer (apparent molecular 
weight 77 kDa, Fig. 7.5, D-F), consistent with the untagged A3H haplotype II data (Fig. 7.5A). 
There is a clear peak shift of the GST-A3H haplotype II and GST-A3H haplotype II R44A/Y46A 
in the SDS-PAGE analysis of the fractions suggesting that GST-A3H haplotype II R44A/Y46A 
fully disrupted dimerization (Fig. 7.5, D and F). Nonetheless, in an attempt to examine the extent 
of the β2 strand contacts and whether GST-A3H haplotype II R44A/Y46A mutant fully disrupted 
dimerization we also made a GST-A3H haplotype II P42S mutant, but this mutant was not stably 
produced from the Sf9 cell system. These data support the conclusion that A3H dimerization is 
mediated by multiple contacts along the predicted β2 strand and involves at least amino acid 
residues 44RGY46. Further, these data demonstrated that the A3H haplotype II dimer was stable 
over a 15-fold concentration range (Fig. 7.5, compare A and D). 
According to the A2 single Z-domain oligomerization model, a β2-β2 mediated dimer 
can tetramerize via hydrophobic amino acids on loop 7[373]. A3H haplotype II formed tetramers 
in solution (Fig. 7.5A). To investigate the amino acids involved in A3H tetramerization we made 
an A3H haplotype II loop 7 double mutant, Y112A/Y113A (Fig. 7.6A). During size exclusion 
chromatography of 150 μg of A3H haplotype II Y112A/Y113A predominantly dimers were 
formed (Fig. 7.6B, apparent molecular weight of 39 kDa), similar to wild type A3H haplotype II 
(Fig. 7.5A). In contrast to wild type A3H haplotype II, the Y112A/Y113A mutant formed less 
tetramers (Fig.7.6B, peak denoted by T). At 300 μg of A3H haplotype II Y112A/Y113A, the 
mutant had no increase in tetramer formation suggesting that Y112 and Y113 primarily  
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Figure 7.6 Loop 7 amino acids Y112 and Y113 mediate A3H tetramerization. (A) Sequence 
alignment of A3H haplotype II (Hap II) and APOBEC2 (A2) loop 7 amino acid sequences. 
Amino acids that were mutated are indicated in red. (B) The size exclusion chromatography 
profile of A3H Hap II Y112A/Y113A (Y112A/Y113A, 150 µg) was used to calculate the 
oligomerization state of the enzyme from a standard calibration curve (Fig. 7.5B). Hap II 
Y112A/Y113A formed dimers (apparent molecular weight of 39 kDa in peak fraction). Overlay: 
Hap II wild type (dashed line) is shown from Fig. 5A for comparison. A3H Hap II 
Y112A/Y113A has less of a tetramer peak than haplotype II wild type. Inset graph: A3H Hap II 
Y112A/Y113A did not resolve with a tetramer peak even when 300 µg enzyme was resolved on 
the size exclusion column. (C) The apparent Kd of A3H Hap II and A3H Hap II Y112A/Y113A 
from a 118 nt ssDNA was analyzed by steady-state rotational anisotropy. The A3H Hap II bound 
ssDNA with a best least squares fit to a sigmoidal binding curve (Hill coefficient of 1.8) and an 
apparent Kd of 0.72 ± 0.14 µM. The A3H Hap II Y112A/Y113A mutant bound ssDNA with a 
best least squares fit to a rectangular hyperbola and an apparent Kd of 0.70 ± 0.13 µM. 
 
	 143	
 
contribute to tetramerization (Fig. 7.6B, inset graph). However, we could not test this hypothesis 
further since another loop 7 mutant, A3H haplotype II H114A/W115A, could not be stably 
produced from Sf9 cells, in agreement with the low cellular stability observed by others [213, 
371]. All together the data support that A3H haplotype II forms dimers through β2 strand 
interactions and tetramerizes through loop 7. 
In solution the tetramers were a small proportion of the total A3H (Fig. 7.5A). However, 
A3H haplotype II bound ssDNA cooperatively (Fig. 7.6C, Hill coefficient of 1.8) suggesting that 
tetramerization was promoted by A3H dimers binding ssDNA. In support of this hypothesis, the 
A3H haplotype II Y112A/Y113A mutant bound ssDNA with a similar apparent Kd to A3H 
haplotype II, but the saturation curve fit a noncooperative rectangular hyperbola (Fig. 7.6C). 
Together these data indicate the formation of tetramers on ssDNA. A3H haplotype II 
Y112A/Y113A was not enzymatically active on several substrates with different deamination 
motifs, e.g., 5′ATC, 5′TTC, 5′CTC, 5′GTC, 5′CCC, and 5′AAC, in agreement with a previous 
study [213, 371] (and data not shown). Loop 7 is known to interact with ssDNA and mediate 
deamination motif preference in DNA binding models for multiple APOBEC deaminases[184-
187]. Since the A3H haplotype II Y112A/Y113A mutant bound ssDNA with an apparent Kd 
similar to A3H haplotype II the data indicated that the loop 7 mutant was likely inactive due to 
an altered conformation of ssDNA in the active site (Fig. 7.6C).  
7.3.5 A3H haplotype II β2 strand mutant exhibits compromised sliding and intersegmental 
transfer. We tested A3H haplotype II R44A/Y46A to determine whether this β2 strand mutant 
was still able to processively scan ssDNA. Interestingly, the A3H haplotype II R44A/Y46A 
mutant bound ssDNA with a cooperative binding curve (Fig. 7.7A, apparent Kd of 0.21 μM; Hill 
coefficient of 1.6), suggesting that the mutant can dimerize through loop 7 amino acids on 
ssDNA and does not remain a monomer as in solution (Fig. 7.5D). Since the Y112A/Y113A 
mutant was not catalytically active (data not shown), we were unable to test deamination ability 
of an A3H R44A/Y46A/Y112A/Y113A mutant. Nonetheless, testing the A3H haplotype II 
R44A/Y46A would reveal the function of the β2-β2 strand dimer on catalytic activity and 
ssDNA scanning. We found that the A3H haplotype II R44A/Y46A could still processively slide 
to processively deaminate multiple cytosines, but not as efficiently as A3H haplotype II. On a  
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Figure 7.7 Analysis of A3H haplotype II β2 strand mutant R44A/Y46A ssDNA binding and 
scanning. (A) A3H haplotype II (Hap II) R44A/Y46A ssDNA binding was analyzed by steady-
state rotational anisotropy. The apparent dissociation constant (Kd) of A3H Hap II R44A/Y46A 
from the 118 nt ssDNA was 0.21 ± 0.04 µM. The binding curve had a best least squares fit to a 
sigmoidal binding curve (Hill coefficient 1.6) demonstrating that the mutant could still 
oligomerize on ssDNA. (B-E). Processivity of A3H Hap II R44A/Y46A (R44A/Y46A) was 
tested on ssDNA substrates that contained fluorescein labeled deoxythymidine (yellow star) 
between two 5'CTC deamination motifs separated by different distances. (B) Deamination of a 
60 nt ssDNA substrate with deamination motifs spaced 5 nt apart. Single deaminations of the 5'C 
and 3'C are detected as the appearance of labeled 42 nt and 23 nt fragments, respectively; double 
deamination of both C residues on the same molecule results in a 5 nt labeled fragment. (C) 
Deamination of a 69 nt ssDNA substrate with deamination motifs spaced 14 nt apart. Single 
deaminations of the 5'C and 3'C are detected as the appearance of labeled 51 nt and 32 nt 
fragments, respectively; double deaminations of both C residues on the same molecule results in 
a 14 nt labeled fragment. (D) Deamination of a 118 nt ssDNA substrate with deamination motifs 
spaced 63 nt apart. Single deaminations of the 5'C and 3'C are detected as the appearance of 
labeled 100 nt and 81 nt fragments, respectively; double deamination of both C residues on the 
same molecule results in a 63 nt labeled fragment. For this assay, an A3H: ssDNA ratio of 1:2 
was kept constant, but reaction components were increased (50 nM: 100 nM; 100 nM: 200 nM; 
150 nM: 300 nM; 200 nM: 400 nM; 250 nM: 500 nM). These reaction conditions enabled the 
investigation of whether A3H haplotype II R44A/Y46A could translocate on ssDNA by 
intersegment transfer. Reaction rate of deamination (percent (%)/min) for each individual 
reaction condition is shown below the gel. (E) Deamination of the same substrate described for 
(D), but with a 20 nt DNA annealed between the two cytosines. For reactions performed on 
substrates described for (B-C) and (E), the A3H: ssDNA ratio was 1: 2. The measurements of 
enzyme processivity (Processivity factor) and the Standard Deviation of the mean (S.D.) are 
shown below the gels. All values are calculated from at least three independent experiments. Gel 
images with a white line between lanes indicates that intervening lane(s) on the same gel were 
cropped for visualization. 
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ssDNA substrate with cytosine separated by 5 nt, the A3H haplotype II R44A/Y46A had a 
processivity factor of 1 demonstrating that it was essentially not able to processively deaminate 
closely spaced cytosines (Fig. 7.7B), in contrast to A3H haplotype II that had a processivity 
factor 2.1 on this substrate (Fig. 7.1A). When the deamination motifs were spaced further apart, 
but still within a distance that requires sliding for processive deamination, the A3H haplotype II 
R44A/Y46A mutant was able to processively deaminate the two motifs (Fig. 7.7C, deamination 
motifs 14 nt apart, processivity factor of 2.1), but the sliding was not as efficient as A3H 
haplotype II (Fig. 7.1B, processivity factor of 3.6). These data indicated that although the A3H 
haplotype II R44A/Y46A mutant had a helix 6 that was able to mediate sliding, the sliding 
movement was compromised in the absence of the β2-β2 strand dimer. The β2 strand 
dimerization may form a ssDNA binding groove that promotes processive sliding in combination 
with helix 6.  
To examine if A3H haplotype II R44A/Y46A was still capable of undergoing 
intersegmental transfer we used the assay that was used for A3H haplotypes II and V (Fig. 7.2). 
The processivity of A3H haplotype II R44A/Y46A did show a 2-fold decrease in the apparent 
processivity with an increased concentration of the reaction components (Fig. 7.7D), similar to 
A3H haplotype II (Fig. 7.2A). However, the rate of the reaction did not increase as the reaction 
components increased (compare Figs. 7.2A and 7.7D). These data indicate that the A3H 
haplotype II R44A/Y46A could transfer to other ssDNA substrates, likely due to the dimerization 
mediated by loop 7 (Fig. 7.7A, cooperative binding curve), but did not readily cycle through the 
ssDNA substrates (Fig. 7.7D, no increase in reaction rate). This may be due to the loop 7 dimer 
being less stable than the β2 strand dimer, which is supported by the lack of a concentration 
dependence of tetramer formation in solution (Fig. 7.5A). However, the data suggested that A3H 
haplotype II R44A/Y46A mutant was able to undergo 3-D translocations since the processivity 
on the ssDNA substrate with the deamination motifs separated by 63 nt was similar to that of 
A3H haplotype II (compare processivity factors of 5.2 (Fig. 7.1C) and 4.6 (Fig. 7.7D, first 
reaction lane)). The 3-D translocation ability of A3H haplotype II R44A/Y46A was confirmed 
by demonstrating that the mutant retained processivity in the presence of a dsDNA region 
between the deamination motifs (Fig. 7.7E).  
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7.4 Discussion 
Human A3H is the most polymorphic human A3 enzyme with seven different haplotypes 
having different cellular stabilities [45, 195, 198]. In comparison to other A3s, stable A3H 
haplotypes are most able to have a restrictive effect on the progression of an HIV infection in the 
early stages [100, 199, 232]. This is due to A3H not being sensitive to all of the HIV Vif variants, 
unlike A3G and A3F [45, 211, 232, 240, 276]. Because the majority of humans of non-African 
descent carry A3H alleles that code for an unstable form of A3H, not all HIV Vif variants are 
adapted to induce degradation of A3H if they are circulating in a geographical location where the 
majority of the population carries unstable A3H alleles [198, 276]. Thus, if an HIV strain from a 
human with inactive A3H alleles infects a human with a stable A3H allele, the Vif will have to 
adapt to degrade the stable A3H [100, 232]. It has been found that stable A3H can suppress HIV 
replication and delay time to treatment early in infection [100]. Thus, stable A3H alleles could 
potentially act as an HIV infection barrier [232]. 
Despite the realized importance of A3H in the A3 repertoire that can suppress HIV 
replication, there has been no biochemical characterization of the ssDNA scanning mechanisms 
of A3H, a biochemical comparison of stable haplotypes, or identification of the residues 
mediating oligomerization. Because oligomerization is required for virion encapsidation and 
enables A3H to be the only single Z-domain A3 naturally capable of restricting HIV replication 
[78, 191], understanding the interfaces where oligomerization occurs is important for realizing 
the determinants for HIV restriction. Thus, we focused our study on the two stable haplotypes, II 
and V, which occur with the highest frequency in humans [45, 198]. Despite only differing by a 
single amino acid, we found biochemical differences in haplotypes II and V. The more rigid 
side-chain and lower isoelectric point of the A3H haplotype II D178 in comparison to the A3H 
haplotype V E178 appeared to affect the ssDNA scanning mechanisms and the binding affinity 
for dsDNA and RNA. Our study of A3H has established the basis of processivity for a single Z-
domain A3 enzyme, that redundant processive mechanisms are used by A3H, a function of the 
A3H amino acid 178 polymorphism, and that helix 6 influences dsDNA and RNA binding 
affinity. 
In general, an enzyme that moves processively on DNA using intersegmental transfer 
must have at least two DNA binding domains to mediate the doubly-bound intermediate state 
where the enzyme simultaneously binds two segments of DNA before transferring to one of the 
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bound segments [146, 148]. However, our data show that intersegmental transfer ability can be 
mediated by A3H at different levels. Both A3H haplotype V and A3H haplotype II R44A/Y46A 
have altered intersegmental transfer ability, but for different reasons (Figs. 7.2B and 7.7D). The 
A3H haplotype II and V data (Fig. 7.2) demonstrates that D178 on predicted helix 6 promotes 
enzyme cycling during intersegmental transfer. The absence of D178, either by mutating A3H to 
a K178 or studying A3H haplotype V that has an E178 inhibited the increased reaction rate 
associated with intersegmental transfer despite the presence of two DNA binding domains 
(compare Figs. 7.2 (A and B), 7.4B, and 7.5A). This data is consistent with Mitra et al. [213], 
who found helix 6 was important for A3H activity and ssDNA binding, although they did not test 
processivity. The polymorphism at amino acid position 178 has no other known function [197]. 
The A3H haplotype II R44A/Y46A mutant demonstrated that the dimer interface is also 
important for promoting intersegmental transfer. Despite cooperative binding of A3H haplotype 
II R44A/Y46A to ssDNA, signifying the formation of oligomers, likely through loop 7, the 
mutant was unable to cycle efficiently after transfers to another DNA molecule (Fig. 7.7, A and 
D). This may either be due to the loop 7-mediated dimer being less stable than a β2 strand-
mediated dimer or that the β2 strand dimer interface creates a ssDNA binding groove along the 
enzyme that promotes interaction of the ssDNA with helix 6. Intersegmental transfer ability is 
unique to A3H among the A3 enzymes characterized thus far [133]. Although A3G has been 
characterized to undergo intersegmental transfer in one report [93], this has not been confirmed 
by others [133, 149, 381]. Further, testing A3G for intersegmental transfer movement under the 
same reaction conditions as A3H showed that the processivity of A3G did not decrease with 
increasing concentration of reaction components (data not shown), demonstrating that A3G uses 
primarily jumping as a 3-D translocation mechanism [132]. It is not known why A3 enzymes 
such as A3G or A3F do not readily undergo intersegmental transfer since there are multiple 
DNA binding domains within a monomeric unit [37, 133, 139]. Based on our results with A3H, 
this may be due to differences in the ssDNA binding properties of the helix 6. Based on results 
with A3C, another factor may be the flexibility between the two ssDNA binding domains [216]. 
Similar to A3G and A3F, A3H also uses helix 6 to mediate sliding movements [133, 139]. 
Jumping movements of A3G are mediated by loop 7 [139], however, we could not test this with 
A3H since the loop 7 mutant was not catalytically active (data not shown), in agreement with 
previous studies [198, 213]. 
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A3H haplotype II was found to use several processive mechanisms to scan ssDNA. A3H 
haplotype II could slide on ssDNA, slide over RNA/DNA hybrids, and translocate by 
intersegmental transfer and jumping (Fig. 7.1 and 7.2A). Although A3H haplotype V exhibited 
diminished sliding and intersegmental transfer ability (Fig. 7.1 A-B and 7.2B), the enzyme was 
able to jump (Fig. 7.1, C- D) and restricted HIV replication similarly to A3H haplotype II (Fig. 
7.3). Thus, the data indicate that for A3H the 3-D translocation mechanisms of intersegmental 
transfer and jumping are redundant. A3H haplotype V could processively slide on ssDNA to 
deaminate cytosines that were 14 nt apart but not 5 nt apart (Fig. 7.1, A-B). However, A3H 
haplotype V-mediated mutagenesis of HIV was not adversely affected, despite a lack of a 
redundant mechanism for searching for closely spaced cytosines (Fig. 7.3). These data suggest 
that deficiencies in sliding are not as detrimental to the efficiency of the search for deamination 
motifs as deficiencies in jumping. This is supported by A3G reaction conditions and A3G 
mutants that removed either sliding or jumping ability [139, 183]. For A3G, larger decreases in 
mutagenic efficiency result from losses in jumping rather than sliding [139, 183]. Altogether, the 
A3H data are consistent with our previous work which found that a high A3 mutagenic potential 
during HIV reverse transcription requires the enzyme to use both a 1-D and 3-D translocation 
mechanism [133]. Our data are also in agreement with others that have shown A3H haplotype V 
to be as restrictive as A3H haplotype II in primary cells during a spreading infection and in 
single-cycle infectivity assays [198, 211, 212, 232]. 
Our results indicate that A3H oligomerizes similar to the model proposed for the N-
terminal 40 amino acid deleted A2 crystal structure [373]. The A3H dimer is highly stable and 
even at very low concentrations of A3H, the dimer interface was maintained (Fig. 7.5D, 10 µg). 
The A2 model of oligomerization where a single Z-domain enzyme dimerizes through the β2 
strands and tetramerizes through loop 7 has been questioned since this structure only forms in the 
N-terminal deleted version of A2 and human A2 in vitro activity has yet to be demonstrated [191, 
373, 382]. The A3H data demonstrates that the A2 model of oligomerization is a valid model for 
single Z-domain enzymes. A caveat of our data is that we could not produce a β2 strand mutant 
that was as stable as wild type A3H haplotype II. Thus, we required a GST tag to stabilize the β2 
strand mutant. It is known that GST alone forms dimers (Fig. 7.5G), but our data demonstrate 
that GST-A3H does not form dimers through the GST tag or we would be unable to resolve A3H 
haplotype II R44A/Y46A as a monomer (Fig. 7.5D). These data suggest that the A3H can block 
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GST dimerization in our GST-A3H fusion construct. Nonetheless, this model of oligomerization 
does not appear to be conserved across all Z-type domains since multiple crystal structures of 
single Z-domain enzymes or C-terminal domains of double Z-domain enzymes have not 
oligomerized according to the A2 model [205, 365, 383-385]. Because A3H is the only Z3-
domain in humans it may be the only A3 to oligomerize in this manner [37]. A3H tetramers form 
primarily during DNA binding and not in solution. This is supported by the data for the A3H 
haplotype II β2 strand mutant R44A/Y46A that could still bind ssDNA cooperatively (Fig. 7.7A) 
and the A3H haplotype II loop 7 mutant Y112A/Y113A that could not (Fig. 7.6C). These data 
are also consistent with size exclusion chromatography profiles of A3H haplotypes II and V 
where tetramers were a minority of the population in comparison to dimers (Fig. 7.5A). Mitra et 
al. [213] have investigated the role of loop 7 in the A3H-ssDNA interactions required for 
catalytic activity. Deamination reactions conducted with A3H haplotype II and mutants 
expressed from 293T cells demonstrated that Y112A and W115A mutants lose deamination 
activity [213]. Interestingly, W115F rescued the deamination activity by 30%, suggesting that 
aromatic residues on loop 7 are involved in nucleic acid interactions that are required for 
catalysis through base stacking [213], in agreement with data from activation-induced cytidine 
deaminase [386] . However, this does not affect the apparent Kd from ssDNA (Fig. 7.6C).  
The A3H dimer organization may provide an advantage by decreasing the Vif-mediated 
degradation efficiency and thus promoting the HIV restriction ability of A3H. We previously 
showed that A3G dimerization is disrupted by Vif [312]. This may contribute to efficient Vif-
induced polyubiquitination. Vif can disrupt A3G dimerization since the primary residue Vif 
interacts with on A3G is Asp-128, which is adjacent to the primary dimerization amino acids, 
Phe-126 and Trp-127 [64, 138, 278, 279, 312]. In contrast, when A3H haplotype II interacted 
with Vif, there was a structural change induced by Vif, but this did not appear to be a complete 
disruption of dimerization [312]. Our data on the A3H dimer interface suggest that this is 
because A3H dimerizes through the β2 strands (Fig. 7.5D) and Vif interacts with A3H on a 
separate structure, predicted helix 4 [265, 387]. Using quantitative immunoblotting it was shown 
that VifHXB2 is 4-fold less efficient at degrading A3H than A3G. Further, both VifNL4-3 and VifHXB2 
could induce polyubiquitination of A3H with K63 and K48 linkages, in contrast to A3G that was 
polyubiquitinated with only K48 linkages [312]. Thus, the A3H β2 strand dimer may decrease 
the effectiveness of Vif and promote alternate ubiquitination modifications. Although during 
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viral infections, HIV Vif can effectively suppress both A3G and A3H to enable viral replication 
[276], the higher resistance of A3H to Vif may provide an advantage during the early stages of 
infection and during Vif adaptation [100, 232]. 
7.5 Material and Methods 
7.5.1 Cloning and site-directed mutagenesis. An A3H haplotype I clone (NCBI Accession 
BC069023) was obtained from Open Biosystems and site directed mutagenesis was used make 
A3H haplotype II (G105R, K121D, E178D) and haplotype V (G105R, K121D). A GST-A3H 
construct was subcloned from a pAcG2T vector (BD Biosciences) into a pFAST-bac1 vector 
(Life Technologies) using EcoRI and NotI restriction sites. Mutants of A3H haplotype II 
(R44A/Y46A, Y111A/Y112A, D178K, and D178A) were made using the A3H haplotype II 
construct for site-directed mutagenesis (QuickChange site-directed mutagenesis protocol, 
Stratagene). The cDNA for A3H haplotypes II and V was also cloned into pcDNA3.1 with an 
HA tag. For generation of RNA in vitro, the HIV 5'UTR (nucleotides 1-497) and human Alu 
sequence were cloned into pSP72 vector (Promega) using XhoI and HindIII sites under the 
control of T7 promoter (5'UTR) or SP6 promoter (Alu). All constructed plasmids were verified 
by DNA sequencing. Primers were obtained from Integrated DNA Technologies and are listed in 
Table 7.5.  
7.5.2 Protein expression and purification. The pFASTbac1-GST-A3H vectors were used to 
produce recombinant baculovirus according to the protocol for the Bac-to-Bac system (Life 
Technologies). Recombinant GST-A3H baculovirus were then used to infect Sf9 cells at a 
Multiplicity of Infection (M.O.I) of 20 and cells were harvested after 72 h. Cells were lysed and 
clarified lysates were incubated with Glutathione Sepharose 4B resin (GE Healthcare) at 4°C and  
subjected to a series of salt washes as previously described. For all A3H haplotypes and mutants, 
except the A3H haplotype II R44A/Y46A, D178K, and D178A mutants, on-column cleavage 
from the GST tag with thrombin (GE Healthcare) was performed at 21°C for 18 h in thrombin 
digestion buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, and 1mM DTT). 
Enzymes were assessed to be 95% pure by SDS-PAGE. Due to the lower expression of the A3H 
haplotype II R44A/Y46A, D178K, and D178A mutants, the enzyme was eluted with the GST tag 
in elution buffer (100 mM Tris pH 8.8, 150 mM NaCl, 10% (v/v) glycerol and 50 mM reduced 
glutathione). A wild type GST-haplotype II was purified in parallel with the mutant for 
comparative analyses. Eluted GST-A3H was dialyzed against 100 mM Tris pH 7.5, 250 mM  
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Table 7.5. Primers and DNA substrates 
Name  Sequence 
pFASTbac1-
A3H Forward  
GAA TTC ATG TCC CCT ATA CTA GGT TA 
pFASTbac1- 
A3H Reverse  
 
GCG GCC GCT CAG GAC TTT ATC CTC TC  
G105R SDM 
Forward 
GCT CAC GAC CAT CTG AAC CTG CGC ATC TTC GCC TCC 
CGC CTG 
 
G105R SDM 
Reverse 
CAG GCG GGA GGC GAA GAT GCG CAG GTT CAG ATG 
GTC GTG AGC 
K121D SDM 
Forward 
TGC AAG CCC CAG CAG GAC GGG CTG CGG CTT CTG 
K121D SDM 
Reverse 
CAG AAG CCG CAG CCC GTC CTG CTG GGG CTT GCA 
E178D SDM 
Forward 
ATA AAG CGA CGG CTT GAC AGG ATA AAG TCC TGA 
E178D SDM 
Reverse 
TCA GGA CTT TAT CCT GTC AAG CCG TCG CTT TAT 
Y112A/Y113A 
SDM Forward  
ATC TTC GCC TCC CGC CTG GCC GCT CAC TGG TGC AAG 
CCC CAG 
Y112A/Y113A 
SDM Reverse 
CTG GGG CTT GCA CCA GTG AGC GGC CAG GCG GGA 
GGC GAA GAT 
H114A/Y115A 
SDM Forward 
GCC TCC CGC CTG TAC TAC GCC GCT TGC AAG CCC CAG 
CAG GAC 
H114A/Y115A 
SDM Reverse 
GTC CTG CTG GGG CTT GCA AGC GGC GTA GTA CAG GCG 
GGA GGC 
R44A/Y46A 
SDM Forward 
AAT GGC TCC ACG CCC ACG GCC GGC GCT TTT GAA AAC 
AAG AAA AAG  
R44A/Y46A 
SDM Reverse 
TTT TTC TTG TTT TCA AAA GCG CCG GCC GTG GGC GTG 
GAG CCA TT 
D178K SDM 
Forward 
ATA AAG CGA CGG CTT AAG AGG ATA AAG TCC TGA 
 
D178K SDM 
Reverse 
TCA GGA CTT TAT CCT CTT AAG CCG TCG CTT TAT 
 
D178A SDM 
Forward 
ATA AAG CGA CGG CTT GCT AGG ATA AAG TCC TGA 
 
D178A SDM 
Reverse 
TCA GGA CTT TAT CCT AGC AAG CCG TCG CTT TAT 
118 nt (CTC) 
ssDNA 
(deamination 
GAA TAT AGT TTT TAG CTC AAA GTA AGT GAA 
GAT AAT [Fam-dT] TAG AGA GTT GTA ATG 
TGA TAT ATG TGT ATG AAA GAT ATA AGA CTC 
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Fam denotes Fluorescein amidite 
assay and 
anisotropy) 
AAA GTG AAA AGT TGT TAA TGT GTG TAG ATA 
TGT TAA 
85 nt (CTC) 
ssDNA  
AAA GTG AAA GTG ATA CTC AAA TTT AAA AGT 
[Fam-dT] AGA TAG AAG GTG ATA CTC AAA 
TAT GAA AGT TAG TAA GAT GTG TAA GTA TGT 
TAA 
20 nt DNA CTT TCA TAC ACA TAT ATC AC 
20 nt DNA 
complement 
Fam-GTG ATA TAT GTG TAT GAA AG 
20 nt RNA   CUU UCA UAC ACA UAU AUC AC 
20 nt RNA  
complement 
Fam-GUG AUA UAU GUG UAU GAA AG 
69 nt (CTC) 
ssDNA 
AAG AAG TTA GTA AGA CTC AAA ATT [Fam-dT] AAA AAC 
TCA AAT GTT AGA TAT GTT AAT GTG TGT GAT GAT GTT 
GA 
60 nt (CTC) 
ssDNA 
AAA GTA AAA GTG ATA CTC A [Fam-dT] GCT CAT AGA 
TTA AAG TTA GTA AGA TGT GTA AGT ATG TTA A 
prot Forward GAC AAG GAA CTG TAT CCT TTA GCT T 
prot Reverse CTG GTA CAG TCT CAA TAG GAC TAA T 
HIV 5'UTR 
Forward 
GAA TTC GCC AGA GAG CTC CCG GGC  
HIV 5'UTR 
Reverse 
AGA TCT TGG AAG GGC TAG TTT ACT C 
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NaCl, 10% glycerol, and 1mM DTT overnight at 4°C. For size exclusion chromatography with 
the A3H haplotype II R44A/Y46A mutant, the GST tag was not cleaved to increase protein 
stability. For deamination reactions with the A3H haplotype II R44A/Y46A, D178K, and D178A 
mutants the GST tag was cleaved in solution with thrombin (GE Healthcare).  
7.5.3 Single-cycle infectivity assay. VSV-G pseudotyped HIV pNL4-3 ΔVif viruses were 
produced by transfecting 3×105 293T cells (ATCC CRL-3216) per well in a 6-well plate with 
GeneJuice (Novagen). Specifically, transfections used 500 ng of pHIVΔVif, which expresses an 
eGFP reporter gene and 200 ng of pMDG, which expresses the VSV-G protein, in the presence 
or absence of A3H haplotype II or A3H haplotype V in pcDNA3.1. Empty pcDNA3.1 was used 
to achieve equivalent amounts of transfected DNA. A titration of A3H expression vector was 
used that ranged from 25-200 ng. The amino acid sequences of the A3s were identical to those 
used in biochemical assays. Twenty-four hours after the transfection the medium was replaced. 
Virus-containing supernatants were collected 48 hours after the media change and filtered 
through 0.45 µm syringe filters. Virus was quantified by a p24 enzyme-linked immunosorbent 
assay (QuickTiter Lentivirus Titer Kit, Cell Biolabs Inc. or HIV-1 p24 ELISA Kit, XpressBio). 
Target 293T cells were infected at an MOI of 0.5 by spinoculation at 800 × g for 1 h in the 
presence of 8 µg/ml of polybrene. Infection levels in 293T cells was determined by flow 
cytometry by detecting eGFP fluorescence at 40 hours post infection and data were normalized 
to HIVΔvif infections in the absence of A3 enzymes. 
7.5.4 Immunoblotting. To detect A3H protein levels, HA-tagged versions of the A3H enzymes 
used for the single-cycle infectivity assays were constructed in pcDNA3.1. For detection of A3H 
in cell lysates (50 µg total protein) and virions (50 ng of p24) anti-rabbit HA (Sigma) was used. 
Loading controls for cell lysates (α-tubulin, Sigma) and virions (p24, Cat #3537, NIH AIDS 
Reagent Program) were detected using mouse monoclonal antibodies. Tagged proteins and 
loading controls were detected simultaneously on the same immunoblot by using the 
Licor/Odyssey system (IRDye 680-labeled goat anti-rabbit and IRDye 800-labeled goat anti-
mouse secondary antibodies). Antibodies were used at a dilution of 1/1000. 
7.5.5 Sequencing of integrated proviral DNA. Infected 293T cells were harvested after 40 h and 
the DNA was extracted using DNAzol Reagent (Life Technologies). DNA was treated with DpnI 
(New England Biolabs) for 1 hour at 37 °C to remove possible contaminating plasmid DNA and 
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the prot (nt 2280-2631) sequences were amplified by PCR using Q5 Polymerase (New England 
Biolabs). Primers were obtained from Integrated DNA Technologies and are listed in Table 7.5. 
PCR products were purified and cloned with the Zero Blunt TOPO PCR cloning kit (Life 
Technologies) or NEB PCR Cloning Kit (New England Biolabs). DNA was sequenced with kit 
specific primers and carried out at the National Research Council of Canada (Saskatoon, 
Saskatchewan) or Eurofins Genomics (Huntsville, Alabama). 
7.5.6 In vitro deamination assay. All ssDNA substrates were obtained from Tri-Link 
Biotechnologies and are listed in Table 7.5. All reactions were carried out under single-hit 
conditions, i.e., <15% substrate usage, to ensure that deaminations on each ssDNA were 
catalyzed by a single enzyme. Under these conditions, a processivity factor can be determined by 
comparing the total amount of deaminations occurring at two sites on same ssDNA to a 
calculated theoretical value of deaminations at these two sites if the deamination events were 
uncorrelated (not processive). In order to achieve less than 15% substrate usage, the ssDNA 
substrate containing two 5'CTC motifs (100 nM) was incubated with 50 nM of A3H for 1.5 to 20 
min at 37 °C in deamination buffer containing 50 mM Tris pH 7.5, 40 mM KCl, 10 mM MgCl2, 
and 1 mM DTT. The reaction time was varied according to the specific activity of the enzyme on 
each ssDNA to achieve ~10% substrate usage. DNA substrates with a dsDNA or RNA/DNA 
hybrid were formed by heat annealing in 50 mM Tris pH 7.5 and 50 mM NaCl. Reactions were 
started by the addition of the ssDNA substrate. To test if intersegmental transfer was occurring, 
the A3H: ssDNA ratio (1:2) was kept constant, but increased amounts of enzyme and substrate 
were titrated into the reaction (ssDNA, 100 nM-700 nM; A3H, 50 nM-350 nM). A3H catalyzed 
deaminations were detected by treating the ssDNA with Uracil DNA Glycosylase (New England 
Biolabs) and heating under alkaline conditions before resolving the Fluorescein labeled ssDNA 
on 10%, 16% or 20% (v/v) denaturing polyacrylamide gels, depending on the sizes of the ssDNA 
fragments. Gel photos were obtained using a Typhoon Trio multipurpose scanner (GE 
Healthcare) and integrated gel band intensities were analyzed using ImageQuant (GE Healthcare) 
as previously described [132]. 
7.5.7  Size exclusion chromatography. The oligomerization states of A3H haplotype II, haplotype 
V, and haplotype II Y112A/Y113A were determined by loading 150 or 300 μg of the purified 
enzymes onto a Superdex 200 10/300 Increase (GE Healthcare). The running buffer contained 20 
mM Tris pH 8.0, 300 mM NaCl, 10% (v/v) glycerol and 1 mM DTT. The oligomerization states 
	 156	
of GST-A3H haplotype II and GST-A3H haplotype II R44A/Y46A were examined by loading 
10 μg of the purified enzymes onto a size exclusion chromatography column. The column was 
prepared by pouring a 10 mL Superdex 200 (GE Healthcare) resin bed contained in a column 
with a 0.5 cm diameter and 16 cm height. The running buffer contained 20 mM Tris pH 8.0, 300 
mM NaCl, 10% (v/v) glycerol and 5 mM DTT. The Bio-Rad gel filtration standard set was used 
to generate a calibration curve from which the apparent molecular masses and oligomerization 
states of the enzymes were determined.  
7.5.8 Steady-state rotational anisotropy. The apparent Kd of A3G, A3H haplotype II, and A3H 
haplotype V for ssDNA, dsDNA, RNA/DNA hybrid, or RNA were determined using steady state 
fluorescence depolarization (rotational anisotropy). The ssDNA substrate was the 118 nt ssDNA 
used for deamination assays and contained an internal Fluorescein-dT (Table 7.5). The dsDNA 
and RNA/DNA hybrid were composed of 20 nt that matched the hybrid regions used to block 
A3H sliding in deamination assays (Table 7.5). 
 Fluorescently labeled RNA was produced by transcribing linearized pSP72 DNA (cut 
with EcoRI (5'UTR) or HindIII (Alu)) in vitro using either T7 RNA polymerase (5'UTR, Roche 
Life Sciences) or SP6 polymerase (Alu, Roche Life Sciences) with a nucleotide mixture 
containing fluorescein-12-UTP (Roche).   
Reactions (50 μl) were conducted in deamination buffer and contained 50 nM fluorescein 
labeled DNA or RNA and increasing amounts of A3 (A3G, 0-1000 nM; A3H haplotypes II and 
V, 0-1500 nM). A QuantaMaster QM-4 spectrofluorometer (Photon Technology International) 
with a dual emission channel was used to collect data and calculate anisotropy. Measurements 
were performed at 21°C. Samples were excited with vertically polarized light at 495 nm (6 nm 
band pass) and vertical and horizontal emissions were measured at 520 nm (6 nm band pass). 
The Kd was obtained by fitting to a rectangular hyperbola or sigmoidal curve equation using 
SigmaPlot 11.2 software. 
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8.0 Exploration of the biological activities of A3 enzymes apart from 
HIV restriction 
 Aside from the antiviral activities against exogenous viruses such as HIV, several studies 
suggest the primitive function of A3 proteins is to prevent the propagation of endogenous 
retroelements [388, 40]. A3s likely represent an ancient form of antiviral defense in mammals 
because A3 genes have been undergoing positive selection throughout the past 30 million years 
of primate evolution and their existence predates HIV [317]. Endogenous retroelements, 
including the Long Terminal Repeat (LTR) and non-LTR retrotransposons, represent a class of 
mobile genetic elements that propagate through an RNA intermediate and they share with 
retroviruses a reverse transcription step (reviewed in [315, 321]). Uncontrolled retrotransposon 
mobilization poses a deleterious effect on the host genome stability and A3 proteins have been 
reported to act differentially to suppress the activities of various retrotransposons [35, 165, 325, 
332, 334-336, 389-391]. In Chapter 7, having comparatively characterized the two most 
frequently occurring A3H haplotypes (Hap II and Hap V) and having elucidated the biochemical 
determinants in A3H that are required for HIV restriction, we next set out to examine if the same 
determinants are needed for restriction of retroelements. Specifically we determined how two 
A3H haplotypes restrict the replication of the non-LTR retrotransposon L1, the only active 
autonomous retrotransposable element present in humans (reviewed in [315, 321]). Although 
A3H’s effects on L1 retrotranspositions have been reported in the literature [45, 289], A3H 
polymorphism confounded the analysis and no studies have clarified the influence of different 
stable haplotypes on L1 replication. Furthermore, despite A3H Hap II and Hap V restricting HIV 
with similar efficiencies, we found the dsDNA and RNA binding abilities differ greatly between 
the two haplotypes [210]. This finding prompted us to test whether the difference in nucleic acid 
binding between A3H Hap II and Hap V leads to a difference in their abilities to affect L1 
replication. In Chapter 9, the L1 restriction capacities of A3H Hap II and Hap V have been 
characterized and compared to that of A3A and A3G, two A3s that have been shown to be either 
a robust L1 restrictor or unable to restrict L1 mobilizations, respectively [41, 333, 334, 390, 391]. 
 The experiments performed in Chapter 9 were conceived by Y.F and L.C and were 
carried out by Y.F with the assistance from M.G. Y.F, M.G and L.C analyzed the data, and Y.F 
and L.C wrote the paper.     
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9.1 Abstract 
L1 is the only autonomous non-LTR retroelement currently present in humans and the 
uncontrolled mobilizations of L1 have been associated with various hereditary diseases and 
represent a threat to genome stability. A3 proteins have been reported to act differentially against 
L1 retrotranspositions, although the mechanisms of A3-mediated L1 inhibition have not been 
well understood. The prevailing view for many years was that A3-mediated L1 inhibition was 
deamination independent and relied on A3s blocking the L1 reverse transcriptase DNA 
polymerization. However, during L1 replication, A3s may act on transiently exposed single-
stranded cDNA to catalyze the formation of uracils which are excised by the uracil DNA N-
glycosylase (UNG), which generates abasic sites and may lead to cDNA degradation. To test the 
hypothesis that A3-deamination mediated L1 restriction was occurring we included a uracil DNA 
glycosylase inhibitor (UGI) in experiments that would inhibit UNG and prevent the degradation 
of L1 cDNA. We predicted that this would allow the recovery of the A3s-catalyzed deamination 
events. By utilizing a neoR-based L1 retrotransposition assay and inspecting A3-mediated G-to-A 
deamination events on transposed neo sequence, we confirmed A3A is a potent inhibitor of L1 
retrotransposition, whereas A3G has very little inhibitory effect against L1. We also reported, for 
the first time, that two most frequently occurring stable A3H haplotypes (Hap II and Hap V) 
restrict L1 activity using a deamination-independent mechanism(s), in contrast to A3A. Our 
study demonstrates different A3 proteins have been evolved to inhibit L1 retrotransposition 
activities through distinct mechanisms.   
9.2 Introduction 
Transposable elements are DNA sequences that can move from one location of the 
genome to another. Approximately 45% of the human genome is recognized as being derived 
from transposable elements. Transposable elements can be grouped into two major classes based 
on whether they mobilize via a DNA intermediate (i.e., DNA transposons) or an RNA 
intermediate (i.e., retrotransposons) [320, 321]. DNA transposons, although not being able to 
	 159	
mobilize in the current human genome, have played a major role during the evolution of the 
eukaryotic genome [37, 392, 393].  Retrotransposons transpose through RNA intermediates 
followed by reverse transcription and integration at new genomic locations. Retrotransposons 
can be divided into two classes: Long Terminal Repeat (LTR) retrotransposons (also known as 
endogenous retroviruses) and the non-LTR retrotransposons. The genetic construct and 
replication strategy of endogenous retroviruses resembles those of the retroviruses, except the 
endogenous retrovirus lacks a functional envelope (env) gene and their life cycles are strictly 
intracellular [320, 321].  
Non-LTR retrotransposons are found throughout the eukaryotes, and examples of non-
LTR retrotransposons include LINE1 (Long Interspersed Nuclear Element) and SINE (Short 
Interspersed Nuclear Element). Human L1s account for ~17% of the genomic DNA with 
~500,000 copies identified, and they represent the only autonomous transposable elements that 
are currently active in humans [324, 394]. Although the vast majority of L1s are inactive due to 
accumulated mutations or 5’ truncations, human genome still contains 80~100 copies of intact 
L1s that are retrotransposition competent [34, 315, 320, 321]. Full-length L1 contains a 5’ UTR, 
two Open Reading Frames (ORFs) that are separated by a 63 nt inter-ORF region, and a 3’ UTR 
that ends with a polyadenosine-rich sequence (poly(A) tail) [395]. Proteins encoded by ORF1 
and ORF2 are both required for efficient L1 retrotransposition. ORF1 encodes a 40kDa nucleic 
binding protein with demonstrated nucleic acid chaperone activity; ORF2 encodes proteins with 
endonuclease (EN) and reverse transcriptase (RT) activities [224, 396, 397]. L1-encoded EN 
preferentially cleaves ssDNA at an AT-rich consensus sequence (5’ TTTT/A, where “/” dictates 
the cleavage sites). L1 RT is a DNA/RNA dependent DNA polymerase and it lacks a detectable 
RNaseH activity [398], a trait that distinguishes itself from the retroviral RTs. As a result, L1 
RNA could be either degraded by a yet unidentified cellular protein or displaced during (+) 
strand cDNA synthesis [399], although experiments are required to test these hypotheses. 
Cellular RNaseH2 cooperates with flap endonuclease 1 (FEN-1) to remove RNA primers during 
lagging strand DNA synthesis and serves as a good candidate [400]. Unlike retroviruses and 
LTR retrotransposons which undergo reverse transcription in cytoplasm, L1 RNA is reverse-
transcribed in the nucleus [401, 402] (Fig. 1.8B). L1 relies on a mechanism termed the Target 
Primed Reverse Transcription (TPRT) for retrotransposition [403] (Fig. 1.9). 
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Despite the positive effects of retroelement mobilizations, such as contributing to genome 
evolution and gene diversity, excessive transposition events need to be suppressed, as several 
genetic diseases have been associated with L1-mediated insertional mutagenesis in germline and 
somatic cells [34, 315]. The retroelement suppression mechanisms include DNA methylation 
[404, 405], RNA interference [406, 407], cellular DNA repair factors [408, 409]. Also, recent 
studies suggest that several cellular proteins are involved in L1 restriction. Examples of these 
cellular proteins include Three primer repair Exonuclease 1 (TREX1) [410], Zinc finger 
Antiviral Protein (ZAP) [411], RNA helicase Mov10 [412], RNaseL [413], SAM domain and 
HD domain-containing protein 1(SAMHD1) [414, 415], and APOBEC family of cytosine 
deaminases [35, 165, 325, 332, 334, 335, 389-391]. 
   APOBECs emerged at the origin of vertebrates and have diversified throughout the 
vertebrate lineage [37, 317]. The most ancient APOBEC family members include Activation 
Induced cytidine Deaminase (AID) and APOBEC2 (A2) proteins that are identified in jawless 
and cartilaginous fish [37]. AID is involved in class-switch recombination and somatic 
hypermutations in adaptive immune response and A2 proteins are involved in cardiac and 
skeletal muscle development [416, 417]. APOBEC4 (A4) and APOBEC5 (A5) then emerged in 
amphibians, although their functions are yet to be identified [418, 419]. Throughout tetrapod 
evolution, duplication of AID leads to the emergence of APOBEC1 (A1) [420]. In placental 
mammals the A3 locus evolved and greatly expanded [37]. While only one A3 gene is present in 
mice, up to seven A3 (A3A-A3H) genes are present in primates. A3 genes have likely acquired the 
anti-L1 activities from the AID/A2-like gene from which they have evolved. Several studies have 
clearly demonstrated that in cell culture system, A3 family members could possess inhibitory 
activities against a number of mammalian L1s [35, 165, 325, 332, 334, 335, 389-391]. However, 
which cellular factors control the mobility of L1 in species that lack A3 genes became an 
intriguing question and it seemed reasonable to hypothesize that L1 restriction by APOBEC 
proteins predates mammals, as A3 genes are only limited to mammalian lineages, whereas the 
L1s are far more ancient, dating back to the emergence of vertebrates. It was not surprising to 
find that APOBEC proteins, such as pre-mammalian AID and reptilian A1 from green anole 
lizard, are indeed capable of inhibiting non-mammalian L1 genomes [35, 388].  
A3s have been reported to restrict L1 by both deamination-dependent or -independent 
mechanisms [41, 325, 332-335, 391, 421]. For a deamination-dependent mechanism, during the 
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reverse transcription of the L1 RNA, (-)cDNA gets transiently exposed after the RNA template 
degradation, which renders it susceptible to A3-mediated C→U deaminations. The uracils 
present on L1 cDNA could trigger cDNA degradation through the actions of host base excision 
repair pathway. Specifically, cellular uracil DNA N-glycosylase (UNG) proteins excise the 
uracils from ssDNA, generating abasic sites and apurinic/apyrimidinic endonuclease (APE) 
produces nicks on DNA which would induce L1 cDNA degradation. Alternatively, an uracil-
containing cDNA may escape the degradation, becomes replicated to form a double-stranded (ds) 
DNA and integrates into the host chromosome and is functionally inactivated through A3 
induced C/G→T/A transition mutations. For a deamination-independent mechanism of L1 
restriction, the A3s can sequester L1 ribonucleoprotein (RNP) complex to the cytoplasmic 
compartment such as stress granule or physically interact with L1 RT and inhibit DNA 
polymerization during TPRT [42, 335, 336]. There are controversies in the literature as to 
whether A3s utilize the deamination-dependent mode for L1 restrictions. These ambiguities 
arose because no G→A mutations, which indicate the occurrence of C→U deamination on the 
L1(-) cDNA, could be detected on the coding strand (i.e., (+) cDNA) of the integrated L1. 
However, none of these cell culture studies blocked the action of UNG [40, 325]. Therefore, the 
unsuccessful attempts to uncover A3-induced mutations were likely due to the degradation of 
uracil-containing cDNA intermediates by the UNG and APE-mediated cellular repair machinery 
[103].  
We reasoned the A3-induced deaminations could contribute to L1 restriction, as traces of 
strand-specific G-to-A mutational signature have been identified in several endogenous 
retroviruses [329, 422, 423] and the sequences of mammalian L1s by genome-wide DNA editing 
analysis [314]. To address this question, we used a cell culture-based L1 retrotransposition assay 
to assess human L1’s restriction abilities by A3 proteins [424, 425]. The results presented here 
focused on three A3 family members, A3A, A3G and A3H, as it has been shown that A3A is 
able to restrict human L1 retrotransposition whereas A3G is unable to restriction L1 efficiently 
[326, 334, 390, 391]. There are up to at least seven A3H haplotypes exist in humans and 
haplotype II (Hap II) and haplotype V (Hap V) comprise the majority of the stable haplotypes 
(see Chapter 7). Although previous research demonstrated stable A3H could inhibit L1 [45, 289], 
A3H polymorphism confounded the analysis and no studies have clarified which stable A3H 
haplotypes contributed to L1 restrictions. In this study, we have demonstrated  
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Figure 9.1 Schematic for L1 retrotransposition assay. A full-length retrotransposition-competent 
L1 (~6 Kb) contains a neo-reporter cassette (green box) in the 3’UTR region. The L1 
transcription initiates with an internal RNA polymerase II promoter within the 5’UTR (black 
arrow) or the CMV promoter from pCEP4 plasmids backbone [424]. Transcription is terminated 
at an SV40 polyadenylation signal. The reporter gene, neomycin phosphotransferase (backwards 
NEO), is in the opposite transcription orientation with respect to L1. Neo gene is interrupted by 
an intron (hatched box), which is in the same transcriptional orientation with L1. The neo-
reporter cassette has its own heterologous promoter (upside down red arrow) and 
polyadenylation signal (upside down red lollipop). Once transcribed, the intron is spliced out 
from the precursor mRNA. The resulting bi-cistronic mRNA is translated, generating two 
proteins, ORF1 proteins (ORF1p, orange circles) and ORF2p (blue circle). ORF1p and ORF2p 
preferentially act in cis and bind to their encoding mRNA, giving rise to the L1 ribonuclear 
protein (RNP) complex, an important L1 retrotransposition intermediate. The RNP complex then 
shuttles to nucleus for L1 TPRT and integration event[426, 427]. Only upon reverse transcription 
and integration into a genomic locus can the neo gene be expressed to confer resistance to G418. 
The retrotransposed L1 is usually 5’ truncated and integration sites are usually flanked by target 
site duplications (TSD) sequences.   
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A3A inhibits L1 replication using a deamination-dependent mechanism and the recovered 
L1 retrotransposition events from Hela cells co-expressing A3A and the UGI protein 
contained A3A-mediated G-to-A deamination signatures. Both A3H Hap II and Hap V 
suppress L1 to a similar level but the inhibition of L1 did not involve DNA deamination.    
9.3 Results 
9.3.1 The effects of A3s on L1 retrotranspositions in mammalian cultured cells. To study the 
influence of A3 proteins on L1 retrotranspositions, a pre-established cell based retrotransposition  
assay was performed [424, 425] (Fig. 9.1). To detect rare retrotransposition events, the 3’ 
untranslated regions (3’UTRs) of a human L1 retrotransposon vector (pJM101/L1.3) is marked 
with a neomycin phosphotransferase (neo) reporter cassette, which, when expressed, can convey 
resistance to G418, a neomycin analog that is used in mammalian cultured cells. The neo 
reporter cassette has its own promoter and polyadenyation signal, and it consists of an antisense 
neo gene disrupted by an intron of the γ-globin gene, which is in the same transcriptional 
orientation as the L1 element (Fig. 9.1). Because the neo gene is rendered inactive by the 
presence of an intron, and G418-resistant (G418R) cells will only arise when a transcript initiated 
from the L1 promoter is spiced, reverse transcribed, its cDNA is re-inserted into the host 
chromosome, and the neo gene is transcribed from its own CMV promoter. The L1 assay relies 
on neo expression as a readout and the rise of a G418R colony demonstrates a successful L1 
retrotransposition event. Hela cells were utilized in this assay, as these cells contain a low 
endogenous L1 copy number (~25 copies per cell) [332], can accommodate high levels of L1 
retrotransposition events from ectopically expressed L1 reporter plasmids [424, 428] and do not 
express endogenous A3A, A3G and A3H proteins [332], thus providing an ideal system for 
measuring the direct effects of ectopically expressed A3 proteins on L1 retranspositions. 
 In order to study the effects of A3 proteins on L1 retrotransposition, Hela cells were co-
transfected with L1 reporter plasmid pJM101/L1.3 in the presence and absence of plasmids 
expressing V5-tagged A3s. Three days post transfection, the cells were subjected to G418 
selection for 11 days and the G418R colonies were stained and counted. Transfection of L1 
vector alone with no A3 expression generates a quantifiable amount (50-150 colonies per well in 
a 6-well dish) of G418R colonies (Fig. 9.2A, no A3). In the presence of A3A and A3G, L1  
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Figure 9.2 Relative L1 retrotransposition frequencies in the presence of wild type and catalytic 
mutants of A3A, A3G and A3H in cultured Hela cells. (A) Representative experimental results of 
the neo-based L1 retrotransposition assay in the presence of wild type A3 proteins. Hela cells 
were co-transfected with 1μg of both a neoR-based L1 reporter plasmid (pJM101/L1.3) and the 
expression plasmids encoding A3A, A3G, A3H (Hap II and Hap V) or an empty vector (pcDNA 
6A). Transfections were performed in the absence or presence of 1 μg of an expression plasmid 
for uracil DNA glycosylase inhibitor (UGI). Cells were subjected to G418 selection and resistant 
colonies were fixed and counted 14 days post-transfection. (B) Quantification of the effects of 
various A3s on L1 transposition efficiencies in the presence or absence of UGI as shown in (A). 
The relative retrotransposition efficiencies were calculated by counting the fixed and stained 
G418R colonies and setting the value determined from control cells co-transfected with a L1 
vector and an empty pcDNA 6A vector at 100%. Date were derived from at least three 
independent transfection experiments and are represented as the means ± standard deviations. (C) 
Representative experimental results of the neoR-based L1 retrotransposition assay in the presence 
of A3 catalytic mutants and A3 catalytic mutants (A3A C101S, A3G E259Q, and A3H E59A) 
demonstrate varying effects on L1 retrotransposition. (D) Quantification of the effects of various 
A3 catalytic mutants on L1 transposition efficiencies as shown in (A). The relative 
retrotransposition efficiencies of the A3 catalytic mutants were calculated by counting the fixed 
and stained G418R colonies and setting the value determined from control cells co-transfected 
with a L1 vector and an empty vector at 100%. Date were derived from at least three independent 
experiments and are represented as the means ± standard deviations. (E) The cellular expression 
of V5-tagged A3 proteins in Hela cells was confirmed by immunoblotting using anti-V5 
antibodies. Each lane was loaded with 40μg cell lysates extracted from Hela cells 72-hrs post co-
transfection of A3 expression plasmid and pJM101/L1.3. α-Tubulin (~50 kDa) expression was 
used as a loading control.  
 
	 166	
 
transcription and splicing
reverse transcription and integration
Transposed cDNA
intron
1496 bp
Plasmid DNA
588 bp
Kb
3.0
2.0
1.5  
1.0  
0.5  spliced product
unspliced product
A 
B 
 
Figure 9.3 Rationale of analyzing A3-mediated deaminations footprints in L1 DNA by examining 
transposed neo gene. (A) Schematic of the neo-cassette before and after L1 retrotransposition 
with specific primers and the size of the expected PCR fragments indicated. The splice-specific 
reverse primers were designed to span the intron by annealing to exonic sequence 5 bp upstream 
and 16 bp downstream. (B) A representative ethidium bromide-stained 1% agarose 
electrophorses gel of the PCR products amplified using the primers shown in (A), with the 1496 
bp fragment specific for the non-transposed parental copies (unspliced product) and the 588 bp 
fragment specific for the retrotranscribed spliced copies (spliced product) indicated. A spurious 
band with the size of ~2.5 kb was occasionally observed depending on the transfection 
conditions.  
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L1 retrotransposition efficiency decreased to 13.5% and 72.6%, respectively (Fig 9.2B), 
suggesting A3A potently inhibits L1 retrotransposition in cultured cells and A3G does not appear  
to have a significant inhibitory effect on L1, in agreement with previous studies [326, 332, 334, 
391]. A3H Hap II and Hap V decreased the L1 retrotransposition efficiency to 55.8% and 37%, 
respectively (Fig 9.2B), suggesting two A3H haplotypes both impose a moderate effect on L1 
mobilizations. If A3-induced L1 inhibition involves deamination activity, then the observed 
decrease in L1 retrotransposition efficiency was due to a combination of the L1 intermediates 
degradation by host DNA repair enzymes and the functional inactivation of L1 through missense 
or nonsense mutations induced by A3s. As a result, we first investigated whether the inhibition 
of L1 by A3s involved deamination by creating a number of catalytic mutants that have been 
reported to have abolished deaminase activities (Fig 9.2C, A3A C101S, A3G E259Q, A3H E57A) 
[57, 213, 334]. These catalytic mutants were created by mutating some key amino acids in A3s, 
such as C101 in A3A that is involved in coordinating active site Zn2+ ion, or E259 in A3G and 
E57 in A3H that act as a proton shuttle and participate directly in catalysis [430, 431]. Of note, 
we undertook this investigation by only studying the catalytic mutant of Hap II. Because two 
A3H haplotypes demonstrated similar L1 restriction abilities in the retrotransposition assay (Fig. 
9.1), presumably mutating E57 to an alanine in Hap II and Hap V would lead to the same result. 
The inhibition of L1 imposed by A3A seemed to require its deaminase activity, as a 4.6-fold 
increase in retrotransposition efficiency was observed when comparing that of wild type A3A to 
A3A C101S (Fig 9.2D, retrotransposition efficiency increased from 13.5% to 62.2%). The L1 
retrotransposition efficiency in the presence of A3G E259Q increased to 98.8% (Fig 9.2D) (Fig 
9.2D, retrotransposition efficiencies increased from 72.6% to 98.8%). No significant increase 
was observed when compare to wild type A3G, further confirming A3G only imposes a slight 
effect on L1. Mutating E57 to an Ala made no significant difference to the L1-restriction abilities 
of A3H (Fig 9.2D, 40% for A3H E57A; 55.8% for Hap II and 37% for Hap V). This finding 
provides evidence that although two haplotypes both impose moderate inhibitory effects on L1, 
deaminase activity is not required for A3H-mediated L1 restriction. To exclude the possibility 
that the observed differences in retrotransposition efficiencies was due to different cellular A3 
level, we assessed A3s (both wild type and catalytic mutants) expression level by Western blot in 
a parallel set of co-transfected Hela cell cultures (Fig. 9.2E). Immunoblotting results of cell 
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extracts harvested 72 hrs after transfection showed that a significant and comparable amount of 
A3 proteins can be detected in Hela cells and the sizes were consistent with the size of each 
protein, i.e., A3A and A3H is ~22 kDa and A3G is ~46 kDa (Fig. 9.2E).  
L1 inhibition imposed by A3s could be partly alleviated by introducing the uracil DNA 
glycosylase inhibitor (UGI) protein from bacillus phage PBS2 that functionally inhibits UDG by 
dissociating the DNA/UDG complex [103, 432]. To further verify whether the inhibition of L1 
retrotransposition by A3s is deamination-dependent, UGI expression vector was co-transfected 
along with L1 and A3 plasmids and the retrotransposition efficiencies were examined (Fig. 9.2, 
A and B). The inhibition in L1 retrotransposition efficiency by A3A was alleviated 2-fold when 
UGI was expressed (Fig. 9.2B, from 13.5% to 27.5%), indicating the L1 inhibition imposed by 
A3A indeed involves deaminations. UGI expression did not cause a significant increase in L1 
retrotransposition efficiencies for A3G and A3H (Fig. 9.2B. For A3G, the retrotransposition 
efficiencies in the presence and absence of UGI are 72.6% and 82.8%; for A3H Hap II, the 
retrotransposition efficiencies in the presence and absence of UGI are 55.8% and 71.6%; for 
A3H Hap V, the retrotransposition efficiencies in the presence and absence of UGI are 37% and 
39.2%), indicating the slight decrease in retrotransposition efficiency in the presence of A3G 
expression (Fig. 9.2B, ~30%) was not due to its deaminase activities and for A3H, the moderate 
inhibitory effects on L1 mobilizations was not caused by A3H-induced deaminations. 
9.3.2 A3-catalyzed mutation analysis in transposed neo genes. Next, we wish to examine any 
potential A3-mediated deamination footprints by sequencing transposed L1. Because the 
detection of L1 retrotransposition event in the L1 assay relies on the expression of the spliced 
neo gene and the neo-cassette located within the 3’UTR remains single-stranded for the longest 
time since it is furthest from the priming site for (+)DNA, clones that contain a heavily mutated 
neomycin phosphotransferase may fail to convey G418-resistance and will be lost during the 
antibiotic selection process. This leads to an underestimation of A3 enzymes’ deamination 
potency. To circumvent this problem, instead of sequencing the L1 region of each individual 
G418R clone, cellular DNA was extracted and used to for PCR reactions three days post-
transfection prior to G418 selections. Because an intron was inserted into the neo gene and a 
spliced neo gene could be produced only after an L1 integration event (Fig. 9.1), we designed 
primers that anneal to exon regions spanning the intron, enabling amplification of PCR products 
with different lengths that correspond to the spliced and unspliced products (Fig. 9.3A). UGI was 
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introduced to these experiments to promote the recovery of mutations. Several bands were 
revealed in the PCR amplification products even with the primers that intend to eliminate the 
amplification of intron sequences (Fig. 9.3B), in agreement with the previous observation that 
retrotransposotion is a rare event [334]. Sequencing confirmed the 588 bp species corresponded 
to the spliced, transposed neo products, whereas the 1496 bp species corresponded to the PCR 
amplification of the unspliced, full-length neo (data not shown).  
Sequencing the transposed intronless neo genes suggest in the absence of A3, the 
background G-to-A mutation rate is 0.24 mutations/kb (Fig. 9.4A, no A3). In the presence of 
A3A, the G-to-A mutation rate increased to 0.68 mutations/ kb (Fig. 9.4B), this 3-fold increase in 
mutation frequency partially explains why A3A is very potent at inhibiting L1 (Fig. 9.2B) and 
despite the degradation of uracil-containing L1 intermediates, some L1 intermediates can still 
escape the degradation of DNA repair enzymes and integrate into the host chromosome. 
Remarkably, when UGI was co-transfected along with L1 and A3 vectors, a 5.6-fold increase in 
G-to-A mutation rate was observed (Fig. 9.4C, A3A+UGI, the G-to-A mutation rate is 3.8 
mutations/ kb). This suggests introducing UGI blocked UNG and allowed more G-to-A 
mutations to be uncovered. Very few C-to-T mutations were observed on the transposed L1 
coding strands, excluding the possibility of A3A deaminating L1 RNA (Fig. 9.4, B and C). 
Because A3A prefers to mutate G-to-A within a 5’GA context (with the underlined G being 
mutated) [206], we next investigated whether these G-to-A mutations have occurred within 
A3A’s preferred deamination motif. In the presence of A3A, out of the 16 G-to-A mutations we 
recovered in neo gene (Fig. 9.4B), only two mutations are within the 5’GA to 5’AA context, and 
mutations in the 5’GC to 5’AC, 5’ GG to 5’AG, 5’GT to 5’AT motifs were observed (data not 
shown). Interestingly, in the presence of UGI, the majority of the G-to-A mutations have 
occurred within the 5’GA to 5’AA context (Fig. 9.4D), suggesting these mutations are related to 
A3A-induced deaminations. Consistent with the previous observation that A3G has little 
inhibitory effect on L1 activity (Fig. 9.2, B and D), a G-to-A mutation frequency of 0.16 
mutations/kb similar to that of the background was observed in neo gene (compare Fig 9.4A and 
9.4E, G-to-A mutation frequency of 0.24 mutations/kb v.s 0.16 mutations/kb). UGI expression 
did not cause an increase in G-to-A mutation frequency for A3G (Fig. 9.4F, G-to-A mutation 
frequency of 0.1 mutations/kb), suggesting the slight inhibitory effect of L1 retrotransposition by 
A3G (Fig. 9.2B, 72.6%) we observed was not caused by A3G-mediated deamination. Taken  
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Figure 9.4 A3A, but not A3G, promotes G-to-A mutations in the transposed neo genes. (A) to (C) 
and (E) to (F): nucleotide preference substitutions detected in the transposed neo genes in the 
presence of A3A and A3G and UGI. n, total number of nucleotides analyzed. The number of G-
to-A transition mutations in the (+) strand cDNA sequence (indicative of C-to-U deamination 
events on (-) strand cDNA) is highlighted. (A) L1 alone (with no A3 transfected) demonstrated a 
background G-to-A mutation frequency of 0.24 mutations/kb. (B) In the presence of A3A, the G-
to-A mutation frequency is 0.68 mutations/kb. (C) UGI expression uncovered the evidence of 
A3A-mediated deamination events in transposed neo gene. In the presence of A3A and UGI, the 
G-to-A mutation frequency is 3.8 mutations/kb. (D) DNA sequencing data from a subset of 
clones showing the sequence context of G-to-A mutations induced by A3A in the transposed neo 
gene in the presence of UGI. Asterisks denote homology. (E) A3G demonstrated the G-to-A 
mutation frequency is 0.16 mutations/kb. (F) UGI expression did not allow more A3G-mediated 
deamination events in transposed neo gene to be revealed. In the presence of A3G and UGI, the 
G-to-A mutation frequency is 0.1 mutations/kb. 
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Figure 9.5 A3H Hap II and Hap V do not appear to promote any significant numbers of G-to-A 
mutations in the transposed neo genes. (A) to (D): nucleotide preference substitutions detected in 
the transposed neo genes in the presence or absence of A3H Hap II, Hap V and UGI. n, total 
number of nucleotides analyzed. The number of G-to-A transition mutations in the (+) strand 
cDNA sequence (indicative of C-to-U deamination events on (-) strand cDNA) is highlighted. (A) 
In the presence of A3H Hap II, the G-to-A mutation frequency of 0.18 mutations/kb. (B) UGI 
expression did not uncovered any more A3H Hap II-induced deamination events in transposed 
neo gene. In the presence of A3H Hap II and UGI, the G-to-A mutation frequency is 0.13 
mutations/kb. (C) In the presence of A3H Hap V, the G-to-A mutation frequency is 0.13 
mutations/kb. (D) UGI expression did not uncovered any more A3H Hap V-induced deamination 
events in transposed neo gene. In the presence of A3H Hap V and UGI, the G-to-A mutation 
frequency is 0.16 mutations/kb. 
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together, these data strengthen the findings that A3A uniquely inhibits L1 retrotransposition 
using a deamination-dependent mode, whereas A3G does not seem to affect L1 mobilization. 
Because A3H catalytic mutant E57A restricts L1 as potently as the wild type A3H (Fig. 9.2D) 
suggesting A3H does not require deamination activity to restrict L1, we hypothesized no  
G-to-A mutations should be uncovered on transposed neo gene in the presence of A3H, in 
contrary to what has been observed for A3A (Fig. 9.4, B and C). Indeed, no enhanced rates of G- 
to-A mutations have been detected in neo genes in the presence of A3H Hap II or Hap V (Fig. 
9.4A, background G-to-A mutation rate is 0.24 mutations/kb; Fig 9.5A, Hap II, G-to-A mutation 
frequency is 0.18 mutations/kb; Fig 9.5B, Hap V, G-to-A mutations frequency is 0.13 
mutations/kb), confirming A3H does not utilize a deamination-dependent mechanism to inhibit 
L1. In addition, introducing UGI did not increase the number of G-to-A mutations for both Hap 
II and Hap V (Fig. 9.5, B and D, in the presence of UGI, A3H Hap II induced 2 G-to-A 
mutations whereas A3H Hap V induced 3 G-to-A mutations). None of the G-to-A mutations 
appeared within a 5’GA to 5’AA context (data not shown). Neither haplotypes appeared to be 
able to deaminate L1 RNA, as no apparent C-to-T mutations with the signature context were 
found (Fig. 9.5). 
9.4 Discussion and future directions 
 In this study, we showed different A3 family members, i.e., A3A, A3G and A3H, have 
varying abilities to inhibit the replication of retrotransposon L1 in a cultured cell assay. 
Specifically, A3A acts as a potent inhibitor for L1 retrotransposition, whereas A3G does not 
appear to inhibit L1 (Fig. 9.2, A and B), in accordance with previous studies [40, 325, 326, 332, 
334, 390]. Previous studies showed the stabilities of A3H haplotypes affect their abilities to 
inhibit L1. Specifically, the ΔN15 and G105-bearing stable haplotype(s) have a strong ability to 
restrict L1 [45, 289], whereas N15 and R105-bearing unstable haplotype have lost this function 
[334, 332]. This knowledge needed to be revisited as our understanding of A3H polymorphisms 
deepened. We found that two prevailing stable A3H haplotypes, Hap II and Hap V, both 
demonstrated a moderate inhibitory effect on L1 mobilizations. This is the first time, to the best 
of our knowledge, that the effects of stable A3H haplotypes on L1 have been comparatively 
examined. Numerous studies have reported the inhibitory effects of different A3 family members 
on L1, and in general a deamination-independent L1 restriction model has been proposed, as no 
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G→A mutations related to A3-related deamination events have been detected with L1 restriction, 
even by A3A [325, 326, 332-334, 390, 391, 421]. This might be largely due to the edited L1s 
being degraded by cellular DNA repair enzymes. Indeed, Richardson et al., studied the effects of 
A3A on L1 retrotransposition in a cell line that stably expresses UGI, and this allowed the 
recovery of A3A-mediated deamination events in the retrotransposed L1 sequences [337]. 
Inspired by this study, we set out to investigate the mechanisms different A3s utilized to restrict 
L1s by conducting experiments in the presence of UGI that has been introduced in a transfected 
plasmid.  
A3A has been demonstrated to be the most potent inhibitor of L1 mobilizations where it 
can restrict L1 retrotransposition frequencies by 75% to 95%, depending on the transfection 
conditions [326, 332, 334, 337, 391]. In our system A3A inhibits L1 retrotransposition by 85% 
(Fig. 9.2D) and deamination-deficient mutant, A3A C101S, only moderately restricts L1 
mobility (Fig. 9.2D, A3A C101S, L1 retrotransposition efficiency decreased by 40%). These 
findings indicate that the deaminase activity of A3A contribute greatly to L1 inhibition. It should 
be note that A3A has been reported to convey cytotoxicity on cells [433-435] and this could be 
responsible for the significant reduction in G418R colonies we observed in the L1 assay in the 
presence of A3A expression. A3A-mediated toxicity on cells likely stems from its ability to gain 
access to ss genomic DNAs that are transiently exposed in transcription bubbles and replication 
forks, leading to cell cycle perturbation [435]. This concern could be addressed by transfecting 
cells with A3A proteins expressed in a plasmid that carries G418-resistance (such as pcDNA3.1 
from Invitrogen) to rule out nonspecific cytotoxicity A3A has contributed to L1 inhibition. To 
test whether excision of uracil bases and APE-mediated L1 cDNA degradation contributed to 
A3A-induced L1 inhibition, we performed L1 assay in the presence of a bacteriophage-derived 
UGI that inhibits UNG activity [103] and found that UGI expression alleviated A3A-mediated 
L1 inhibition by 2-fold (Fig. 9.2B, from 13.5% to 27.5%), consistent with what Richardson et al. 
have reported using transient transfection [337]. The alleviation of inhibition by UGI is 
inefficient with transient transfection, as A3A still strongly inhibits L1 in the presence of UGI by 
~70% (Fig. 9.2B), and there are a number of explanations for this observation. First and foremost, 
the inhibition of UNG activity by UGI was likely not 100% due to transient transfection method. 
To make sure UNG activity is fully inhibited before the co-transfection of L1 and A3 vectors, a 
cell line that stably express UGI could be adopted, as it has been suggested that with a cell line 
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that stably express UGI, A3A almost lost its ability to restrict L1 and only 20% L1 inhibition was 
observed [337]. Alternatively, UGI expression vector could be transfected one day before the co-
transfection of UGI, L1 and A3 vectors to boost the expression of UGI. Secondly, mammalian 
cells express two nuclear UNGs with activities on ssDNA: UNG2, which is inhibited by UGI, 
and SMUG1, which is not affected by UGI [436-438]. Hence, SMUG1 could contribute to 
degrading the lesion-containing L1 substrates when UNG2 is blocked by UGI. Nevertheless, to 
further prove UNG is involved in degrading ss L1 intermediates at which A3A has been acted 
upon, one could test the inhibitory effects of L1 by A3A C101S in the presence of UGI and UGI 
expression should have little effect on L1 activity in assays conducted with A3A C101S.  
 Customarily, to verify whether the mode of L1 inhibition involves A3-mediated 
deaminations, the integrated genomic DNA present in individual G418R clones is sequenced to 
examine for the presence of G-to-A mutations on L1 coding strand, which serves as a direct 
evidence for A3-mediated deamination events [40, 337]. This approach tends to produce an 
underestimated low G-to-A mutation frequency, because clones that have heavily mutated 
genomes, which rendered neo gene to be non-functional, would be lost during the G418 selection 
process. We chose to PCR and sequence the intronless neo DNA that can only be generated in a 
spliced and reverse-transcribed L1, before G418 selection, to preserve the deamination events 
that have generated high numbers of mutations (Fig. 9.3). Interestingly, we noticed a high 
percentage (81%) of A→C transversion mutations present in the background (Fig. 9.4A, no A3) 
and G→A transition mutations account for the second most frequent mutation types occurred 
(19%) (Fig. 9.4A, no A3). A large amount of A→C mutations were persistently observed across 
different transfection conditions (Fig. 9.4, A-C, E-F and Fig. 9.5), suggesting their occurrence is 
not due to a specific A3 enzyme and may be an insertion bias of the L1 reverse transcriptase. 
A3A appeared to be a strong inhibitor of L1, as A3A induced a G-to-A mutation frequency that 
is 3 times above the background G-to-A mutation level (compare Fig. 9.4A and Fig. 9.4B, G-to-
A mutation frequency of 0.24 mutations/kb v.s 0.68 mutations/kb). In contrast, an A3 that is not 
competent at inhibiting L1, such as A3G, induces a G-to-A mutation frequency that is similar to 
that of the background (compare Fig. 9.4A and Fig. 9.4E, G-to-A mutation frequency of 0.24 
mutations/kb vs. 0.16 mutations/kb). Due to the limited numbers of G-to-A mutations revealed in 
the presence of A3G (Fig. 9.4, E and F), no dinucleotide sequence specificity can be examined. 
Remarkably, the G→A mutation profile induced in the presence of UGI and A3A demonstrated a 
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16-fold increase in the G→A mutations rate as compared to that of the background (compare Fig. 
9.4A and Fig. 9.4C, G-to-A mutation frequency of 0.24 mutations/kb vs. 3.8 mutations/kb), 
suggesting introducing UGI blocked UNG activity and allowed a significant amount of C→U 
lesion-containing L1 cDNA to escape degradations by cellular repair enzymes. It is noteworthy 
that in the presence of A3A and UGI, a large number of G→A mutations occurred in the 5’GA to 
5’AA context, consistent with the preference of A3A to deaminate 5'TC motifs in (-)DNA. Few 
deamination hotspots were visible after inspecting the neo sequences (Fig. 9.4D), consistent with 
A3A being non-processive [206].  
 Taken together, we propose a model for how A3A is involved in the L1 life cycle and 
inhibits L1 retrotransposition. During TPRT, the transiently exposed (-) strand L1 cDNA 
becomes the substrates for A3A-catalyzed deamination. Usually, if not repaired promptly the 
uracil-containing L1 cDNA intermediates would be vulnerable to the combined actions of 
cellular DNA repair enzymes, such as UNG and APE, and this leads to either the complete 
degradation of L1 cDNA or the integration of 5’ truncated L1 cDNA that lacks any evidence of 
A3A-mediated deaminations. By introducing an ectopically expressed UGI, A3A-mediated 
deamination events become uncovered in retrotransposed L1 sequences. The significant decrease 
of L1 retrotransposition efficiency in the presence of A3A (Fig. 9.2B) was attributed by the 
combined action UNG/APE-mediated L1 cDNA degradation and the mutations induced by A3A. 
The former may contribute more to the general inhibitory effects observed. One way to clarify 
the contribution of these two inhibitory actions is to introduce UGI, thus blocking the L1 
degradation pathway and only allows the effects of A3A deamination to be revealed. In our 
system, blocking UGI only alleviated the inhibition by 2-fold and A3A still strongly inhibits L1 
activity up to 27.5% (Fig. 9.2D). This neither suggests the rest of ~70% of L1 inhibition is 
caused by A3A-mediated deaminations or reflect the contributions UNG/APE-mediated 
degradation pathway made towards L1 inhibition, as the inhibition of UND by UGI was likely 
incomplete based on our transfection methods, as discussed above. Due to A3A catalytic mutant 
only restored L1 activity to ~60% (Fig. 9.2D), our model does not necessarily exclude 
possibilities of deamination-independent mode of actions, such as A3A inhibiting TPRT by 
inhibiting L1 RT or EN activity; nevertheless, this deamination-independent activity would be 
only 40% of the total restriction activity at best. 
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Previously through the characterization of A3H Hap II and Hap V we found that two 
A3H Haplotypes differ in their RNA binding abilities [210]. Specifically, A3H Hap II 
demonstrated stronger binding affinities for HIV 5’ UTR and Alu RNA than A3H Hap V. These 
two haplotypes did not show any differences in HIV restriction capacities [210]. Hence, it 
seemed interesting to investigate whether the difference in RNA binding ability could contribute 
to a difference in the abilities for two haplotypes to restrict L1, as it has been demonstrated the 
ability to bind RNA is crucial for L1 inhibiting abilities to some A3 family members, such as 
A3C and A3D [335, 336]. We found A3H Hap II and Hap V are able to suppress L1 
retrotransposition to a moderate level (Fig. 9.2, A and B) and there are no apparent differences in 
their L1 restriction abilities (Fig. 9.2B, Hap II restricts L1 retrotranspostion efficiency to 55.8%, 
Hap V restricts L1 retrotransposition efficiency to 33.7%). Three lines of evidence suggest both 
A3H haplotypes inhibit L1 mobilization in a manner that does not involve deaminations. Firstly, 
we found Hap II and V produced a similar G→A mutation profile and the genomic L1 
retrotransposition event that occurred in the presence of both A3H haplotypes are devoid of any 
G-to-A mutations (Fig. 9.5). Secondly, UGI expression had little effect on L1 activity in assays 
performed in the presence of two A3H haplotypes (Fig. 9.2B). Lastly, A3H catalytic mutant 
E57A still decreases L1 retrotransposition efficiency (Fig. 9.2D). Altogether, these findings 
suggest two stable A3H haplotypes utilize one or multiple deamination-independent mechanisms 
to restrict L1 activities.  
At early stage of L1 life cycle, L1 forms a ribonucleoprotein (RNP) complex as a 
retrotransposition intermediate by associating its own mRNA with ORF1p and ORF2p in the 
cytoplasm [426, 427]. The RNP complex then shuttles back to the nucleus and L1 replication 
requires reverse transcription from of its own RNA genome using reverse transcriptase encoded 
by ORF2p. For all A3s that have been reported to be capable of restricting L1, cellular 
localization of an A3 protein does not necessarily dictate its ability to restrict L1, as different 
mechanisms can be utilized by A3s to inhibit various stages of L1 mobilizations. Cytoplasmic 
A3s can inhibit L1 by binding ORF1p in an RNA-dependent manner and prevent the nuclear 
import of L1 RNP complex [335]. In contrast, A3s that locate in nucleus [333, 439] have been 
reported to inhibit L1’s TPRT process either by deaminating (-)cDNA or physically impair RT’s 
activity. Based on these observations and that both A3H Hap II and Hap V are primarily 
cytoplasmic proteins [45], we hypothesize A3H could inhibit L1 activity using a sequestration 
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mechanism similar to that of A3C [335]. As a first step to investigate this hypothesis, one could 
test whether A3H interacts with ORF1p by co-immunoprecipitation and whether this interaction 
can be disrupted by RNase treatment. The nature of RNA molecule that mediates A3H-ORF1p 
interaction can be investigated by immunoprecipitating A3H after transfection and detecting 
RNA in the eluted samples by quantitative PCR. L1 RNA and 7SL RNA serve as good candidate 
as 7SL RNA has been reported to be associated with L1 RNPs [440]. In addition, 
immunofluorescence microscopy can be used to examine whether A3H and ORF1 co-localize in 
the same cytoplasmic compartment, such as stress granule.  
9.5 Material and Methods 
9.5.1 Plasmids, cloning and site-directed mutagenesis. L1 expression plasmid pJM101/L1.3-Neo 
(construct enables resistance to G418) was kindly provided by Dr. John V. Moran (University of 
Michigan, Ann Arbor). Mutants of A3 (A3A C101S, A3G E259Q, A3H E57A) were made using 
the WT A3 construct for site-directed mutagenesis (QuickChange site-directed mutagenesis 
protocol, Stratagene). cDNA of WT A3A, A3G and A3H and mutants were cloned from 
pcDNA3.1 (Invitrogen) into pcDNA6-V5/His.A using XbaI and XhoI cloning sites. A3 proteins 
expressed from this vector have V5-His fusion tags present at the C terminus. Uracil DNA 
glycosylase inhibitor (phage gene synthesized by GeneScript) was subcloned into pcDNA6-
V5/His. A stop codon was introduced at the end of the UGI sequence so native UGI can be 
expressed. All constructed plasmids were verified by sequencing.  
9.5.2 Cells. Human Hela cells (ATCC® CCL2-1TM) were grown in Dulbecco’s modified Eagle 
medium (DMEM) (HyClone) containing 10% fetal bovine serum (FBS) (Gibco) and maintained 
in a humidified 37 °C incubator with 5% CO2. To test the minimal amount of G418 required to 
kill the untransfected Hela cells, an antibiotic killing curve was performed. In detail, Hela cells 
(2 x105 cells/well) were seeded into a 6-well plate 20 hrs before adding G418. The next day, a 
titrating amount of G418 (0-1000 μg/mL) was added to the media and cells were maintained for 
11 days in G418-containing media. Selection media were changed every 3 days. It was 
determined that 400 μg/mL of G418 provides the lowest antibiotic concentration at which cell 
death can visualized after 2 weeks and should be used for the retrotransposition assay (see 
below). 
9.5.3 Retrotransposition assay. Hela cells were seeded in each well of a 6-well tissue culture 
plate at a density of 2 x105 cells/well in growth media. Approximately 22 hrs after plating, Hela 
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cells were co-transfected with 1μg of L1 retrotransposon encoding plasmid (pJM101/L1.3) and 
with 1μg of the respective A3 protein encoding plasmid. Empty vectors were used to equalize 
transfected amount. Transfections were performed using GeneJuice (EMD Millipore) according 
to the manufacturer’s protocol. Media was replaced the following day. Approximately 48 h post-
transfection, cells were re-seeded to 6-well plate (at 1 in 5 dilution) and the next day attached 
cells were subjected to selection with 400 μg/mL G418 (Life Technologies). G418 selection was 
carried out for 11 days and the selection media were replaced every other day. G418R colonies 
were washed with 1x phosphate buffered saline (PBS) for two times, fixed with 2% 
paraformaldehyde/0.4% glutaraldehyde (Sigma), and stained with 0.1% crystal violet solution.  
9.5.4 Immunoblotting. To detect A3 protein expression levels in L1 assay, the same transfection 
conditions were used as described in the retrotransposition assay. Because all A3 protein 
expression plasmid were constructed with a C-terminal V5 tag, the proteins could be detected 
using antibodies specific for V5 epitope. Approximately 72hr post-transfection, cells were 
washed in 1x PBS and harvested in Laemmli sample buffer (58 mM Tris (pH 6.8), 5% glycerol, 
2% sodium dodecyl sulphate (SDS), 1.5% dithiothreitol (DTT)). The amount of proteins in the 
cell lysates was determined using Lowry assay (Total Protein Kit, Mirco Lowry, Peterson’s 
Modification, Sigma-Aldrich). Samples were heated at 95°C for 10 min prior to SDS-PAGE, and 
equal amount of lysates (40 μg) were loaded. Proteins were transferred to nitrocellulose 
membranes using electrophoresis (100 V, 1h at 4°C) and A3 proteins in the cell lysates were 
probed with primary antibodies (mouse monoclonal V5, 1:1000, Sigma). Monoclonal α-tubulin 
antibodies (rabbit monoclonal α-tubulin, 1:1000, Sigma) were used to examine equal amount of 
loadings in each well. After incubation with the secondary antibodies (A3 proteins: IRDye 800-
labeled goat anti-mouse (Mandel Scientific, catalog # 926-32210); α-tubulin: IRDye 680-labeled 
goat anti-rabbit (Mandel Scientific. Catalog # 926-68071)).  Tagged proteins and loading 
controls were detected simultaneously on the same immunoblot by using the Licor/Odyssey 
system. 
9.5.5 Nucleic acid extraction and PCR. Hela cells were co-transfected with 1 μg of A3 and L1 
plasmids in the presence or absence of 1 μg UGI vector as described above.  Cellular DNA (both 
genomic and episomal) from the transfected cells was extracted 72 hr post-transfection using 
DNAzol reagent (Thermo Fisher). DNA was treated with DpnI (New England Biolabs) for 1hr at 
37°C to remove residual episomal DNA from transfected plasmids. Extracted DNA was used as 
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a template for PCR amplification of the spliced neo gene using the forward primer (G418Neoseq 
For) 5’-TCGGGAGCGGCGATACCGT-3’ and the reverse primer (G418Neoseq Rev) 5’-
CGGTGCCCTGAATGAGCTTCA-3’. The PCR reaction (50 μL) contains 0.6 μg of 
cellular DNA, 1x Q5 reaction buffer and 1 unit of Q5 High-Fidelity DNA polymerase (NEB), 
200 μM of deoxynucleoside triphosphates (dNTPs) mixture, 0.5 μM of each primer, with an 
initial denaturation step at 98 °C (3 min) followed by 35 cycles of amplification (30 sec at 98°C, 
30 sec at 65.5 °C and 18 sec at 72 °C). PCR products were electrophoresed on 1% agarose gel in 
the presence of 0.1 μg/mL of ethidium bromide and exposed using ChemiDoc imager (Bio-rad). 
To examine the editing potency of A3 enzymes on retrotransposed L1 without prior G418 
selection, the spliced PCR product was gel purified with the GenElute Gel Extraction kit (Sigma), 
and cloned into pJET1.2/blunt vector (CloneJet PCR cloning kit, Thermo Scientific). After 
transformation into Escherichia coli DH5α cells, clones were picked and sent for  
sequencing using a kit-specific primer (pJET1.2 Forward) at the National Research Council 
DNA sequencing Facility (Saskatoon, SK). Sequence alignments were performed using Clustal 
Omega.  
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10.0 Discussion and Future Directions 
In this thesis, I have addressed the relationship of the biochemical properties of A3H and 
A3G as ssDNA cytosine deaminases to their biological functions as host innate immune 
restriction factors against exogenous retroviruses HIV and retrotransposon L1. One major 
conclusion derived from our studies with the biochemical characterization of A3H in comparison 
to A3G is that the mechanisms an A3 uses to scan non-target DNA in search for its deamination 
motif, instead of enzyme specific activities, determines its catalytic efficiency. Also, A3G and 
A3H (A3H, Z3-type single domain enzyme; A3G, Z2-Z1-type double domain enzyme) 
demonstrate very different properties as ssDNA cytidine deaminases, and this can be reflected in 
differences in nucleic acid binding, enzyme specific activity, ssDNA scanning motion and mode 
of oligomerization. These biochemical differences may provide clues as to why A3G and A3H 
have evolved to work more efficiently in certain biological environments, but not others. This 
may also be part of the reason that Vif has evolved a different interaction interface with A3G and 
A3H, for these two enzymes use different amino acids to affect oligomerization and processivity. 
By studying the restriction abilities of A3G and A3H under the scenarios of HIV and L1 
replication, we found that A3G and A3H are processive enzymes and can be considered equally 
potent at inhibiting HIV replication [45, 210]; however, in our experimental system A3G is not 
able to inhibit L1 mobilization whereas A3H can. Both A3G and A3H are cytoplasmic proteins 
[45, 96] and this has likely limited their scope of L1 inhibition to the cytoplasm. Although the 
specific mechanism awaits elucidation, that A3H is able to bind RNA 10-fold more tightly than 
A3G (Table 7.3) [140, 210] may allow A3H to interact with L1 RNA more efficiently and thus 
prevent L1 RNP from entering the nucleus.  
 A large portion of this thesis was devoted to the exploration of the ssDNA scanning 
mechanisms of A3G and A3H (i.e., the mechanisms of facilitated diffusion). Facilitated diffusion 
allows the enzymes to search for their specific targets faster than the simple diffusion-limited 
rate and the processivity assays we performed under the multiple turnover conditions provide a 
powerful tool to quantify and compare the ability of different A3s to diffuse along DNA and to 
locate a specific site for deamination. Understanding how A3 enzymes scan ssDNA in search for 
their deamination targets has been a subject that is near and dear to our heart for two reasons. 
First of all, as compared to the dsDNA scanning enzymes, such as transcription factors [441], 
DNA repair, recombination and replication proteins [442, 443] and restriction enzymes [444-
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446], there is a paucity of mechanistic studies on ssDNA scanning enzymes. Secondly, 
knowledge gained on the ssDNA scanning mechanisms of A3 enzymes could be extrapolated 
more broadly to other DNA binding proteins with positively charged DNA binding sites and 
allows us to rationalize how these proteins search the genome during their varying biological 
activities.  
The sliding and jumping motions are two facilitated diffusion mechanisms that have been 
well characterized for A3G [132, 133, 139, 140]. Upon the characterization of A3H haplotypes 
we were surprised to find that A3H is able to use a different facilitated diffusion mechanism, 
namely, intersegmental transfer, to translocate over longer distances on ssDNA; however, 
jumping and intersegment transfer mechanisms seem to be redundant to the mutagenic efficiency 
of A3H [210]. This conclusion was reached because A3H haplotype II that can undergo both 
jumping and intersegmental transfer did not restrict HIV replication more than haplotype V, 
which can only efficiently jump and has diminished intersegmental transfer ability [210]. The 
advantage conveyed by a 3-D jumping movement of an A3 enzyme on ssDNA is that during 
HIV reverse transcription it provides an approach for overcoming a DNA/RNA hybrid on (-
)cDNA (Fig 1.2); however, the advantage conveyed by intersegmental transfer movement of 
A3H during HIV replication, other than providing an alternative approach for long distance 
translocation, remained unclear. We have demonstrated that undergoing intersegmental transfer 
accelerates the rate of target searching process using a bulk biochemistry assay [210] and it 
would be interesting to validate this finding in vivo or with an in vitro model HIV replication 
system with the kinetics of reverse transcription being monitored. It is also possible that 
intersegment transfer motions of A3H facilitate template switching events by bringing different 
regions of the HIV RNA or (-)DNA together, which is a process during reverse transcription 
where HIV RT dissociates from its original template and reassociates with another template [122, 
123], thus playing a role in increasing the recombination rate and expanding viral genome 
diversities. A3G is unable to undergo intersegment transfer under the same experimental 
condition tested with A3H [210] and has been found to be unable to affect the rate of 
recombination [76].  
To test whether an enzyme is able to undergo intersegment transfer, we designed an assay 
that included increasing the concentration of enzyme and ssDNA substrate while keeping the 
ratio of each component the same [210]. A decrease in the apparent processivity factor and an 
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increase in the reaction rate as the concentration of the reaction components increases would 
indicate the occurrence of intersegment transfer [374]. Intersegment transfer could also be 
examined under a more stringent condition by keeping the concentration of the enzyme constant, 
but adding a titrating amount of competitor DNA to the reaction [133, 442]. Regardless of the 
reaction set up, it should be noted that if intersegment transfer is inherent to an enzyme, this type 
of translocation should have already occurred at the lowest DNA concentration, despite that the 
probability of an enzyme translocating to a separate DNA molecule nearby is low. Under this 
situation, in a mechanism that resembles jumping, A3H likely undergoes intersegment transfer 
by translocating to a distal site on the same DNA, although more severe structural alterations in 
the ssDNA, such as bending or looping, are likely involved [141, 149]. It would be interesting to 
investigate, either kinetically or structurally, whether a direct evidence to differentiate jumping 
from intersegment transfer could be obtained. 
Historically, the mechanism of intersegment transfer has been defined as a protein with 
two DNA binding sites simultaneously bound to two DNA sites and forming an “intermediate” 
binding state before translocating to another DNA [145, 444]. Hence, an early assumption was 
that being oligomeric, or at least having two DNA binding domains per polypeptide, would allow 
an A3 enzyme to undergo intersegment transfer efficiently. However, as shown by the findings 
that A3G and A3F, A3s with two DNA binding domains per polypeptide, cannot undergo 
intersegment successfully [133, 140, 210], this prediction is likely incorrect. Despite the protein 
being overall positively charged, the CTDs of A3G and A3F are negatively charged and do not 
favor interaction with DNA [140, 182]; therefore, the re-association with DNA might be the rate 
limiting step and eventually allows an attempt by A3G or A3F to undergo intersegment transfer 
to be resolved as a jumping movement. This does not seem to be an issue for A3s with a single 
DNA binding domain per polypeptide chain, such as A3H and A3C, which are overall positively 
charged and likely use a groove around helix 6 to interact with DNA. A consensus for  the 
structural requirements for A3s to undergo intersegmental transfer has not been achieved. For 
example, the ability of A3H to perform intersegment transfer depends on its ability to dimerize 
and the specific amino acid residue E178 on helix 6 [210]. The ability of A3C to perform 
intersegment transfer depends only on enzyme dimerization and not a specific amino acid 
residue [216]. In addition, Adolph et al. [216] found that A3Cs in dimer/monomer equilibrium, 
rather than stable dimers, constitute the favourable conformation for A3C to undergo 
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intersegment transfer. Altogether, these findings suggest mechanisms utilized by different A3s 
when they undergo intersegment transfer are different and the parameters required by an A3 to 
perform intersegment transfer could be better refined. 
Due to the potential therapeutic value of disrupting the host-pathogen interaction thus 
fully unleashing the antiviral effects of A3s, the field has devoted a significant amount of work 
in defining the interacting residues between each individual A3 and Vif. It has been found that 
the interaction between Vif and each A3 enzyme (A3D/F, A3G and A3H) is different and that 
each pairwise combination can be mapped to physically distinct protein surfaces [284, 287, 292], 
suggesting each individual A3 likely exerts a unique type of selection pressure on Vif, in 
accordance with the observations that different A3s have very different biochemical properties. 
In good agreement with these previous studies, our work with the degradation-dependent 
inhibition mechanisms of A3G and A3H by Vif validated that the Vif interaction interface are 
different for single Z-domain A3H and double Z-domain A3G enzymes and that these different 
Vif-A3 interfaces affect the degradation efficiency of A3s by Vif [312]. Interestingly, our 
biochemical analysis suggests Vif-A3G interaction disrupts A3G dimerization and Vif 
interaction with A3H does not break its dimerization [312]. Because the double-domain A3G 
monomer is equivalent in size to the single-domain A3H dimer, it seemed likely that no large 
structural alterations within Cul5 E3-Vif-A3 would be required when an Cul5 E3-Vif mediates 
the degradation of double-domain as compared to single-domain A3 proteins and this could be 
an advantageous property for Vif as the degradation of A3s with different domain architecture 
would be more efficient. However, an optimal configuration still seems to be required by a Cul5 
E3-Vif ligase complex to allow efficient degradation of A3s, based on the finding that despite 
A3G and A3H interacting with VifHXB2 with similar affinities, the different Vif-A3 interfaces still 
enabled VifHXB2 to degrade A3G 4-fold more than A3H [312]. It should be noted that all three 
recent studies [284, 287, 292] that allowed the identification of amino acid interfaces between 
Vif with A3G/F/H were performed using a similar approach involving identifying A3/Vif 
anchoring points using mutagenesis, functional infectivity assays and forced evolution 
experiments, followed by modeling of the interface using molecular docking [284, 292] or MD-
simulation [287] based on pre-existing A3 structures solved by nuclear magnetic resonance 
(NMR) or crystallography. The limitations of this research are that they could not provide 
information on any potential structural rearrangements at the protein-protein interface upon an 
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A3 binding to Vif. Based on our research using purified proteins and rotational anisotropy, we 
demonstrated that a conformational change in A3G and A3H occurs upon Vif binding [312] (Fig. 
5.2 and 5.3). Notwithstanding, solving the Cul5-E3-Vif-A3 co-crystal or NMR co-structure 
remains to be the “holy grail” in the A3 field. This would greatly strengthen our understanding of 
host-viral interaction and facilitate the small molecular inhibitor design that aims at inhibiting the 
A3-Vif interaction.     
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